Amorphous nilotinib microparticles and uses thereof

ABSTRACT

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor nilotinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer. In some embodiments, the pharmaceutical compositions can be administered without regard to food consumption. In other embodiments, the pharmaceutical compositions can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect.

REFERENCE TO RELATED APPLICATION

The present application claims the benefit of U.S. Provisional App. No.62/968,749 (filed Jan. 31, 2020), the entire disclosure of which ishereby incorporated by reference.

BACKGROUND

Protein kinase inhibitors (PKIs) have been studied for their potentialuse in treating various disorders of cellular proliferation, includingcancer. The potential for PKIs as a treatment is based on the role thatprotein kinases are known to play in regulating many cellular pathways,including those involved in signal transduction. Dysregulation ofprotein kinases has been implicated in the development and progressionof many cancers, which suggests that PKIs may be useful as a treatmentfor disorders or diseases such as cancer that are caused by uncontrolledoverexpression or upregulation of protein kinases.

One such PKI is nilotinib, which is currently marketed as animmediate-release formulation for oral administration under the brandname TASIGNA. TASIGNA is indicated for (a) treatment of adult andpediatric patients greater than or equal to 1 year of age with newlydiagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase; (b) treatment of adult patients with chronicphase and accelerated phase Ph+ CML resistant or intolerant to priortherapy that included imatinib; and (c) treatment of pediatric patientsgreater than or equal to 1 year of age with chronic phase Ph+ CML withresistance or intolerance to prior tyrosine-kinase inhibitor therapy.

Presently, oral dosage of TASIGNA is accompanied by a food effect. Infact, the prescribing information for TASIGNA contains a boxed warningthat includes the statement, “[a]void food 2 hours before and 1 hourafter taking the dose.” According to the prescribing information,“[s]ignificant prolongation of the QT interval may occur when TASIGNA isinappropriately taken with food and/or strong CYP3A4 inhibitors and/ormedicinal products with a known potential to prolong QT. Therefore,co-administration with food must be avoided . . . . ” This effect on theQT interval is likely due to the increase in exposure (expressed asarea-under-the-curve, or AUC) and/or maximum plasma concentration(C_(max)) that can occur when TASIGNA is taken with food. For example, asingle 400-mg dose of TASIGNA taken 30 minutes after a high-fat meal,increased AUC and C_(max) by 82% and 112%, respectively, as compared tolevels obtained under fasting conditions. Such an increase in serumlevels may also exacerbate or increase the prevalence of common sideeffects such as nausea, diarrhea, rash, headache, muscle and joint pain,tiredness, vomiting, and fever; as well as more serious side effectssuch as low blood cell counts, decreased blood flow to the heart orbrain, pancreas inflammation, liver problems, and bleeding problems.

The current prescribing information for TASIGNA instructs the patient todose TASIGNA twice daily on an empty stomach, and avoid food 2 hoursbefore and 1 hour after taking a dose. The requirement to take TASIGNAtwice-a-day without food (for a three-hour period for each dose) is aconsiderable burden to patients. Further, in light of the side effectsthat can occur with TASIGNA, poor adherence to the dosingrecommendations can be very detrimental to patients.

In addition, the solubility of nilotinib significantly decreases withincreasing pH, and therefore nilotinib absorption may be compromised ifTASIGNA is administered along with gastric acid-reducing agents. Use ofTASIGNA with common gastric acid-reducing agents is restricted inaccordance with prescribing information. For example, the prescribinginformation for TASIGNA states, “[a]void concomitant use of [proton pumpinhibitor] with Tasigna.” The prescribing information further suggeststo “[u]se short-acting antacids or H2 blockers as an alternative toproton pump inhibitors” because “[c]oncomitant use with a [proton pumpinhibitor] decreased nilotinib concentrations compared to Tasigna alone. . . which may reduce Tasigna efficacy.” For safe use of TASIGNA withgastric acid-reducing agents, the following instruction is provided inthe prescribing information: “As an alternative to PPIs, use H2 blockersapproximately 10 hours before or approximately 2 hours after the dose ofTasigna, or use antacids approximately 2 hours before or approximately 2hours after the dose of Tasigna.” These restrictions on how patients canaddress indigestion or excess gastric acidity while treated with TASIGNAare burdensome, especially in light of how often such symptoms can occurwithin the patient population. Moreover, poor adherence to theprescribing information's warnings about taking gastric acid-reducingagents while being treated with TASIGNA can be detrimental to thepatient.

Thus, there remains a need in the art for a means for patients toreceive the full benefits of nilotinib while minimizing the risk ofexperiencing adverse side effects, especially those that are associatedwith TASIGNA's food effect, as well as for a nilotinib treatment thatdoes not require such restricted co-administration of nilotinib with agastric acid-reducing agent.

SUMMARY OF DISCLOSURE

An aspect of the disclosure relates to an amorphous solid dispersion(“ASD”) comprising nilotinib. The ASD comprises nilotinib and one ormore polymers. In some embodiments, the ASD comprises nilotinib and oneor more polymers that exhibits pH-dependent solubility.

In another aspect, the disclosure provides pharmaceutical compositionscomprising the ASDs.

Yet another aspect of the disclosure relates to a method of treating adisease which responds to an inhibition of protein kinase activity, suchas a proliferative disorder. In some embodiments, the method comprisesadministration of an ASD or pharmaceutical composition of the presentdisclosure to a patient. In some embodiments, the composition isadministered without regard to consumption of food. In some embodiments,the composition is administered without regard to whether the patient isin a fasted state or a fed state.

In another embodiment, the disclosure provides a method of safelydelivering nilotinib to a patient in need thereof, the methodcomprising: (a) administering to the patient a therapeutically effectiveamount of a pharmaceutical composition of the disclosure; and (b)administering a meal to the patient; wherein steps (a) and (b) occurwithin less than two hours of each other.

In other embodiments, the disclosure provides kits for sale to a user.The kits comprise a pharmaceutical composition according to thedisclosure, and a package insert. In one embodiment, the package insertinforms the user that the pharmaceutical composition can be administeredwith food. In another embodiment, the package insert informs the userthat the pharmaceutical composition can be administered with or withoutfood. In another embodiment, the package insert does not include awarning that the pharmaceutical composition should not be administeredwith food.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows pharmacokinetic profiles for (a) male beagles in a fastedstate administered TASIGNA Suspension after pretreatment withpentagastrin (pH 1-2) (Leg A1); or (b) male beagles in a fasted stateadministered TASIGNA Capsule after pretreatment with phosphate buffer(pH˜2.5) (Leg B1); as described in Example 4.

FIG. 2 shows pharmacokinetic profiles for (a) male beagles in a fastedstate administered TASIGNA Capsule after pretreatment with phosphatebuffer (pH˜2.5) (Leg B1); and (b) male beagles in a fed stateadministered TASIGNA Suspension (Leg A3); as described in Example 4.

FIG. 3 shows pharmacokinetic profiles for (a) male beagles in a fastedstate administered TASIGNA Capsule after pretreatment with phosphatebuffer (pH˜2.5) (Leg B1); (b) male beagles in a fasted stateadministered ASD Capsule (nilotinib and HPMC-AS) after pretreatment withphosphate buffer (pH˜2.5) (Leg B2); (c) male beagles in a fasted stateadministered ASD Suspension (nilotinib and HPMC-AS) after pretreatmentwith phosphate buffer (pH˜2.5) (Leg B3); and (d) male beagles in afasted state administered ASD Tablet (nilotinib and HPMC-AS) afterpretreatment with phosphate buffer (pH˜2.5) (Leg B4); as described inExample 4.

FIG. 4 shows pharmacokinetic profiles for (a) male beagles in a fastedstate administered TASIGNA Capsule after pretreatment with phosphatebuffer (pH˜2.5) (Leg B1); (b) male beagles in a fasted stateadministered ASD Suspension (nilotinib and EUDRAGIT L100-55) withSOLUPLUS after pretreatment with phosphate buffer (pH˜2.5) (Leg C1); (c)male beagles in a fasted state administered ASD Suspension (nilotiniband HPMC-AS) with SOLUPLUS after pretreatment with phosphate buffer(pH˜2.5) (Leg C2); and (d) male beagles in a fasted state administeredASD Suspension (nilotinib and HPMC-AS) after pretreatment with phosphatebuffer (pH˜2.5) (Leg C3); as described in Example 4.

FIG. 5 shows pharmacokinetic profiles for (a) healthy human subjects ina fasted state orally administered 200 mg TASIGNA IR Capsule; (b)healthy human subjects in a fasted state orally administered 50 mgComposition 1 (ASD of nilotinib and HPMC-AS); and (c) healthy humansubjects in a fasted state orally administered 50 mg Composition 2(ASDof nilotinib and HPMC-AS, with SOLUPLUS); as described in Example 5.

FIG. 6 shows pharmacokinetic profiles for (a) healthy human subjects ina fasted state orally administered 200 mg TASIGNA IR Capsule; (b)healthy human subjects in a fasted state orally administered 50 mgComposition 1 (ASD of nilotinib and HPMC-AS); and (c) healthy humansubjects in a fed state orally administered 50 mg Composition 1 (ASD ofnilotinib and HPMC-AS); as described in Example 5.

FIG. 7 shows pharmacokinetic profiles for (a) healthy human subjects ina fasted state orally administered 200 mg TASIGNA IR Capsule; (b)healthy human subjects in a fasted state orally administered 65 mgComposition 2 (ASD of nilotinib and HPMC-AS, with SOLUPLUS); and (c)healthy human subjects in a fed state orally administered 65 mgComposition 2 (ASD of nilotinib and HPMC-AS, with SOLUPLUS); asdescribed in Example 5.

DETAILED DESCRIPTION

The present disclosure relates to nilotinib ASDs, pharmaceuticalcompositions of nilotinib ASDs, and methods of use comprisingadministration of nilotinib ASDs or the pharmaceutical compositions. Thenilotinib ASDs and the pharmaceutical compositions of the presentdisclosure may provide particular advantages over conventionalimmediate-release crystalline nilotinib formulations, such as TASIGNA.For instance, as described herein, the prescribing information forTASIGNA warns to avoid food 2 hours before and 1 hour after taking adose. In contrast, certain ASDs and pharmaceutical compositions of thepresent disclosure can be administered without regard to foodconsumption.

Moreover, certain ASDs and pharmaceutical compositions of the presentdisclosure unexpectedly provide a pharmacokinetic profile similar tothat of TASIGNA, even when the dose of nilotinib administered by thepharmaceutical compositions is a fraction of the dose of nilotinibnormally administered when using TASIGNA. Therefore, the disclosureprovides pharmaceutical compositions that can be administered at a lowerdose than TASIGNA, but that would be expected to provide a comparabletherapeutic effect.

As another advantage, pharmaceutical compositions of the disclosure mayachieve a reduced inter-subject and/or intra-subject variability, ascompared to the variability observed for TASIGNA.

Thus, the ASDs and the pharmaceutical compositions of the presentdisclosure may offer a safer but equally effective presentation ofnilotinib as compared to the currently available immediate-releaseproduct.

Nilotinib

Nilotinib is a kinase inhibitor having the following structure:

The chemical name for nilotinib is4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide.The molecular formula is C₂₈H₂₂F₃N₇O, which corresponds to a molecularweight of 529 g/mol (nilotinib base, anhydrous).

Nilotinib is marketed under the tradename TASIGNA, as animmediate-release formulation containing nilotinib monohydrochloridemonohydrate. It is thought that the nilotinib monohydrochloridemonohydrate in TASIGNA is in a crystalline form. Currently availableTASIGNA capsules (marketed in the United States under New DrugApplication 22-068) are labeled as containing 50 mg, 150 mg, or 200 mgnilotinib base, anhydrous (equivalent to 55 mg, 166 mg, and 221 mgnilotinib monohydrochloride monohydrate, respectively.) As used herein,“TASIGNA IR Capsule” refers to commercially available TASIGNAimmediate-release capsules.

Nilotinib monohydrochloride monohydrate is characterized as a Class IVcompound (low/moderate aqueous solubility and low permeability)according to the Biopharmaceutical Classification System (“BCS”). Apreparation of nilotinib in a form that is intended to enhance itssolubility could increase its bioavailability. One approach forenhancing solubility is to produce an amorphous solid dispersion.

Amorphous Solid Dispersions of Nilotinib

One aspect of the present disclosure relates to amorphous soliddispersions (“ASDs”) comprising nilotinib and one or more polymers. Apharmaceutically suitable amorphous solid dispersion generally comprisesa pharmaceutically active ingredient, such as nilotinib, dispersed in apharmacologically inert carrier, such as a polymer. One aim of apharmaceutically suitable amorphous solid dispersion is to improve thebioavailability of the pharmaceutically active ingredient. Thisimprovement can occur, for example, because of enhanced surface area,improved wettability or dispersibility, increased dissolution rate, orother factors.

In general, it is favorable if the pharmaceutically active ingredient isdispersed in the polymer to form what has been termed in the art as a“glass solution.” However, other forms of dispersion, such as thosetermed as “solid solution” or “glass suspension,” may also be suitable.The precise characterization of the solid dispersion is not important,provided that the amorphous solid dispersion is capable of providingdesired characteristics and performance.

In the ASDs of the disclosure, the nilotinib may be as a free base or asa salt such as a hydrochloride. In some embodiments, the nilotinib is asa free base and is anhydrous. Such forms of nilotinib and processes ofpreparing nilotinib are disclosed, for example, in WO 2004/005281 and WO2007/015871. In the description of the amorphous solid dispersions andpharmaceutical compositions below, and in the claims, any reference to“nilotinib” refers broadly to nilotinib free base, salts of nilotinib,anhydrous nilotinib (or salts thereof), hydrates or solvates ofnilotinib, and hydrates or solvates of nilotinib salts as suitablealternatives, unless specified.

The one or more polymers, which should be pharmacologically inert,should be suitable to provide structure and stability to the ASD. By“pharmacologically inert,” it is meant that the material does notinitiate a pharmacological response or an adverse reaction whenintroduced to a relevant biological system (such as the gastrointestinaltract).

In some embodiments, the ASD comprises nilotinib and one or morepolymers. In certain embodiments, the ASD consists of nilotinib and theone or more polymers. In certain other embodiments, the ASD consistsessentially of nilotinib and the one or more polymers.

Polymers that can be used in the ASDs of the present disclosure mayinclude, but are not limited to, those described below. The term“polymer” includes, but is not limited to, organic homopolymers,copolymers (such as for example, block, graft, random, and terpolymers,etc.), and blends and modifications thereof. The term “copolymer” refersto polymers containing two or more different monomeric units orsegments, and includes terpolymers, tetrapolymers, etc. Informationregarding suitable polymers, and commercial sources therefor, can befound in Sheskey P J (ed.) Handbook of Pharmaceutical Excipients, 9^(th)Ed. London: Pharmaceutical Press; 2020 (ISBN 0857113755); alternatively,the most up-to-date edition of the same title may be consulted.

Polymers that can be used in the ASDs of the present disclosure mayinclude ionizable or non-ionizable polymers, or a combination thereof.

In some embodiments, the one or more polymers may be non-ionizablepolymers. In certain embodiments, the ASD consists of nilotinib and oneor more non-ionizable polymers. In certain other embodiments, the ASDconsists essentially of nilotinib and one or more non-ionizablepolymers.

In some embodiments, the one or more polymers may be ionizable polymers.In certain embodiments, the ASD consists of nilotinib and one or moreionizable polymers. In certain other embodiments, the ASD consistsessentially of nilotinib and one or more ionizable polymers.

In yet other embodiments, a combination of ionizable and non-ionizablepolymers may be used. In certain embodiments, the ASD consists ofnilotinib and a combination of one or more non-ionizable polymers andone or more ionizable polymers. In certain other embodiments, the ASDconsists essentially of nilotinib and a combination of one or morenon-ionizable polymers and one or more ionizable polymers.

Polymers that can be used in the ASDs of the present disclosure mayinclude polymers that exhibit pH-dependent solubility, or polymers thatare generally insensitive to pH, or a combination thereof.

In some embodiments, the one or more polymers may exhibit pH-dependentsolubility. In certain embodiments, the ASD consists of nilotinib andone or more polymers that exhibits pH-dependent solubility. In certainother embodiments, the ASD consists essentially of nilotinib and one ormore polymers that exhibits pH-dependent solubility.

In other embodiments, the one or more polymers may be generallyinsensitive to pH. In certain embodiments, the ASD consists of nilotiniband one or more polymers generally insensitive to pH. In certain otherembodiments, the ASD consists essentially of nilotinib and one or morepolymers generally insensitive to pH.

In yet other embodiments, a combination of polymers may include one ormore polymers exhibiting pH-dependent solubility and one or morepolymers generally insensitive to pH. In certain embodiments, the ASDconsists of nilotinib and a combination of one or more polymersexhibiting pH-dependent solubility and one or more polymers generallyinsensitive to pH. In certain other embodiments, the ASD consistsessentially of nilotinib and a combination of one or more polymersexhibiting pH-dependent solubility and one or more polymers generallyinsensitive to pH.

Non-ionizable polymers. Suitable non-ionizable polymers may include:polysaccharides and polysaccharide derivatives (including celluloseethers and non-ionizable cellulose esters); polymers or copolymers ofN-vinylpyrrolidone and/or vinyl acetate; polymers of ethylene oxide;homopolymers or copolymers of lactic acid and/or glycolic acid; maleicanhydride copolymers; polyvinyl caprolactam-polyvinylacetate-polyethylene glycol graft copolymer; and poloxamers.

Suitable non-ionizable polysaccharides and polysaccharide derivativesmay include cellulose ethers and non-ionizable cellulose esters.Examples of suitable cellulose ethers include methylcellulose (“MC”;e.g., METHOCEL A15 LV, METHOCEL A4M), ethylcellulose (“EC”; e.g.,ETHOCEL), hypromellose or hydroxypropyl methylcellulose (“HPMC”; e.g.,METHOCEL E3, METHOCEL E5, METHOCEL E6, METHOCEL E15, AFFINISOL HPMCHME), hydroxyethyl cellulose (“HEC”; e.g., NATROSOL 250 Pharm), andhydroxypropyl cellulose (“HPC”; e.g., HPC EF, HPC LF, HPC JF, HPC L,KLUCEL).

Examples of non-ionizable cellulose esters that may be suitable includecellulose acetate, cellulose propionate, cellulose butyrate, andcellulose acetate butyrate.

Examples of suitable polymers or copolymers of N-vinylpyrrolidone and/orvinyl acetate include polyvinylpyrrolidone (“PVP”; e.g., PVP K25, PVPK90, VIVAPHARM PVP), crospovidone or crosslinked polyvinylpyrrolidone(e.g., KOLLIDON CL, VIVAPHARM PVPP), copovidone orvinylpyrrolidone/vinyl acetate copolymer (“PVP/VA”; e.g., KOLLIDON VA64, VIVAPHARM PVP/VA 64), and polyvinyl alcohol (“PVA”; e.g., VIVAPHARMPVA).

Examples of suitable polymers of ethylene oxide include polyethyleneglycol (“PEG”; e.g., KOLLISOLV PEG 8000) and poly(ethylene oxide)(“PEO”; e.g., POLYOX).

Examples of suitable homopolymers or copolymers of lactic acid and/orglycolic acid include polylactide or poly(lactic acid) (“PLA”),polyglycolide or poly(glycolic acid) (“PGA”), andpoly(lactic-co-glycolic acid) (“PLGA”).

Non-ionizable maleic anhydride copolymers such as poly(methyl vinylether/maleic anhydride) (“PVM/MA”) may also be suitable. Non-ionizablepoloxamers (e.g., PLURONIC, KOLLIPHOR) may also be suitable.

A polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graftcopolymer (e.g., SOLUPLUS) may also be a suitable non-ionizable polymer.

Ionizable polymers. Suitable ionizable polymers may be considered“anionic” or “cationic” polymers. Anionic and cationic polymers oftenexhibit pH-dependent solubility.

Anionic polymers often include carboxylate (such as acetate), phthalate,succinate, or acrylate functionalities. Anionic polymers are generallyinsoluble at low pH and more soluble at higher pH. Suitable anionicpolymers may include anionic polysaccharides and polysaccharidederivatives (such as ionizable cellulose esters), copolymers ofmethacrylic acid and/or alkyl acrylate, and derivatized vinyl acetatepolymers, for example.

An example of an ionizable polysaccharide that may be suitable isxanthan gum. Examples of suitable ionizable cellulose esters may includecarboxymethylcellulose (“CMC”; carboxymethylcellulose sodium),hypromellose acetate succinate, or hydroxypropyl methylcellulose acetatesuccinate (“HPMC-AS”; e.g., AFFINISOL HPMC-AS, AQUASOLVE, AQOAT),hydroxypropyl methylcellulose phthalate (“HPMC-P”; e.g., HP-50, HP-55),and cellulose acetate phthalate (“CAP”; e.g., EASTMAN C-A-P).

Suitable copolymers of methacrylic acid and/or alkyl methacrylate mayinclude methacrylic acid/methyl methacrylate copolymer (e.g., EUDRAGITL100) and methacrylic acid/ethyl acrylate copolymer (e.g., EUDRAGITL100-55, KOLLICOAT MAE).

An example of a derivatized vinyl acetate polymer that may be suitableis polyvinyl acetate phthalate (PVA-P; PHTHALAVIN).

Cationic polymers often include amine functionalities. Cationic polymersare generally soluble at low pH and less soluble at higher pH. Suitablecationic polymers may include cationic polysaccharides andpolysaccharide derivatives, and amine-functionalized copolymers ofmethacrylic acid and/or alkyl acrylate, for example.

An example of a cationic polysaccharide that may be suitable ischitosan.

Suitable amine-functionalized copolymers of methacrylic acid and/oralkyl acrylate include, for example, dimethylaminoethylmethacrylate/butyl methacrylate/methyl methacrylate copolymer (e.g.,EUDRAGIT E100) and aminoalkyl methacrylate copolymer such as poly(ethylacrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylatechloride (e.g., EUDRAGIT RL100, EUDRAGIT RL PO, EUDRAGIT RS PO).

In some embodiments, the one or more polymers comprise polymers that arecharacterized by pH-dependent solubility. In some embodiments, the oneor more polymers comprise an anionic polymer characterized bypH-dependent solubility. In some embodiments, the one or more polymersconsist essentially of one or more anionic polymers characterized bypH-dependent solubility. In some embodiments, the one or more polymersconsist of one or more anionic polymers characterized by pH-dependentsolubility.

HPMC-AS and EUDRAGIT L100-55 are examples of suitable anionic polymersthat demonstrate pH-dependent solubility, but other polymers thatdemonstrate pH-dependent solubility may also be employed.

In certain embodiments, the one or more polymers comprise HPMC-AS. Incertain embodiments, the polymer consists of HPMC-AS. In certainembodiments, the polymer consists essentially of HPMC-AS.

HPMC-AS is available in a variety of grades, which each demonstratepH-dependent aqueous solubility. Generally speaking, HPMC-AS is largelyinsoluble in an aqueous medium at pH of 4 or lower, and largely solublein an aqueous medium at pH 7 or greater. It is insoluble in normalgastric fluid, but swells and dissolves in the higher pH environment ofthe upper small intestine. The grades of HPMC-AS are differentiated bythe relative proportion of acetyl/succinyl substituents. Low-gradeHPMC-AS comprises 5-9% acetyl substituents and 14-18% succinylsubstituents; mid-grade HPMC-AS comprises 7-11% acetyl substituents and10-14% succinyl substituents; high-grade HPMC-AS comprises 10-14% acetylsubstituents and 4-8% succinyl substituents. In the practice of thedisclosure, any grade of HPMC-AS may be suitable, or a mixture of two ormore grades may be suitable. In certain embodiments, mid-grade HPMC-ASis particularly suitable.

In certain embodiments, the ASD consists of nilotinib and HPMC-AS. Incertain embodiments, the ASD consists essentially of nilotinib andHPMC-AS. In certain embodiments, the ASD consists of anhydrous, freebase nilotinib and HPMC-AS. In certain embodiments, the ASD consistsessentially of anhydrous, free base nilotinib and HPMC-AS. In certainembodiments, the ASD consists of nilotinib and mid-grade HPMC-AS. Incertain embodiments, the ASD consists essentially of nilotinib andmid-grade HPMC-AS. In certain embodiments, the ASD consists ofanhydrous, free base nilotinib and mid-grade HPMC-AS. In certainembodiments, the ASD consists essentially of anhydrous, free basenilotinib and mid-grade HPMC-AS.

In some embodiments, the one or more polymers comprise a copolymer ofmethacrylic acid and/or alkyl methacrylate. In some embodiments, the oneor more polymers comprise methacrylic acid/methyl methacrylate copolymer(e.g., EUDRAGIT L100) or methacrylic acid/ethyl acrylate copolymer(e.g., EUDRAGIT L100-55).

In some embodiments, the one or more polymers comprise methacrylicacid/ethyl acrylate copolymer. In certain embodiments, the polymerconsists of methacrylic acid/ethyl acrylate copolymer. In certainembodiments, the polymer consists essentially of methacrylic acid/ethylacrylate copolymer.

In some embodiments, the ASD comprises nilotinib and methacrylicacid/ethyl acrylate copolymer. In certain embodiments, the ASD consistsof nilotinib and methacrylic acid/ethyl acrylate copolymer. In certainother embodiments, the ASD consists essentially of nilotinib andmethacrylic acid/ethyl acrylate copolymer. In certain embodiments, theASD comprises anhydrous, free base nilotinib and methacrylic acid/ethylacrylate copolymer. In certain embodiments, the ASD consists ofanhydrous, free base nilotinib and methacrylic acid/ethyl acrylatecopolymer. In certain embodiments, the ASD consists essentially ofanhydrous, free base nilotinib and methacrylic acid/ethyl acrylatecopolymer.

In any of the foregoing, the methacrylic acid/ethyl acrylate copolymercan be EUDRAGIT L100-55, for example. EUDRAGIT L100-55 is an anioniccopolymer demonstrating pH-dependent aqueous solubility. Generallyspeaking, EUDRAGIT L100-55 is largely insoluble in an aqueous medium atpH of 5 or lower, and largely soluble in an aqueous medium at pH 5.5 orgreater.

In some embodiments of the ASD, the one or more polymers does notcomprise a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycolgraft co-polymer (e.g., SOLUPLUS). In some embodiments, the ASD issubstantially free from a polyvinyl caprolactam-polyvinylacetate-polyethylene glycol graft co-polymer. In some embodiments, theASD is essentially free from a polyvinyl caprolactam-polyvinylacetate-polyethylene glycol graft co-polymer. In some embodiments, theASD is free from a polyvinyl caprolactam-polyvinyl acetate-polyethyleneglycol graft co-polymer. In yet other embodiments, the ASD comprisesnilotinib and one or more polymers, with the proviso that the one ormore polymer is not a polyvinyl caprolactam-polyvinylacetate-polyethylene glycol graft co-polymer.

In some embodiments of the ASD, the one or more polymers does notcomprise a poloxamer. In some embodiments, the ASD is substantially freefrom a poloxamer. In some embodiments, the ASD is essentially free froma poloxamer. In some embodiments, the ASD is free from a poloxamer. Inyet other embodiments, the ASD comprises nilotinib and one or morepolymers, with the proviso that the one or more polymer is not apoloxamer.

In some embodiments of the ASD, the one or more polymers does notcomprise an anionic polymer comprising phthalate functionalities. Insome embodiments, the ASD is substantially free from an anionic polymercomprising phthalate functionalities. In some embodiments, the ASD isessentially free from an anionic polymer comprising phthalatefunctionalities. In some embodiments, the ASD is free from an anionicpolymer comprising phthalate functionalities. In yet other embodiments,the ASD comprises nilotinib and one or more polymers, with the provisothat the one or more polymer is not an anionic polymer comprisingphthalate functionalities.

In some embodiments of the ASD, the one or more polymers does notcomprise a hydroxypropyl methylcellulose phthalate. In some embodiments,the ASD is substantially free from a hydroxypropyl methylcellulosephthalate. In some embodiments, the ASD is essentially free from ahydroxypropyl methylcellulose phthalate. In some embodiments, the ASD isfree from a hydroxypropyl methylcellulose phthalate. In yet otherembodiments, the ASD comprises nilotinib and one or more polymers, withthe proviso that the one or more polymer is not a hydroxypropylmethylcellulose phthalate.

In some embodiments of the ASD, the one or more polymers does notcomprise a polyvinyl acetate phthalate. In some embodiments, the ASD issubstantially free from a polyvinyl acetate phthalate. In someembodiments, the ASD is essentially free from a polyvinyl acetatephthalate. In some embodiments, the ASD is free from a polyvinyl acetatephthalate. In yet other embodiments, the ASD comprises nilotinib and oneor more polymers, with the proviso that the one or more polymer is not apolyvinyl acetate phthalate.

In some embodiments of the ASD, the one or more polymers does notcomprise a polymer or copolymer of N-vinylpyrrolidone. In someembodiments, the ASD is substantially free from a polymer or copolymerof N-vinylpyrrolidone. In some embodiments, the ASD is essentially freefrom a polymer or copolymer of N-vinylpyrrolidone. In some embodiments,the ASD is free from a polymer or copolymer of N-vinylpyrrolidone. Inyet other embodiments, the ASD comprises nilotinib and one or morepolymers, with the proviso that the one or more polymer is not a polymeror copolymer of N-vinylpyrrolidone. In the foregoing, the polymer orcopolymer of N-vinylpyrrolidone can be polyvinylpyrrolidone,crospovidone or crosslinked polyvinylpyrrolidone, copovidone orvinylpyrrolidone/vinyl acetate copolymer.

As used herein, the phrase “substantially free from” means that thestated component represents not more than 10% of the ASD, based onweight. The phrase “essentially free from” means that the statedcomponent represents not more than 5% of the ASD, based on weight. Theterm “free from” means that the stated component represents not morethan 2% of the ASD, based on weight.

In the ASDs described in the disclosure, the amount of nilotinib ascompared to the amount of the one or more polymers may vary. Forexample, nilotinib and the one or more polymers may be present in a w/wratio (nilotinib:polymer) of 20:80 to 95:5. In certain embodiments,nilotinib and the one or more polymers may be present in a w/w ratio of25:75 to 90:10, or 30:70 to 85:15, or 35:65 to 80:20. In someembodiments, nilotinib and the one or more polymers may be present in aw/w ratio of 40:60 to 70:30. In particular embodiments, the w/w ratio is20:80, 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35,70:30, 75:25, 80:20, 85:15, 90:10, or 95:5.

In some embodiments, the ASD consists of nilotinib and one or morepolymers. In some embodiments, the ASD consists essentially of nilotiniband one or more polymers. In other embodiments, the ASDs of the presentdisclosure may additionally comprise one or more other pharmaceuticallyacceptable functional components, such as one or more antioxidants,wetting agents, or solubilizers.

As used herein, the phrase “pharmaceutically acceptable” means that thecomponent does not initiate a pharmacological response or an adversereaction when introduced to a relevant biological system. By way ofnon-limiting example only, a substance found in the U.S. Food & DrugAdministration's “Generally Recognized as Safe” (“GRAS”) list, or asubstance used in accordance with guidelines in its Inactive IngredientDatabase, would be considered pharmaceutically acceptable. Similarly, asubstance in a corresponding database or list maintained by a parallelregulatory body, such as the European Medicines Agency, would beconsidered pharmaceutically acceptable. In general, in thepharmaceutical compositions of the disclosure, it is desirable to employonly components that do not cause an unacceptable level of physical orchemical instability in the resulting composition.

Examples of antioxidants that that may be used in the ASDs of thepresent disclosure include, but are not limited to, acetylcysteine,ascorbyl palmitate, butylated hydroxyanisole (“BHA”), butylatedhydroxytoluene (“BHT”), monothioglycerol, potassium nitrate, sodiumascorbate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodiumbisulfite, vitamin E or a derivative thereof, propyl gallate,ethylenediaminetetraacetic acid (“EDTA”) (e.g., disodium edetate),diethylenetriaminepentaacetic acid (“DTPA”), bismuth sodiumtriglycollamate, or a combination thereof. Antioxidants may alsocomprise amino acids such as methionine, histidine, cysteine and thosecarrying a charged side chain, such as arginine, lysine, aspartic acid,and glutamic acid. Any stereoisomer (e.g., l-, d-, or a combinationthereof) of any particular amino acid (e.g., methionine, histidine,arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine andcombinations thereof) or combinations of these stereoisomers, may bepresent so long as the amino acid is present either in its free baseform or its salt form.

In some embodiments, the one or more antioxidants comprise BHT. In someembodiments, the one or more antioxidants consist of BHT.

The one or more antioxidants may be present in the ASD in an amount of0.001% to 2.0%, or 0.01% to 1.5%, or 0.05% to 1.0%, or 0.1% to 0.5%, or0.3% to 0.4%, by weight. Examples of the amount of the one or moreantioxidants in the ASD include 0.001%, or 0.003%, or 0.005%, or 0.008%,or 0.01%, or 0.015%, or 0.02%, or 0.025%, or 0.03%, or 0.035%, or 0.04%,or 0.05%, or 0.075%, or 0.1%, or 0.2%, or 0.3%, or 0.4%, or 0.5%, or0.75%, or 1.0%, or 1.5%, or 2.0%, by weight.

A variety of pharmaceutically acceptable wetting agents may be included.As a non-limiting example of a wetting agent, poloxamers, such aspoloxamer 407 (e.g., PLURONIC F-127) or poloxamer 188 (e.g., PLURONICF-68), may be suitable. Other known pharmaceutically acceptable wettingagents may be suitably employed. A wetting agent may be included in theASD in an amount of 0.5% to 10%, or 1% to 8%, or 2% to 6%, by weight.

A variety of pharmaceutically acceptable solubilizers may be included.Non-limiting examples of suitable solubilizers include vitamin E TPGS(D-α-tocopherol polyethylene glycol succinate), SLS (sodium laurylsulfate), and docusate sodium. Other known pharmaceutically acceptablesolubilizers may be suitably employed. A solubilizer may be included inthe ASD in an amount of 0.1% to 10%, or 0.25% to 5%, or 0.5 to 1%, byweight.

In some embodiments, the ASD comprises nilotinib, one or more polymers,and one or more antioxidants. In certain embodiments, the ASD consistsessentially of nilotinib, one or more polymers, and one or moreantioxidants. In certain embodiments, the ASD consists of nilotinib, oneor more polymers, and one or more antioxidants.

In some embodiments, the ASD comprises nilotinib, HPMC-AS, and BHT. Incertain embodiments, the ASD consists essentially of nilotinib, HPMC-AS,and BHT. In certain embodiments, the ASD consists of nilotinib, HPMC-AS,and BHT. In some embodiments, the ASD comprises nilotinib, mid-gradeHPMC-AS, and BHT. In certain embodiments, the ASD consists essentiallyof nilotinib, mid-grade HPMC-AS, and BHT. In certain embodiments, theASD consists of nilotinib, mid-grade HPMC-AS, and BHT.

In particular embodiments, the ASD consists essentially of nilotinib andHPMC-AS at a ratio of 50:50, and BHT in at a level of 0.1-0.5% by weightof the ASD. In particular embodiments, the ASD consists of nilotinib andHPMC-AS at a ratio of 50:50, and BHT in at a level of 0.1-0.5% by weightof the ASD.

In some embodiments, the ASD comprises nilotinib, methacrylic acid/ethylacrylate copolymer (such as EUDRAGIT L100-55), and BHT. In certainembodiments, the ASD consists essentially of nilotinib, a methacrylicacid/ethyl acrylate copolymer, and BHT. In certain embodiments, the ASDconsists of nilotinib, methacrylic acid/ethyl acrylate copolymer, andBHT.

In particular embodiments, the ASD consists essentially of nilotinib,methacrylic acid/ethyl acrylate copolymer (such as EUDRAGIT L100-55),and BHT at a level of 0.1-0.5%, by weight of the ASD. In particularembodiments, the ASD consists of nilotinib, methacrylic acid/ethylacrylate copolymer, and BHT at a level of 0.1-0.5%, by weight of theASD.

The drug load of nilotinib in the ASDs of the present disclosure maysuitably range from 20% to 95%, or 25% to 90%, or 30% to 80%, or 35% to70%, or 40% to 60%, or 45% to 55%. As used herein, the phrase “drugload” refers to the ratio (by weight %) of nilotinib in an ASD to thetotal solids weight of the ASD. By way of example, for an ASD consistingof nilotinib and a polymer, a 1:1 w/w ratio of nilotinib:polymer wouldrepresent a 50% drug load; a 1:2 w/w ratio of nilotinib: polymer wouldrepresent a 33.3% drug load, etc. Examples of the drug load of nilotinibin specific embodiments of the ASDs include 40%, or 45%, or 50%, or 55%,or 60%, or 65%, or 70%, or 75%, or 80%, or 85%, or 90%.

The nilotinib ASDs may be in the form of particles. In some embodiments,the particles do not comprise a surfactant. In other embodiments, theparticles do not comprise a wetting agent. In other embodiments, theparticles do not comprise a solubilizer. In other embodiments, theparticles comprise neither a surfactant nor a solubilizer. In otherembodiments, the particles are free from surfactants, wetting agents,and solubilizers. In other embodiments, the particles consist of polymerand nilotinib, and no additional functional components.

Particles of the ASDs of the disclosure may generally comprise theshapes of spheroids. As measured by conventional light scattering orlaser diffraction techniques, the diameter of the particles maygenerally range from about 0.05 μm to about 100 μm. The median diameter(D50 or Dv0.5) of the particle distribution may be in the range from 0.2μm to 60 μm, or 0.5 μm to 50 μm, or 0.5 μm to 40 μm.

In some embodiments, the median diameter of the particle distributionmay be from 1 μm to 40 μm, or from 2 μm to 25 μm, or from 3 μm to 20 μm.By way of example only, such particle size distributions can be achievedby known methods of spray drying.

In some embodiments, the median diameter of the particle distributionmay be from 0.1 μm to 10 μm, or from 0.2 μm to 5 μm, or from 0.5 μm to 2μm. By way of example only, such particle size distributions can beachieved by methods involving electrospraying, discussed further below.

The nilotinib ASDs of the present disclosure may demonstrate a desirablelevel of physical and/or chemical stability, which can be assessed bydifferent measures. Stability is generally assessed using conventionalanalytical techniques commonly known in pharmaceutical sciences.

Physical and chemical stability is generally assessed after storageunder controlled, elevated environmental conditions (“acceleratedconditions”) over a specified period of time. The storage conditions maybe one or more of 25° C./60% relative humidity (“RH”), or 25°C./protected, or 30° C./65% RH, or 40° C./75% RH, or 40° C./protected,or 50° C./80% RH. (As used herein in this context, “protected” meanssamples were sealed in foil pouches and placed in a controlled chamberfor the storage period). The period of time may be one or more of 1week, or 2 weeks, or 4 weeks or 1 month, or 2 months, or 3 months, or 4months, or 6 months, or 9 months, or 12 months, or 15 months, or 18months, or 21 months, or 24 months, or any period of time therebetween.

The nilotinib ASDs may demonstrate stability by having a particularassay value or a particular level of total related substances (e.g.,impurities), as measured by high performance liquid chromatography(“HPLC”), after storage under accelerated conditions over a specifiedperiod of time. The assay value is generally presented as a percentageof the quantity of analyte (e.g., nilotinib) detected relative to thequantity expected, where 100% is a favorable result and large deviationsfrom 100% are unfavorable. The total related substances is generallypresented as a percentage relative to the total quantity of substancesdetected (i.e., analyte plus impurities), where near 0% is favorable andlarge deviations from 0% are unfavorable.

In some embodiments, the nilotinib ASDs may have an assay as measured byHPLC of at least 90%, or at least 93%, or at least 95%, or at least 97%,or at least 98%, or at least 99%. In some embodiments, the nilotinibASDs may have a level of total related substances as measured by HPLC ofno more than 3%, no more than 2.5%, no more than 2%, or no more than1.5%, or no more than 1%, or no more than 0.9%, or no more than 0.8%, orno more than 0.7%, or no more than 0.6%, or no more than 0.5%.

In some embodiments, the nilotinib ASDs may have an assay as measured byHPLC of at least 90%, or at least 93%, or at least 95%, or at least 97%,or at least 98%, after storage at 25° C./60% RH for 1 month, or 2months, or 3 months, or 6 months, or 9 months, or 12 months; or afterstorage at 40° C./75% RH for 1 month, or 2 months, or 3 months, or 6months.

In some embodiments, the nilotinib ASDs may have a level of totalrelated substances as measured by HPLC of no more than 2%, or no morethan 1.5%, or no more than 1%, or no more than 0.9%, or no more than0.8%, or no more than 0.7%, or no more than 0.6%, or no more than 0.5%,after storage at 25° C./60% RH for 1 month, or 2 months, or 3 months, or6 months, or 9 months, or 12 months; or after storage at 40° C./75% RHfor 1 month, or 2 months, or 3 months, or 6 months.

Stability may also be assessed by evaluating changes in glass transitiontemperature of the nilotinib ASDs under different storage conditionsover time. Glass transition temperature can be evaluated by modulatedDSC (“mDSC”) using conventional techniques. In some embodiments, the ASDis characterized by a single glass transition, the transition observedin the range from 25° C. to 200° C., or more suitably from 40° C. to150° C., by DSC or mDSC. In other embodiments, the ASD is characterizedby more than one transition, the transitions observed in the range from25° C. to 200° C., or more suitably from 40° C. to 150° C., by DSC ormDSC.

In some embodiments, the glass transition temperature as measured bymDSC does not change by more than 5° C., or more than 4° C., or no morethan 3° C., or no more than 2° C., after storage at 25° C./60% RH for 1month, or 2 months, or 3 months, or 6 months, or 9 months, or 12 months.In some embodiments, the glass transition temperature as measured bymDSC does not change by more than 6° C., or more than 5° C., or morethan 4° C., or more than 3° C., or more than 2° C., or no more than 1°C., after storage at 40° C./75% RH for 1 month, or 2 months, or 3months, or 6 months.

Further, stability may be assessed by evaluating changes incrystallinity of the nilotinib ASDs under different storage conditionsover time, such as by suitable conventional x-ray diffraction (“XRD”)techniques (also known in the art as powder XRD or PXRD). In thepractice of the present disclosure, it is preferred (but not required)that the nilotinib ASDs remain amorphous or essentially amorphous. Insome embodiments, “amorphous” may be defined as having no detectablecrystallinity as determined using methods known in the art, forinstance, by using XRD. An example of using XRD to determine amorphicityis provided in Example 1.

In some embodiments, “amorphous” may be defined as having a percentcrystallinity no more than 5%, or no more than 4%, or no more than 3%,or no more than 2%, or no more than 1%, as determined by XRD. In someembodiments, “essentially amorphous” may be defined as having a percentcrystallinity of no more than 8%, or no more than 7%, or no more than6%, as measured by XRD.

The ASDs of the disclosure may be amorphous or essentially amorphouswhen analyzed promptly after preparation, i.e., at t=0. For thesepurposes, the phrase “promptly after preparation” means that the ASD isanalyzed within a few days after preparation, and stored under protectedconditions at ambient temperature and humidity after preparation andbefore analysis.

The ASDs may be amorphous or essentially amorphous after storage undervarious storage conditions (e.g., 25° C./60% RH, 25° C./protected, 40°C./75% RH, 40° C./protected, 50° C./80% RH, etc.) for a period of atleast 1 week, or a period of at least 2 weeks, or a period of at least 3weeks, or a period of at least 4 weeks or 1 month, or a period of atleast 2 months, or a period of at least 3 months, or a period of atleast 4 months, or a period of at least 5 months, or a period of atleast 6 months, or a period of at least 9 months, or a period of atleast 12 months or 1 year. In some embodiments, the ASDs of thedisclosure may be amorphous or essentially amorphous under conditions ofhigh temperature and humidity (e.g., 40° C./75% RH) for a period of atleast 1 month, or a period of at least 2 months, or a period of at least3 months, or a period of at least 6 months.

The nilotinib ASDs of the present disclosure can be characterized forwater content, such as by using standard Karl Fischer coulometrictitration methods. In some embodiments, the nilotinib ASDs may comprisea water content as assessed by Karl Fischer coulometric titration methodof no more than 3%, or no more than 2.5%, or no more than 2%, or no morethan 1.5%, or no more than 1%.

In some embodiments, the nilotinib ASDs may comprise a water content asassessed by Karl Fischer coulometric titration method of no more than5%, or no more than 4.5%, or no more than 4%, or no more than 3.5%, orno more than 3%, or no more than 2.5%, or no more than 2%, after storageat 25° C./60% RH for 1 month, or 2 months, or 3 months, or 6 months, or9 months, or 12 months. In some embodiments, the nilotinib ASDs maycomprise a water content as assessed by Karl Fischer coulometrictitration method of no more than 8%, or no more than 7%, or no more than6%, or no more than 5%, or no more than 4.5%, or no more than 4%, or nomore than 3.5%, or no more than 3%, or no more than 2.5%, or no morethan 2%, after storage at 40° C./75% RH for 1 month, or 2 months, or 3months, or 6 months, or 9 months, or 12 months.

Methods of Making Amorphous Solid Dispersions

The nilotinib ASDs of the present disclosure may be prepared by avariety of methods known in the art. Suitable methods generally includemixing, dissolving, or compounding the nilotinib and the one or morepolymers and, if present, one or more other functional components (suchas antioxidants, wetting agents, or solubilizers) to integrate thevarious components. In the practice of the various methods, thenilotinib may be introduced as nilotinib free base, or as a salt ofnilotinib, or as a solvate or hydrate of nilotinib.

Suitable methods are generally known in the art, and include kneading,co-grinding, melting, melt extrusion, melt agglomeration, dropping, andthe like. After the integration step, the material can be furtherprocessed by drying, grinding or crushing, sieving, etc.

In the practice of certain methods, nilotinib and the one or morepolymers (and other functional components, if present) may be mixed ordissolved with one or more solvents to provide a liquid feedstock.Suitable solvents may include, but are not limited to, water; analcohol, such as ethanol, methanol, propanol or isopropanol; an ether,such as ethyl ether or methyl tert-butyl ether; acetonitrile;tetrahydrofuran or methyl tetrahydrofuran; an acetate, such as methylacetate or ethyl acetate; a ketone, such as acetone or 2-butanone(methyl ethyl ketone, or “MEK”); toluene; ethyl formate; 1,4-dioxane;dimethylsulfoxide; N-methyl 2-pyrrolidone; volatile halogenated solventssuch as chloroform or dichloromethane; and combinations thereof. Themixing or dissolving of these contents may be by methods known in theart. For example, the contents may be mixed by manually mixing, or maybe mixed with a mixing device continuously, periodically, or acombination thereof. Examples of mixing devices may include, but are notlimited to, a magnetic stirrer, shaker, a paddle mixer, homogenizer, andany combination thereof.

After the nilotinib and the one or more polymers (and other functionalcomponents, if present) are mixed, the liquid feedstock may be formedinto an amorphous solid dispersion, such as through solvent evaporation,lyophilization, precipitation or co-precipitation, spray drying,electrospraying, supercritical fluid extraction, etc. These methods areknown and commonly understood in the art.

In certain embodiments of the disclosure, the liquid feedstock may beformed into an amorphous solid dispersion through electrospraying.Electrospraying, which has also been referred to as electrohydrodynamicatomization, has been used to produce amorphous solid dispersionparticles on a micron or sub-micron scale from suitable liquidfeedstocks.

In one suitable electrospraying technique, the liquid feedstock isemitted through one or more nozzles toward a substrate in the presenceof an electric potential applied between the nozzles and the substrate.The liquid feedstock experiences electrical shear stress due to theapplied potential. When the shear stress overcomes the surface tensionof the liquid feedstock, droplets are emitted from the tips of thenozzles.

Conditions are controlled such that a cone jet of droplets is emitted atthe tip of the nozzles. The droplets take on an electric charge andrepel one another, which prevents their coagulation and promotesself-dispersion. The charged droplets accelerate toward the substrate asa result of the applied electric field.

During the short flight path, the solvent “flashes off” from the chargeddroplets. This fast evaporation creates a situation in which the chargeddroplets shrink in size but increase in charge density. At a criticallimit, the droplets will break up into yet smaller droplets. Anessentially monodisperse population of fine droplets is ultimatelyproduced. The size of the droplets can range from sub-micron to severalmicrons.

The essentially complete evaporation of solvent from the chargeddroplets results in the formation of relatively uniform particles of thenon-volatile components from the liquid feedstock. The evaporationprocess occurs at a time-scale that does not permit crystallization ofthe non-volatile components. Additionally, evaporative coolingassociated with the extremely rapid solvent evaporation contributes aquenching effect to preserve the particles in an amorphous state.Furthermore, electrospray conditions can be selected and the system canbe configured such that the amorphous particles contain little residualsolvent.

In some embodiments of the disclosure, the liquid feedstock may beformed into an ASD using electrospray techniques and/or devices.Suitable methods and equipment are described, for example, in U.S. Pat.Nos. 6,746,869, 6,764,720, 7,279,322, 7,498,063, 7,951,428, 7,972,661,8,992,603, 9,040,816, 9,050,611, 9,108,217, 9,642,694, 10,562,048, U.S.Patent Publication No. 2014-0158787, U.S. Patent Publication No.2015-0190253, U.S. Patent Publication No. 2016-0038968, U.S. PatentPublication No. 2016-0175881, U.S. Patent Publication No. 2016-0235677,U.S. Patent Publication No. 2019-0193109, and U.S. Patent PublicationNo. 2020-0179963.

As noted above, by using an electrospray technique, the median diameterof the nilotinib ASD particle distribution may be from 0.1 μm to 10 μm,or from 0.2 μm to 5 μm, or from 0.5 μm to 2 μm. It should further benoted that the nilotinib in the amorphous particles is generally notconsidered to be solvated. Even where the liquid feedstock may have beenprepared using a solvate or hydrate form of nilotinib, the solvate orhydrate is understood to flash off with the other solvents, and theelectrosprayed amorphous particles comprise non-solvated nilotinib (suchas anhydrous nilotinib).

In some embodiments, the electrospray technique may be performed at roomtemperature. In certain embodiments, no heated air is used. In otherembodiments, the liquid feedstock is held at an elevated temperatureduring the electrospray process.

In some embodiments, the electrospray technique may be performed usingone or more capillary nozzles. In certain embodiments, the electrospraytechnique does not use pneumatic nozzles such as nozzles that rely onkinetic energy; pressure nozzles; rotary nozzles; or nozzles that relyon centrifugal energy; or ultrasonic nozzles such as nozzles that relyon acoustic energy. In some embodiments, the electrospray techniquegenerates a yield of over 85%, or over 90%, or over 95%, or over 98%.

In other embodiments, the liquid feedstock may be formed into an ASDthrough spray drying. Generally speaking, spray drying involves theatomization of a liquid feedstock into very small droplets within a hotdrying gas. The feedstock is pumped or otherwise propelled through anozzle or other atomizing apparatus to form droplets within a dryingchamber. Within the drying chamber, the droplets are exposed to anenvironment of the heated drying gas (usually flowing air or nitrogen),leading to flash drying of the droplets (by evaporative removal ofsolvent) and resultant production of solid particles. The driedparticles are collected, generally at an output port in the dryingchamber.

Various apparatus and methods of spray drying may be employed to form anASD of the disclosure. In the practice of the present disclosure, themedian diameter of the ASD particle distribution achieved by spraydrying may be from 1 μm to 40 μm, or from 2 μm to 25 μm, or from 3 μm to20 μm.

In some embodiments, the process for forming an ASD does not require asecondary drying step, i.e., a drying step that occurs after theparticles are produced. In other embodiments, a secondary drying step isemployed to further remove most or all of the residual solvents. Thesecondary drying step can be done under suitable conditions that allowfor the removal of solvent but do not result in the recrystallization ofthe nilotinib. For example, a secondary drying step can be done below aglass transition temperature. A secondary drying step can also be doneat reduced pressure. A combination of elevated temperature and reducedpressure can also be used for a secondary drying step.

Pharmaceutical Compositions

An aspect of the present disclosure relates to pharmaceuticalcompositions comprising nilotinib ASD. The pharmaceutical compositionsof the present disclosure may be in a dosage form appropriate for oraladministration. In some embodiments, the pharmaceutical compositions maybe in the form of granules, or may be prepared as granules as anintermediate step to forming another oral dosage form, such as tablets,sprinkles, or pellets. In some embodiments, the pharmaceuticalcompositions may be in a solid dosage form for oral administration, suchas a capsule, tablet, sprinkle, or pellet. The pharmaceuticalcomposition may also be in the form of an aqueous or nonaqueoussuspension or solution. Such compositions may be prepared using knownexcipients and known preparation methods.

The compositions may comprise a nilotinib ASD of the present disclosureand one or more pharmaceutically acceptable excipients, such as one ormore solubilizers, one or more buffering agent(s), one or morepH-adjusting agents, one or more surfactants, one or more antioxidants,and/or one or more carriers. Pharmaceutical compositions in the form ofsolid oral dosage forms may also comprise one or more filling agents,one or more binding agents, one or more lubricants, one or moredisintegrants, and/or other conventional excipients such as one or moreglidants, for example.

Information regarding suitable excipients, and commercial sourcestherefor, can be found in Sheskey P J (ed.) Handbook of PharmaceuticalExcipients, 9th Ed. London: Pharmaceutical Press; 2020 (ISBN0857113755); alternatively, the most up-to-date edition of the sametitle may be consulted.

The pharmaceutical compositions of the present disclosure may beprepared using methods known in the art. For example, the nilotinib ASDand the one or more pharmaceutically acceptable additives may be mixedby simple mixing, or may be mixed with a mixing device continuously,periodically, or a combination thereof. Examples of mixing devices mayinclude, but are not limited to, a magnetic stirrer, shaker, a paddlemixer, homogenizer, and any combination thereof.

Solubilizers that may be used in the pharmaceutical compositions of thepresent disclosure include, but are not limited to, polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol copolymer (SOLUPLUS),d-α-tocopherol acid polyethylene glycol (PEG) 1000 succinate (TPGS),PEG-40 hydrogenated castor oil (CREMOPHOR RH40), PEG-35 castor oil(CREMOPHOR EL), PEG-40 stearate (MYRJ 540), hard fat (such as GELUCIRE33/01), polyoxylglycerides (such as GELUCIRE 44/14), stearoylpolyoxylglycerides (such as GELUCIRE 50/13), PEG-8 caprylic/capricglycerides (such as LABRASOL) and poloxamers (such as PLURONIC,KOLLIPHOR).

In some embodiments, the pharmaceutical compositions may comprise anilotinib ASD and one or more pharmaceutically acceptable excipients,with the proviso that the pharmaceutically acceptable excipients do notcomprise polyvinyl caprolactam-polyvinyl acetate-polyethylene glycolgraft co-polymer (e.g., SOLUPLUS).

Buffering agents that that may be used in the pharmaceuticalcompositions of the present disclosure include, but are not limited to,triethylamine, meglumine, diethanolamine, ammonium acetate, arginine,lysine, histidine, a phosphate buffer (e.g., sodium phosphate tribasic,sodium phosphate dibasic, sodium phosphate monobasic, or o-phosphoricacid), sodium bicarbonate, a Britton-Robinson buffer, a Tris buffer(containing Tris(hydroxymethyl)-aminomethane), a HEPES buffer(containing N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid),acetate, a citrate buffer (e.g., citric acid, citric acid anhydrous,citrate monobasic, citrate dibasic, citrate tribasic, citrate salt),ascorbate, glycine, glutamate, lactate, malate, formate, sulfate, andmixtures thereof.

Further, pH-adjusting agents that that may be used in the pharmaceuticalcompositions of the present disclosure include pharmaceuticallyacceptable acids or bases. For example, acids may include, but are notlimited to, one or more inorganic mineral acids such as hydrochloric,hydrobromic, sulfuric, phosphoric, nitric, and the like; or one or moreorganic acids such as acetic, succinic, tartaric, ascorbic, citric,glutamic, benzoic, methanesulfonic, ethanesulfonic, trifluoroacetic, andthe like. The bases may be one or more inorganic bases or organic bases,including, but not limited to, alkaline carbonate, alkaline bicarbonate,alkaline earth metal carbonate, alkaline hydroxide, alkaline earth metalhydroxide, or amine. For example, the inorganic or organic base may bean alkaline hydroxide such as lithium hydroxide, potassium hydroxide,cesium hydroxide, sodium hydroxide, or the like; an alkaline carbonatesuch as calcium carbonate, sodium carbonate, or the like; or an alkalinebicarbonate such as sodium bicarbonate, or the like; the organic basemay also be sodium acetate.

Surfactants that that may be used in the pharmaceutical compositions ofthe present disclosure may include, but are not limited to, sodiumlauryl sulfate, docusate sodium, dioctyl sodium sulfosuccinate, dioctylsodium sulfonate, benzalkonium chloride, benzethonium chloride,lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenatedcastor oil (e.g., polyoxyethylene hydrogenated castor oil 10, 50, or60), glycerol monostearate, polysorbate (e.g., polysorbate 40, 60, 65,or 80), sucrose fatty acid ester, methyl cellulose, polyalcohols andethoxylated polyalcohols, thiols (e.g., mercaptans) and derivatives,poloxamers, polyethylene glycol-fatty acid esters (e.g., KOLLIPHORRH40,KOLLIPHOR EL), lecithins, and mixtures thereof.

Antioxidants that that may be used in the pharmaceutical compositions ofthe present disclosure include, but are not limited to, acetylcysteine,ascorbyl palmitate, BHA, BHT, monothioglycerol, potassium nitrate,sodium ascorbate, sodium formaldehyde sulfoxylate, sodium metabisulfite,sodium bisulfate, vitamin E or a derivative thereof, propyl gallate,EDTA (e.g., disodium edetate), DTPA, bismuth sodium triglycollamate, ora combination thereof. Antioxidants may also comprise amino acids suchas methionine, histidine, cysteine and those carrying a charged sidechain, such as arginine, lysine, aspartic acid, and glutamic acid. Anystereoisomer (e.g., l-, d-, or a combination thereof) of any particularamino acid (e.g., methionine, histidine, arginine, lysine, isoleucine,aspartic acid, tryptophan, threonine and combinations thereof) orcombinations of these stereoisomers, may be present so long as the aminoacid is present either in its free base form or its salt form.

Carriers that that may be used in the pharmaceutical compositions of thepresent disclosure include, but are not limited to, water, saltsolutions (e.g., Ringer's solution and the like), alcohols, oils,gelatins, and carbohydrates such as lactose, amylose or starch, fattyacid esters, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidine, and mixtures or solutions includingany of the foregoing. The carrier may be used in combination with abuffering agent.

In some embodiments, the composition of the present disclosure maycomprise a carrier at a pH from 5 to 9, or from 6 to 8. In certainembodiments, the composition may comprise a carrier having a neutral pH.In certain embodiments, the pH of the carrier may be at or nearphysiological pH.

In some embodiments, the pharmaceutical compositions of the presentdisclosure may include other suitable pharmaceutical additives suchtonicity-adjusting agents, preservatives, emulsifiers, sweeteners,flavoring agents, suspending agents, thickening agents, colors,viscosity regulators, stabilizers, and osmo-regulators.

Pharmaceutical compositions in solid form may comprise one or morefilling agents, one or more binding agents, one or more lubricants, oneor more disintegrants, and/or other conventional excipients such as oneor more glidants, for example.

Suitable filling agents include acacia, calcium carbonate, calciumsulfate, calcium sulfate dihydrate, compressible sugar, dibasic calciumphosphate anhydrous (e.g., FUJICALIN, EMCOMPRESS), dibasic calciumphosphate dihydrate, tribasic calcium phosphate, monobasic sodiumphosphate, dibasic sodium phosphate, lactose monohydrate, lactoseanhydrous, magnesium oxide, magnesium carbonate, silicon dioxide,magnesium aluminum silicate, maltodextrin, mannitol, methyl cellulose,microcrystalline cellulose (e.g., AVICEL PH-101, AVICEL PH-102),powdered cellulose, starches, sorbitol, dextrose, dextrates, dextrin,sucrose, xylitol and mixtures thereof.

Suitable binding agents include various celluloses and cross-linkedpolyvinylpyrrolidone, microcrystalline cellulose (e.g., AVICEL PH-101,AVICEL PH-102, AVICEL PH-105), or silicified microcrystalline cellulose(e.g., PROSOLV SMCC), for example.

One or more lubricants may be included to reduce friction with andadherence to processing equipment during processing. Examples ofsuitable lubricants include, but are not limited to, magnesium stearate,calcium stearate, zinc stearate, stearic acid, stearyl alcohol, glycerylmonostearate, sodium stearyl fumarate, talc, glyceryl behenate, sodiumbenzoate, sodium lauryl sulfate, and the like. When included, the one ormore lubricant is generally present in the range of 0.1% to 5%, byweight of the pharmaceutical composition. In some embodiments, the oneor more lubricant is generally present in the range of 0.25% to 2%, byweight of the pharmaceutical composition. In certain embodiments, thelubricant is magnesium stearate.

Suitable disintegrants in the practice of the disclosure includenatural, modified or pre-gelatinized starch, sodium starch glycolate,sodium carboxymethyl cellulose, calcium carboxymethyl cellulose,croscarmellose sodium, crospovidone, polyvinylpolypyrrolidone, andmixtures thereof.

Glidants are employed to improve flow properties of a powder or granulemixture prior to further processing (such as tablet compression, forexample). Suitable glidants that may be employed in the compositions ofthe present disclosure include, but are not limited to, colloidal silica(e.g., hydrophobic colloidal silica, such as AEROSIL), silica gel,precipitated silica, and the like. When included, the one or moreglidant is generally present in the range of 0.1% to 5%, by weight ofthe pharmaceutical composition. In some embodiments, the one or moreglidant is generally present in the range of 0.25% to 2%, by weight ofthe pharmaceutical composition.

In some cases, a single excipient may provide more than one function.For example, microcrystalline cellulose (when present) can function asboth a filling agent and a binding agent. Alternatively, suchmulti-functional excipients can be used in combination with otherfunctional excipients. (For example, microcrystalline cellulose may beused with other filling agents and/or other binding agents.)

In some embodiments, the pharmaceutical compositions may be in the formof granules, or may be prepared as granules as an intermediate step toforming another oral dosage form, such as a tablet or pellet, or as afill for a capsule. In some embodiments, the granules may comprise oneof more of the pharmaceutically acceptable excipients described above.In certain embodiments, the granules may comprise the ASD in an amountof 50% to 70% by weight of the granule; one or more filling agents in anamount of 20% to 40% by weight of the granule; one or more disintegrantsin an amount of 1% to 15% by weight of the granule; and one or morelubricants in an amount of 0.2% to 5% by weight of the granule. Inparticular embodiments, the granule may comprise the components as setforth in Table 1.

TABLE 1 Components of an exemplary granule formulation in accordancewith particular embodiments of the disclosure. Component % By Weight ofthe Granule Nilotinib ASD 50-70% Mannitol 20-40% Croscarmellose Sodium 2-10% Hydrophobic Colloidal Silica 0.2-5% (optional) Magnesium stearate0.2-5% (optional)

In some embodiments, the pharmaceutical compositions are in the form ofa tablet. In certain embodiments, the tablet may comprise the ASD in anamount of 20% to 40% by weight of the tablet; one or more filling agents(such a mannitol and/or microcrystalline cellulose) in an amount of 40%to 70% by weight of the tablet; one or more disintegrants (such ascroscarmellose sodium) in an amount of 5% to 15% by weight of thetablet; one or more lubricants and/or glidants (such as hydrophobiccolloidal silica and/or magnesium stearate) in an amount of 0.5% to 5%by weight of the tablet; one or more binding agents (such ascrospovidone) in an amount of 1% to 10% by weight of the tablet.

Pharmaceutical compositions of the disclosure in the form of a tabletmay be prepared using methods known in the art. For example, thenilotinib ASD and the one or more pharmaceutically acceptable additivesmay be blended to provide a tableting blend by hand or bag blending, orusing a suitable device. Examples of suitable blending devices mayinclude, but are not limited to, a tumble blender, v-blender, acousticblender, paddle mixer, screw mixer, and the like.

Suitable tableting blends may then be compressed into tablets weighingfrom 100 to 1000 mg using, for example, a manual tablet press or aconventional mechanical tablet press. Compression force is selected toachieve desired mechanical properties of the tablet without compromisingperformance.

In some embodiments, it may be desirable to form granules as anintermediate step to forming a tableting blend. Granules typically haveimproved flow, handling, blending, and compression properties relativeto ungranulated materials. The granules may be prepared from the ASDparticles by processes known in the art, including wet granulation anddry granulation. In some embodiments, a granule blend is formed bydry-blending granule components, and then the granule blend is densifiedusing a roller compactor which typically forms ribbons of material. Theribbons are then reduced in size by milling to form granules.

Wet granulation techniques may also be employed to form granules,provided the solvents and process selected do not alter the propertiesof the ASD. Improved wetting, disintegrating, dispersing and dissolutionproperties may be obtained by the inclusion of suitable excipients, asdescribed above.

The granule blend (and accordingly the resulting granules) can includesome or all of the components of the tablet. In some embodiments, thegranules may comprise one of more of the pharmaceutically acceptableexcipients described above. After granulation, the granules can beincluded into a tableting blend and compressed into tablets, asdescribed above.

The pharmaceutical compositions of the present disclosure maydemonstrate a desirable level of physical and/or chemical stability oversome suitable period of time, and optionally under acceleratedconditions. The stability of the pharmaceutical compositions can beassessed by different measures. For instance, the pharmaceuticalcompositions may demonstrate chemical stability by having a particularassay value or a particular level of total related substances (e.g.,impurities), measured after storage under accelerated conditions over aspecified period of time. In some embodiments, the pharmaceuticalcompositions may be amorphous as assessed using XRD (i.e., nocrystalline character detected) after storage under the specifiedconditions.

In some embodiments, the pharmaceutical compositions may besubstantially amorphous as assessed using XRD, after storage under thespecified conditions. The storage conditions may be one or more of 25°C./60% RH, or 30° C./65% RH, or 40° C./75% RH. The period of time may beone or more of 1 week, or 2 weeks, or 1 month, or 2 months, or 3 months,or 4 months, or 6 months, or 9 months, or 12 months, or 15 months, or 18months, or 21 months, or 24 months, or any period of time therebetween.

In some embodiments, pharmaceutical compositions of the presentdisclosure are “gastric acid-insensitive compositions,” as furtherdescribed below. In some embodiments, pharmaceutical compositions of thepresent disclosure are “food-insensitive compositions,” as furtherdescribed below. In some embodiments, pharmaceutical compositions of thepresent disclosure are “improved variability compositions,” as furtherdescribed below.

Treatment of Proliferative Disorders

Aspects of the present disclosure relate to uses of the nilotinib ASDsof the present disclosure, or pharmaceutical compositions comprising theASDs. In the practice of such embodiments of the present disclosure, thenilotinib ASDs or pharmaceutical compositions may be suitablyadministered to subjects or to patients.

In some embodiments, the nilotinib ASD or pharmaceutical composition isadministered to a subject. The subject in the methods of the presentdisclosure may be a mammal, which includes, but is not limited to, ahuman, monkey, cow, hog, sheep, horse, dog, cat, rabbit, rat, and mouse.In certain embodiments, the subject is a human. As used herein, thephrase “healthy human subject” means a human that is generally healthyand is not being treated for the disease or condition for which thepharmaceutically active component (e.g., nilotinib) is generally usedfor therapy. Selection of suitable healthy human subjects forpharmacokinetic assessment is within the expertise of one skilled in theart of clinical trial design.

In other embodiments, the pharmaceutical composition is administered toa human patient. The human patient may be adult or of a pediatric age,e.g., younger than 17 years old. In certain embodiments, the humanpatient is 1 year of age or older. As used herein, a “patient” is asubject, particularly a human, who is being treated for a disease orcondition for which the pharmaceutically active component (e.g.,nilotinib) is generally used for therapy.

An aspect of the present disclosure relates to the use of the nilotinibASDs of the present disclosure or pharmaceutical compositions of thepresent disclosure to treat a proliferative disorder. Some embodimentsrelate to a method of treating a proliferative disorder, the methodcomprising administering a nilotinib ASD of the present disclosure, or apharmaceutical composition of the present disclosure, to a patient inneed thereof. Some embodiments relate to a use of a nilotinib ASD or apharmaceutical composition of the present disclosure for treating aproliferative disorder in a patient in need thereof, the use comprisingadministering the nilotinib ASD or pharmaceutical composition to thepatient. Some embodiments relate to a nilotinib ASD or a pharmaceuticalcomposition of the present disclosure for use in treating aproliferative disorder in a patient in need thereof, the use comprisingadministering the nilotinib ASD or the pharmaceutical composition to thepatient. Some embodiments relate to a use of a nilotinib ASD orpharmaceutical composition of the present disclosure in the manufactureof a medicament for treating a proliferative disorder.

In one aspect, the present disclosure relates to a method of treating aproliferative disorder in a patient in need thereof, the methodcomprising administering a therapeutically effective amount of an ASD ofthe present disclosure or of a pharmaceutical composition of the presentdisclosure to the patient.

The proliferative disorder may be cancer. Examples of such proliferativedisorders may include, but are not limited to, leukemias such as acutelymphocytic leukemia (or acute lymphoblastic leukemia), acute myeloidleukemia (or acute myelogenous leukemia), chronic lymphocytic leukemia(or chronic lymphoblastic leukemia), chronic myeloid leukemia (orchronic myelogenous leukemia); age-related macular degeneration anddiabetic retinopathy, anal and oral cancers, angiosarcoma, basal cellcarcinoma and squamous cell carcinoma, bladder cancer, brain cancer,glioma, breast cancer, cancer of the central nervous system, cervical,cervix uteri cancer, choriocarcinoma, colon cancer, gastrointestinalstromal tumor, corpus uteri cancer, esophageal cancer, Ewing's Sarcoma,eye or ocular cancer, head and neck cancer, hemangioendothelioma,hemangiomas and lymphangiogenesis, Kaposi's Sarcoma, larynx cancer,liver cancer, lung cancer, lymphoma, mouth/pharynx cancer, multiplemyeloma; cardiac hypertrophy, neuroblastoma, neurofibromatosis, ovarycancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer,rhabdomyosarcoma, skin melanoma, small cell lung cancer, stomach cancer,testis cancer, throat cancer, tuberous sclerosis, and Wilms Tumor.

In certain embodiments, the proliferative disorder may be Philadelphiachromosome-positive (“Ph+”) chronic myeloid leukemia (“CML”) in chronicphase. In certain embodiments, the proliferative disorder may be Ph+ CMLin accelerated phase. In certain embodiments, the proliferative disordermay be Ph+ CML with resistance or intolerance to prior tyrosine-kinaseinhibitor therapy. In certain embodiments, the proliferative disordermay be chronic phase or accelerated phase Ph+ CML with resistance orintolerance to prior therapy that included imatinib.

Nilotinib has further been investigated for use in treating Parkinson'sDisease, Huntington's Disease, Alzheimer's Disease, dementia with Lewybodies, cerebellar ataxia, and other non-proliferative disorders. Thecompositions, regimens, kits and other embodiments disclosed hereincould suitably be employed in the treatment of such non-proliferativeconditions.

In the methods and uses of the present disclosure, a therapeuticallyeffective amount of the pharmaceutical composition of the presentdisclosure will be based on, among other factors, the route ofadministration, the age and size of the patient, and the proliferativedisorder being treated. As used herein, the term “therapeuticallyeffective amount” means that amount that is expected to elicit thebiological or medical response that is being sought by a clinician.

In some embodiments, a therapeutically effective amount may be from 50mg/m² to 250 mg/m² of nilotinib, or from 50 mg/m² to 150 mg/m² ofnilotinib, or from 60 to 120 mg/m² of nilotinib. In other embodiments, atherapeutically effective amount may be fixed dose. For instance, thefixed dose may be 20 mg to 400 mg, or 30 mg to 300 mg, or 40 mg to 200mg, per day of nilotinib. In certain embodiments, the fixed dose may be50 mg, or 55 mg, or 60 mg, or 65 mg, or 70 mg, or 75 mg, or 80 mg, or 85mg, or 90 mg, or 95 mg or 100 mg, or 110 mg, or 120 mg, or 125 mg, or130 mg, or 140 mg, or 150 mg, or 160 mg, or 170 mg, or 175 mg, or 180mg, or 190 mg, or 200 mg, or 210 mg, or 220 mg, or 225 mg, or 230 mg, or240 mg, or 250 mg, or 260 mg, or 270 mg, or 275 mg, or 280 mg, or 290mg, or 300 mg, of nilotinib.

Depending on the treatment regimen, the quantity of nilotinib dosed perday may be dosed twice-per-day, or may be dosed all at once (once-dailydosing), based on labeling guidelines or physician's recommendation. Insome embodiments, dosing is twice daily at approximately 12-hourintervals.

As described further below, pharmaceutical compositions of the presentdisclosure may provide enhanced or otherwise desirable bioavailabilityunder a variety of administration conditions. The term “bioavailability”refers to the rate and extent to which an active ingredient is absorbedfrom a pharmaceutical composition and becomes available at the site ofaction. In the case of orally administered pharmaceuticals,bioavailability is generally assessed by monitoring a subject's bloodplasma over time for the presence of an active ingredient (or suitablesurrogate, such as a metabolite) after administration of apharmaceutical composition, to evaluate the pharmacokinetic profile.

From the pharmacokinetic profile, certain relevant pharmacokineticparameters can be established. Such pharmacokinetic parameters caninclude C_(max), T_(max), and/or AUC, for example. C_(max) indicates themaximum observed plasma concentration over the observed time period.T_(max) indicates the time point at which the maximum plasmaconcentration is observed.

AUC indicates the numerical area-under-the-curve (“AUC”) for theconcentration-time curve, and can be assessed for a specified timeinterval 0-t, denoted as AUC_(0-t) (alternatively denoted as AUC_(t)).AUC_(0-t) is generally obtained by numerical integration of theconcentration-time curve over the period t=0 to the time “t” (e.g.,AUC_(0-24 h) or AUC_(24h) indicates the integral over the time periodfrom t=0 to t=24 hours). AUC_(0-last) (alternatively denoted asAUC_(last)) indicates the integral from t=0 to the last time pointsampled in the observed time period. AUC_(0-inf) (alternatively denotedas AUC_(inf)) indicates the integral from t=0 to t=“infinity,” which isdetermined by extrapolation of obtained data using commonly employedpharmacokinetic statistical modeling techniques.

Typically, plasma concentration data is log-transformed for analysis.For most pharmacokinetic analyses, data for a number of test subjects ispooled for analysis. When data is pooled, the relevant pharmacokineticparameters may be expressed as a population geometric mean, inaccordance with conventional pharmacokinetic statistical analyses andmethods.

Administration of an ASD or pharmaceutical composition of the presentdisclosure can be characterized by the pharmacokinetic profile, or bythe observed or calculated pharmacokinetic parameters resulting from theadministration of the ASD or pharmaceutical composition at certaindosages to a subject or patient, under stated administration conditions.By way of example only (and as further described below), administrationof the ASD or pharmaceutical composition of the present disclosure undera fasted state or fasting conditions can be characterized by thepharmacokinetic profile resulting from the administration, or byobserved pharmacokinetic parameters.

Methods of Administering with Food

An aspect of the present disclosure relates to a method of treating aproliferative disorder in a patient in need thereof, the methodcomprising administering a therapeutically effective amount of apharmaceutical composition of the present disclosure to the patientwithout a food effect.

In another aspect, the present disclosure relates to a method oftreating a proliferative disorder in a patient in need thereof, themethod comprising administering a therapeutically effective amount of apharmaceutical composition of the present disclosure to the patientwithout regard to consumption of food.

In another aspect, the present disclosure relates to a method oftreating a proliferative disorder in a patient in need thereof, themethod comprising administering a therapeutically effective amount of apharmaceutical composition of the present disclosure to the patientwithout regard to whether the patient is in a fasted state or in a fedstate.

In yet another aspect, the present disclosure relates to a method ofsafely delivering nilotinib to a patient in need thereof, comprisingstep (a), administering a therapeutically effective amount of apharmaceutical composition of the present disclosure to the patient; andstep (b), administering a meal to the patient. In some embodiments, step(b) occurs before step (a). In other embodiments, step (a) occurs beforestep (b). In some embodiments, steps (a) and (b) occur within less thantwo hours of each other. In some embodiments, steps (a) and (b) occurwithin 90 minutes of each other. In some embodiments, steps (a) and (b)occur within one hour of each other. In some embodiments, steps (a) and(b) occur within thirty minutes of each other. In some embodiments,steps (a) and (b) occur within fifteen minutes of each other.

In some embodiments, step (b) occurs less than one hour after step (a).In some embodiments, step (b) occurs less than 30 minutes after step(a). In some embodiments, step (b) occurs less than 15 minutes afterstep (a).

In some embodiments, step (a) occurs less than two hours after step (b).In some embodiments, step (a) occurs less than 90 minutes after step(b). In some embodiments, step (a) occurs less than one hour after step(b). In some embodiments, step (a) occurs less than 30 minutes afterstep (b). In some embodiments, step (a) occurs less than 15 minutesafter step (b).

In some embodiments, the “meal” is any solid food that is consumed thatprovides at least 200 calories to the patient or subject. In otherembodiments, the meal is any solid food that is consumed that providesat least 400 calories to the patient or subject. In yet otherembodiments, the meal is any solid food that is consumed that providesat least 600 calories to the patient or subject. In some embodiments,the meal is a high-fat test meal as described below. In otherembodiments, the meal is a low-fat test meal as described below.

In another aspect, the present disclosure relates to a method ofdelivering a therapeutically effective amount of nilotinib to a patientwithout regard to a food effect, comprising administering atherapeutically effective amount of a pharmaceutical composition of thepresent disclosure to the patient.

In a further aspect, the present disclosure relates to a method ofdelivering a therapeutically effective amount of nilotinib to a patientwithout regard to consumption of food, comprising administering atherapeutically effective amount of a pharmaceutical composition of thepresent disclosure to the patient.

In another aspect, the present disclosure relates to a method ofdelivering a therapeutically effective amount of nilotinib to a patientwithout regard to whether the patient is in a fed state or in a fastedstate, comprising administering a therapeutically effective amount of apharmaceutical composition of the present disclosure to the patient.

As generally interpreted, “food effect” broadly refers to all aspects ofinteractions of food on drug dissolution, absorption, distribution,metabolism and elimination. The implications of food effect includechanges in bioavailability, rate of on-set, duration of therapeuticeffect and incidence and seriousness of side effects. The magnitude of afood effect is generally greatest when the drug product is administeredshortly after a meal is ingested. An example of a drug product is with afood effect is TASIGNA, which as described above can produce an increaseof AUC and C_(max) by 82% and 112%, respectively, when orally taken 30minutes after a high-fat meal as compared to levels obtained underfasting conditions.

In practice, a food effect is generally assessed by measuring standardpharmacokinetic parameters observed upon administration of a drugproduct to a subject in a fasted state, versus the same measurementsobserved upon administration to the same subject in a fed state.Relevant pharmacokinetic parameters can include AUC, C_(max), and/orT_(max). AUC can be assessed for a specified time interval (such asAUC_(0-12 h) or AUC_(0-24 h), for example), or as AUC_(0-last) orAUC_(0-inf). Typically, data for a number of test subjects is pooled foranalysis.

For further information about food effect studies, refer to “Guidancefor Industry: Food-Effect Bioavailability and Fed BioequivalenceStudies” (Center for Drug Evaluation and Research (CDER), Food and DrugAdministration (FDA), December 2002), which is hereby incorporated byreference in its entirety. Reference is also made to “Guidance forIndustry: Assessing the Effects of Food on Drugs in INDs andNDAs—Clinical Pharmacology Considerations (Draft Guidance)” (CDER, FDA,February 2019), which is hereby incorporated by reference in itsentirety.

As used in relation to the methods of the present disclosure the phrase“food effect” refers to a relative difference in one or more of AUC,C_(max), and/or T_(max) for an active substance, when said substance ora formulation thereof (such as a solid dispersion or pharmaceuticalcomposition) is administered orally to a human subject, concomitantlywith food or in a fed state, as compared to the measured value for thesame parameter when the same formulation is administered to the samesubject in a fasted state. The food effect F is calculated as

F=(Y _(fed) −Y _(fasted))/Y _(fasted)

wherein Y_(fed) and Y_(fasted) are the measured values of AUC, C_(max)or T_(max) in the fed and fasted state, respectively.

The phrase “positive food effect” refers to a food effect where the AUCand/or C_(max) is higher when the drug product is administered orally ina fed state than when it is administered in a fasted state. The phrase“negative food effect” refers to a food effect where the AUC and/orC_(max) is lower when the drug product is administered orally in the fedstate than when it is administered in the fasted state.

In assessing food effect, data obtained from fasted and fed studies isprocessed using conventional pharmacokinetic statistical analyses andmethods. Fasted and fed studies may be single-dose studies orsteady-state studies, as appropriate. Using pooled data from a suitablenumber of subjects, an absence of food effect is indicated when the 90percent confidence interval (“CI”) for the ratio of population geometricmeans between fed and fasted administrations, based on log-transformeddata, is contained in the equivalence limits of 80% to 125% forAUC_(0-inf) (or AUC_(0-t) when appropriate) and C_(max). On the otherhand, an absence of food effect is not established if the 90 percent CIfor the ratio of population geometric means between fed and fastedadministrations, based on log-transformed data, is not contained in theequivalence limits of 80% to 125% for either AUC_(0-inf) (or AUC_(0-t)when appropriate) or C_(max).

In the methods of the present disclosure, “without a food effect” meansthat the relative difference is not substantially large, e.g., less than20%, or less than 15%, or less than 10%, for AUC (which can be, forexample, AUC_(0-24 h), AUC_(0-last) or AUC_(0-inf)) and/or C_(max), fornilotinib when the ASD or pharmaceutical composition of the presentdisclosure is administered orally, concomitantly with food or in a fedstate, as compared to the measured value for the same parameter when thesame ASD or pharmaceutical composition is administered in a fastedstate. (As used herein, for a relative difference stated as apercentage, each stated range is with respect to the absolute value ofthat relative difference; i.e., “less than 20%” means that the relativedifference F falls in the range −20%<F<+20%.)

In the methods of the present disclosure, “without regard to consumptionof food” means that no consideration has to be made whether the ASD orpharmaceutical composition of the present disclosure is beingadministered to the subject or patient concomitantly with food, orwhether the patient or subject is in a fed state or fasted state. Theadministration will be expected to provide a therapeutically relevantexposure, and will not be expected to cause an unsafe overexposure,regardless of whether the patient or subject is in a fed state or fastedstate.

“Therapeutically relevant exposure” as used herein means an exposurethat provides AUC_(0-t) (such as AUC_(0-24 h)) and/or C_(max), in thesubject's plasma that would be expected to produce the desiredtherapeutic effect. One way to determine a similar therapeutic effect isif the AUC_(0-t) or C_(max) is within the 80% to 125% bioequivalencecriteria compared to administration of an appropriate strength(determined with reference to the product's labeling) of a conventionalimmediate-release nilotinib composition to the same subject or subjects,dosed according to its labeled instructions.

As used herein, the phrase “conventional immediate-release nilotinibcomposition” refers to a commercially available composition comprisingnilotinib monohydrochloride monohydrate, generally in crystalline form.The conventional immediate-release nilotinib composition may be in acapsule dosage form. One suitable conventional immediate-releasenilotinib composition is TASIGNA IR Capsule (marketed in the UnitedStates under New Drug Application 22-068). TASIGNA is understood tocontain crystalline nilotinib monohydrochloride monohydrate in animmediate-release capsule formulation.

The phrase “concomitantly with food,” as used herein, refers toadministration to the subject from 30 minutes after the subject ingestsfood to 1 hour after the subject ingests food. The phrase“administration in a fed state” (or equivalently “administration underfed conditions”) as used herein, refers to administration to the subjectfrom 30 minutes after the subject starts ingesting a meal to 1 hourafter complete ingestion of a meal. Similarly, “fed state” or “fedconditions” refers to the condition of a subject 30 minutes after thesubject starts ingesting a meal to 1 hour after complete ingestion of ameal.

In some embodiments, the meal is a “high-fat test meal” (oralternatively, “high-fat meal”), which in accordance with FDA's Guidancefor Industry (December 2002) referenced above, is a high-fat andhigh-calorie (approximately 800 to 1000 calories) meal comprisingapproximately 150 calories from protein, 250 calories from carbohydrate,and 500-600 calories from fat. In other embodiments, the meal is a“low-fat test meal,” which in accordance with FDA's Draft Guidance forIndustry (February 2019) referenced above, is a lower-calorie(approximately 400 to 500 calories) meal comprising approximately 11-14grams of fat and approximately 25% calories from fat (with the balancefrom protein and carbohydrate).

The phrase “administration in a fasted state” (or equivalently“administration under fasting conditions”) as used herein refers toadministration to the subject at least 2 hours, more suitably at least 4hours, or more suitably at least 8 hours after the subject's previousmeal. Preferably, administration in a fasted state or under fastingconditions follows an overnight fast of at least 10 hours. Similarly,“fasted state” or “fasting conditions,” as used herein, refers to thecondition in which the subject has not eaten for at least two hours,more suitably at least 4 hours, or more suitably at least 8 hours; orthe condition of the subject following an overnight fast of at least 10hours. Moreover, administration in a fasted state or under fastingconditions may also require continued fasting for at least 1 hour, moresuitably at least 2 hours, or more suitably at least 4 hours followingthe administration.

In certain embodiments, the ASD or pharmaceutical composition isadministered without regard to whether the subject is in a fasted state.In certain embodiments, the ASD or pharmaceutical composition isadministered without regard to whether the subject is in a fed state. Incertain embodiments, the ASD or pharmaceutical composition isadministered without regard to whether the subject is in a fasted stateor in a fed state. In certain embodiments, the ASD or pharmaceuticalcomposition is administered without regard to a food effect. In certainembodiments, the ASD or pharmaceutical composition is administeredconcomitantly with food.

Some embodiments relate to a method of delivering nilotinib to a subjectwithout regard to whether the subject is in a fasted state, the methodcomprising administering to the subject an ASD or pharmaceuticalcomposition according to the disclosure.

Some embodiments relate to a method of delivering nilotinib to a subjectwithout regard to whether the subject is in a fed state, the methodcomprising administering to the subject an ASD or pharmaceuticalcomposition according to the disclosure.

Some embodiments relate to a method of delivering nilotinib to a subjectwithout regard to whether the subject is in a fasted state or a fedstate, the method comprising administering to the subject an ASD orpharmaceutical composition according to the disclosure.

Administration of the ASD or pharmaceutical composition of the presentdisclosure can be characterized by the pharmacokinetic profile or bycalculated pharmacokinetic parameters (such as C_(max) and/or AUC_(0-t),which can be, for example, AUC_(0-24 h), AUC_(0-last) or AUC_(0-inf))resulting from the administration of the ASD or pharmaceuticalcomposition at certain dosages to a subject in a fasted state or a fedstate.

For example, in some embodiments, administration to a healthy humansubject in a fasted state of the ASD or pharmaceutical composition ofthe disclosure at a dose of 40 mg to 80 mg nilotinib may result in aplasma C_(max) of nilotinib of 501 ng/mL to 621 ng/mL; a plasmaAUC_(0-12 h) of nilotinib of 3790 ng·h/mL to 4820 ng·h/mL; a plasmaAUC_(0-24 h) of nilotinib of 5590 ng·h/mL to 7340 ng·h/mL; a plasmaAUC_(0-last) of nilotinib of 7610 ng·h/mL to 10600 ng·h/mL; and/or aplasma AUC_(0-inf) of nilotinib of 7760 ng·h/mL to 11000 ng·h/mL.

In some embodiments, administration to a healthy human subject in fedstate of the ASD or pharmaceutical composition of the disclosure at adose of 40 mg to 80 mg nilotinib may result in a plasma C_(max) ofnilotinib of 456 ng/mL to 525 ng/mL; a plasma AUC_(0-12 h) of nilotinibof 3770 ng·h/mL to 4320 ng·h/mL; a plasma AUC_(0-24 h) of nilotinib of6310 ng·h/mL to 7130 ng·h/mL; a plasma AUC_(0-last) of nilotinib of 9490ng·h/mL to 11000 ng·h/mL; and/or a plasma AUC_(0-inf) of nilotinib of9840 ng·h/mL to 11300 ng·h/mL.

Administration of the ASD or pharmaceutical composition of the presentdisclosure can also be characterized by how the pharmacokinetic profileresulting from administration of the ASD or pharmaceutical compositionto a subject in a fed state compares to the pharmacokinetic profileresulting from administration of the ASD or pharmaceutical compositionto a subject in a fasted state. As an example, for some embodiments,administration of the ASD or pharmaceutical composition of the presentdisclosure to a subject in a fed state and in a fasted state may resultin a relative difference in the plasma exposure of nilotinib between thefed state and the fasted state of less than 50%, less than 40%, or lessthan 35%, or less than 30%, or less than 25%, or less than 20%, or lessthan 15%, or less than 10%, or less than 5%. Exposure may be expressedas AUC_(0-12 h), AUC_(0-24 h), AUC_(0-last), or AUC_(0-inf), forexample. Exposure can be demonstrated for an individual subject, oralternatively for a suitable number of subjects (n>1). When comparing anumber of subjects for which data is pooled, the exposure may beexpressed as a population geometric mean, in accordance withconventional pharmacokinetic statistical analyses and methods.

In certain embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fed state mayresult in plasma AUC_(0-12 h) of nilotinib that is less than the plasmaAUC_(0-12 h) of nilotinib that may result from administration of thepharmaceutical composition to the subject in a fasted state. In certainembodiments, administration of the ASD or pharmaceutical composition ofthe present disclosure to a subject in a fed state may result in plasmaAUC_(0-12 h) of nilotinib that is within 25%, or within 20%, of theplasma AUC_(0-12 h) of nilotinib that may result from administration ofthe pharmaceutical composition to the subject in a fasted state. PlasmaAUC_(0-12 h) can be for an individual subject, or a geometric mean froma number of subjects.

In certain embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fed state mayresult in plasma AUC_(0-24 h) of nilotinib that is less than the plasmaAUC_(0-24 h) of nilotinib that may result from administration of thepharmaceutical composition to the subject in a fasted state. In certainembodiments, administration of the ASD or pharmaceutical composition ofthe present disclosure to a subject in a fed state may result in plasmaAUC_(0-24 h) of nilotinib that is within 50%, or within 40%, or within35%, or within 30%, or within 25%, or within 20%, or within 15%, orwithin 10%, of the plasma AUC_(0-24 h) of nilotinib that may result fromadministration of the pharmaceutical composition to the subject in afasted state. Plasma AUC_(0-24 h) can be for an individual subject, or ageometric mean from a number of subjects.

In certain embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fed state mayresult in plasma AUC_(0-last) of nilotinib that is less than the plasmaAUC_(0-last) of nilotinib that may result from administration of thepharmaceutical composition to the subject in a fasted state. In certainembodiments, administration of the ASD or pharmaceutical composition ofthe present disclosure to a subject in a fed state may result in plasmaAUC_(0-last) of nilotinib that is within 50%, or within 40%, or within35%, or within 30%, or within 25%, or within 20%, or within 15%, orwithin 10%, of the plasma AUC_(0-last) of nilotinib that may result fromadministration of the pharmaceutical composition to the subject in afasted state. Plasma AUC_(0-last) can be for an individual subject, or ageometric mean from a number of subjects.

In certain embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fed state mayresult in plasma AUC_(0-inf) of nilotinib that is less than the plasmaAUC_(0-inf) of nilotinib that may result from administration of thepharmaceutical composition to the subject in a fasted state. In certainembodiments, administration of the ASD or pharmaceutical composition ofthe present disclosure to a subject in a fed state may result in plasmaAUC_(0-inf) of nilotinib that is within 50%, or within 40%, or within35%, or within 30%, or within 25%, or within 20%, or within 15%, orwithin 10%, of the plasma AUC_(0-inf) of nilotinib that may result fromadministration of the pharmaceutical composition to the subject in afasted state. Plasma AUC_(0-inf) can be for an individual subject, or ageometric mean from a number of subjects.

For some embodiments, administration of an ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fed state and ina fasted state may result in a relative difference in the plasma C_(max)of nilotinib between the fed state and the fasted state of less than50%, less than 30%, or less than 25%, or less than 20%, or less than15%, or less than 10%, or less than 5%. In certain embodiments,administration of the ASD or pharmaceutical composition of the presentdisclosure to a subject in a fed state may result in plasma C_(max) ofnilotinib that is less than the C_(max) of nilotinib that may resultfrom administration of the ASD or pharmaceutical composition of thepresent disclosure to the subject in a fasted state. C_(max) can bedemonstrated for an individual subject, or alternatively for a suitablenumber of subjects (n>1). When comparing a number of subjects for whichdata is pooled, the C_(max) may be expressed as a population geometricmean, in accordance with conventional pharmacokinetic statisticalanalyses and methods.

In yet other embodiments, administration of the ASD or pharmaceuticalcomposition to a subject in a fed state provides an exposure ofnilotinib that is similar to the exposure resulting from administrationof the pharmaceutical composition to the subject in a fasted state.Exposure may be expressed as AUC_(0-12 h), AUC_(0-24 h), AUC_(0-last),or AUC_(0-inf), for example; exposure can be for an individual subject,or a geometric mean from a number of subjects.

In some embodiments, administration of the ASD or pharmaceuticalcomposition to a subject in a fed state provides a plasma C_(max) ofnilotinib that is similar to the plasma C_(max) of nilotinib resultingfrom administration of the ASD or pharmaceutical composition to thesubject in a fasted state. Plasma C_(max) can be for an individualsubject, or a geometric mean from a number of subjects.

As used herein in this context, “similar” exposure means a relativedifference in the plasma exposure of nilotinib between the fed state andthe fasted state of less than 25%, or less than 20%, or less than 15%,or less than 10%, or less than 5%; and “similar” C_(max) likewise meansa relative difference in the plasma C_(max) of nilotinib between the fedstate and the fasted state of less than 25%, or less than 20%, or lessthan 15%, or less than 10%, or less than 5% (each stated percentage isunderstood to be an absolute value; i.e., “less than 20%” means that therelative difference F falls in the range −20%<F<+20%).

In some embodiments, the pharmaceutical composition of the presentdisclosure may provide a plasma C_(max) of nilotinib of 501 ng/mL to 621ng/mL resulting from administration of a dose of 40 mg to 80 mgnilotinib to a healthy human subject in a fasted state, and may providea plasma C_(max) of nilotinib of 456 ng/mL to 525 ng/mL resulting fromadministration of a dose of 40 mg to 80 mg nilotinib to a healthy humansubject in fed state.

In some embodiments, the pharmaceutical composition of the presentdisclosure may provide a plasma AUC_(0-12 h) of nilotinib of 3790ng·h/mL to 4820 ng·h/mL resulting from administration of a dose of 40 mgto 80 mg nilotinib to a healthy human subject in a fasted state, and mayprovide a plasma AUC_(0-12 h) of nilotinib of 3770 ng·h/mL to 4320ng·h/mL resulting from administration of a dose of 40 mg to 80 mgnilotinib to a healthy human subject in fed state.

In some embodiments, the pharmaceutical composition of the presentdisclosure may provide a plasma AUC_(0-24 h) of nilotinib of 5590ng·h/mL to 7340 ng·h/mL resulting from administration of a dose of 40 mgto 80 mg nilotinib to a healthy human subject in a fasted state, and mayprovide a plasma AUC_(0-24 h) of nilotinib of 6310 ng·h/mL to 7130ng·h/mL resulting from administration of a dose of 40 mg to 80 mgnilotinib to a healthy human subject in fed state.

In some embodiments, the pharmaceutical composition of the presentdisclosure may provide a plasma AUC_(0-last) of nilotinib of 7610ng·h/mL to 10600 ng·h/mL resulting from administration of a dose of 40mg to 80 mg nilotinib to a healthy human subject in a fasted state, andmay provide a plasma AUC_(0-last) of nilotinib of 9490 ng·h/mL to 11000ng·h/mL resulting from administration of a dose of 40 mg to 80 mgnilotinib to a healthy human subject in fed state.

In some embodiments, the pharmaceutical composition of the presentdisclosure may provide a plasma AUC_(0-inf) of nilotinib of 7760 ng·h/mLto 11000 ng·h/mL resulting from administration of a dose of 40 mg to 80mg nilotinib to a healthy human subject in a fasted state, and mayprovide a plasma AUC_(0-inf) of nilotinib of 9840 ng·h/mL to 11300ng·h/mL resulting from administration of a dose of 40 mg to 80 mgnilotinib to a healthy human subject in fed state.

As used herein, the phrase “food-insensitive composition” indicates apharmaceutical composition of the present disclosure that can beadministered without regard to the patient's or subject's fed or fastedstate. A food-insensitive composition provides a therapeuticallyrelevant exposure to the patient or subject regardless of whether thepatient or subject has recently ingested a meal, or whether the patientor subject ingests a meal shortly after administration of thepharmaceutical composition, or whether the patient or subject was in afasted state at the time of administration and remains in the fastedstate for some time following administration.

Methods of Administering at Reduced Dosage

In addition, administration of the ASD or pharmaceutical composition ofthe present disclosure can be characterized by how the pharmacokineticprofile resulting from administration of the ASD or pharmaceuticalcomposition compares to the pharmacokinetic profile resulting fromadministration of a conventional immediate-release nilotinibcomposition.

For instance, in some embodiments, administration of an ASD orpharmaceutical composition of the present disclosure may result in apharmacokinetic profile that is comparable to the pharmacokineticprofile obtained by orally administering a conventionalimmediate-release nilotinib formulation, but administered at a fractionof the dosage. For this comparison, administration must be done in afasted state, since TASIGNA should only be administered in a fastedstate.

For embodiments of the disclosure that can be administered at a fractionof the dosage as compared to the dosage required when administering aconventional immediate-release nilotinib composition, it can be reasonedthat the inventive formulation is inherently safer than thecorresponding conventional immediate-release nilotinib composition. Bydecreasing the required dosage while still providing an efficaciousexposure to the patient, the risks of overexposure are reduced.Overexposure to nilotinib is associated with the risk of QT prolongationdiscussed above, which is currently the subject of a “black box warning”on the TASIGNA label. The risk of overexposure affects the entirepatient population treated with nilotinib. As such, a reduced dosageinherently decreases the risk of sudden death in the patient population,since QT prolongation is reported to cause sudden cardiac death inapproximately one out of every 300 TASIGNA patients.

In addition to reducing the overall risk of overexposure, theformulations of the disclosure may limit risk associated with anundesirably high C_(max). For certain risks such as QT prolongation,C_(max) may in fact be the more relevant pharmacokinetic parameter. Asizable increase in C_(max), such as between fasted and fed states, maybe highly undesirable and potentially unsafe. In some embodiments, theformulations of the disclosure reduce or eliminate the possibility thata patient may experience an undesirably high C_(max).

With respect to the respective pharmacokinetic profiles, by“comparable,” it is meant that the administration of the ASD or thepharmaceutical composition of the disclosure to the subject may provideAUC_(0-t) (such as AUC_(0-24 h) or AUC_(0-inf)) or C_(max) in thesubject's plasma that are within the 80% to 125% bioequivalence criteriacompared to administration of the immediate-release crystallinenilotinib formulation to the same subject, dosed according to itslabeled instructions.

As used herein, “fraction of the dosage” may mean that the dose ofnilotinib in the ASD or pharmaceutical composition of the presentdisclosure may be 80% less, or 75% less, or 70% less, or 65% less, or60% less, or 55% less, or 50% less, or 45% less, or 40% less, or 35%less, or 30% less, or 25% less, or 20% less, as compared to the labeleddosage of the immediate-release crystalline nilotinib formulation.

By way of example only, a pharmaceutical composition of the presentdisclosure containing approximately 50 mg nilotinib free base mayprovide a pharmacokinetic profile that is comparable to thepharmacokinetic profile obtained by orally administering animmediate-release crystalline nilotinib formulation labeled to contain200 mg of nilotinib (such as 200 mg TASIGNA IR Capsule). In thisexample, the dose of nilotinib in the inventive pharmaceuticalcomposition is 75% less than the dosage of the immediate-releasecrystalline nilotinib formulation.

In some embodiments, the dose of nilotinib in the ASD or pharmaceuticalcomposition of the present disclosure is 80% less, or 75% less, or 70%less, or 65% less, or 60% less, or 55% less, or 50% less, as compared tothe labeled dosage of the immediate-release crystalline nilotinibformulation.

For some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma exposure of nilotinib that is within 20%, or within15%, or within 10%, of the plasma exposure of nilotinib that may resultfrom administration to a subject in a fasted state of animmediate-release crystalline nilotinib formulation, where the ASD orpharmaceutical composition is administered at a fraction of the dosage.In certain embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma exposure of nilotinib that is greater than the plasmaexposure of nilotinib that that may result from administration to asubject in a fasted state of an immediate-release crystalline nilotinibformulation, where the ASD or pharmaceutical composition is administeredat a fraction of the dosage. Exposure may be expressed as AUC_(0-12 h),AUC_(0-24 h), AUC_(0-last), or AUC_(0-inf), for example. Exposure can befor an individual subject, or a geometric mean from a number ofsubjects.

For some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma C_(max) of nilotinib that is within 20%, or within 15%,or within 10%, of the plasma C_(max) of nilotinib that may result fromadministration to a subject in a fasted state of an immediate-releasecrystalline nilotinib formulation, where the ASD or pharmaceuticalcomposition is administered at a fraction of the dosage. In certainembodiments, administration of the ASD or pharmaceutical composition ofthe present disclosure to a subject in a fasted state may result inplasma C_(max) of nilotinib that is greater than the plasma C_(max) ofnilotinib that may result from administration to a subject in a fastedstate of an immediate-release crystalline nilotinib formulation, wherethe ASD or pharmaceutical composition is administered at a fraction ofthe dosage. C_(max) can be for an individual subject, or a geometricmean from a number of subjects.

In the practice of some embodiments, the dosage of immediate-releasecrystalline nilotinib formulation is a multiple of the dose of thenilotinib contained in the pharmaceutical composition according to thedisclosure. In some embodiments, the immediate-release crystallinenilotinib formulation may comprise at least two times, at least threetimes, at least four times, or at least five times, the amount ofnilotinib as the pharmaceutical composition according to the disclosure.In some embodiments, the immediate-release crystalline nilotinibformulation may comprise from two times to five times the amount ofnilotinib as the pharmaceutical composition according to the disclosure.In some embodiments, the immediate-release crystalline nilotinibformulation may comprise from two times to four times the amount ofnilotinib as the pharmaceutical composition according to the disclosure.

In some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma AUC_(0-12 h) of nilotinib that is greater than theplasma AUC_(0-12 h) of nilotinib that may result from the administrationof an immediate-release crystalline nilotinib formulation that has fourtimes, or three times, or twice, the amount of nilotinib as the ASD orpharmaceutical composition. Plasma AUC_(0-12 h) can be for an individualsubject, or a geometric mean from a number of subjects.

In some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma AUC_(0-12 h) of nilotinib that is within 20%, or within15%, of the plasma AUC_(0-12 h) of nilotinib that may result from theadministration of an immediate-release crystalline nilotinib formulationthat has four times, or three times, or twice, the amount of nilotinibas the ASD or pharmaceutical composition. Plasma AUC_(0-12 h) can be foran individual subject, or a geometric mean from a number of subjects.

In some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma AUC_(0-24 h) of nilotinib that is greater than theplasma AUC_(0-24 h) of nilotinib that may result from the administrationof an immediate-release crystalline nilotinib formulation that has fourtimes, or three times, or twice, the amount of nilotinib as the ASD orpharmaceutical composition. Plasma AUC_(0-24 h) can be for an individualsubject, or a geometric mean from a number of subjects.

In some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma AUC_(0-24 h) of nilotinib that is within 20%, or within15%, of the plasma AUC_(0-24 h) of nilotinib that may result from theadministration of an immediate-release crystalline nilotinib formulationthat has four times, or three times, or twice, the amount of nilotinibas the ASD or pharmaceutical composition. Plasma AUC_(0-24 h) can be foran individual subject, or a geometric mean from a number of subjects.

In some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma AUC_(0-last) of nilotinib that is within 20%, or within15%, of the plasma AUC_(0-last) of nilotinib that may result from theadministration of an immediate-release crystalline nilotinib formulationthat has four times, or three times, or twice, the amount of nilotinibas the ASD or pharmaceutical composition. Plasma AUC_(0-last) can be foran individual subject, or a geometric mean from a number of subjects.

In some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma AUC_(0-inf) of nilotinib that is within 25%, or within20%, of the plasma AUC_(0-inf) of nilotinib that may result from theadministration of an immediate-release crystalline nilotinib formulationthat has four times, or three times, or twice, the amount of nilotinibas the ASD or pharmaceutical composition. Plasma AUC_(0-inf) can be foran individual subject, or a geometric mean from a number of subjects.

In some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma C_(max) of nilotinib that is greater than the plasmaC_(max) of nilotinib that may result from the administration of animmediate-release crystalline nilotinib formulation that has four times,or three times, or twice, the amount of nilotinib as the ASD orpharmaceutical composition. Plasma C_(max) can be for an individualsubject, or a geometric mean from a number of subjects.

In some embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted state mayresult in plasma C_(max) of nilotinib that is within 25%, or within 20%,of the plasma C_(max) of nilotinib that may result from theadministration of an immediate-release crystalline nilotinib formulationthat has four times, or three times, or twice, the amount of nilotinibas the ASD or pharmaceutical composition. Plasma C_(max) can be for anindividual subject, or a geometric mean from a number of subjects.

In yet other embodiments, administration of an ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted stateprovides an exposure of nilotinib that is similar to the exposureresulting from administration of an immediate-release crystallinenilotinib formulation, but administered at a fraction of the dosage.Exposure may be expressed as AUC_(0-12 h), AUC_(0-24 h), AUC_(0-last),or AUC_(0-inf), for example; exposure can be for an individual subject,or a geometric mean from a number of subjects.

In yet other embodiments, administration of an ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fasted stateprovides plasma C_(max) of nilotinib that is similar to the plasmaC_(max) of nilotinib resulting from administration of animmediate-release crystalline nilotinib formulation, but administered ata fraction of the dosage. Plasma C_(max) can be for an individualsubject, or a geometric mean from a number of subjects.

In yet other embodiments, administration of an ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fed stateprovides an exposure of nilotinib that is similar to the exposureresulting from administration of an immediate-release crystallinenilotinib formulation to the subject in a fasted state, but administeredat a fraction of the dosage. Exposure may be expressed as AUC_(0-12 h),AUC_(0-24 h), AUC_(0-last), or AUC_(0-inf), for example; exposure can befor an individual subject, or a geometric mean from a number ofsubjects.

In yet other embodiments, administration of an ASD or pharmaceuticalcomposition of the present disclosure to a subject in a fed stateprovides plasma C_(max) of nilotinib that is similar to the plasmaC_(max) of nilotinib resulting from administration of animmediate-release crystalline nilotinib formulation to the subject in afasted state, but administered at a fraction of the dosage. PlasmaC_(max) can be for an individual subject, or a geometric mean from anumber of subjects.

As used herein in this context, “similar” exposure means a relativedifference in the plasma exposure of nilotinib between administration ofthe pharmaceutical composition and administration of theimmediate-release crystalline nilotinib formulation, of less than 25%,or less than 20%, or less than 15%, or less than 10%, or less than 5%;and “similar C_(max)” means a relative difference in the plasma C_(max)of nilotinib between administration of the pharmaceutical compositionand administration of the immediate-release crystalline nilotinibformulation, of less than 25%, or less than 20%, or less than 15%, orless than 10%, or less than 5% (each stated percentage is understood tobe an absolute value; i.e., “less than 20%” means that the relativedifference F falls in the range −20%<F<+20%).

Effective Bioequivalence to Reference Composition

In another aspect, the disclosure provides pharmaceutical compositionsthat are effectively bioequivalent to a suitable reference compositionwhen administered to healthy human subjects in a fasted state, but at alower molar dose of the active ingredient as compared to the referencecomposition. In some embodiments, the reference composition is aconventional immediate-release nilotinib composition comprisingnilotinib monohydrochloride monohydrate. In some embodiments, thereference composition is TASIGNA IR Capsule.

Pertaining to bioequivalence studies, FDA has published “Guidance forIndustry: Bioequivalence Studies with Pharmacokinetic Endpoints forDrugs Submitted Under an ANDA (Draft Guidance)” (CDER, FDA, December2013), which is hereby incorporated by reference in its entirety.Pertaining to statistical methods for determining bioequivalence, FDAhas published “Guidance for Industry: Statistical Approaches toEstablishing Bioequivalence” (CDER, FDA, January 2001), which is herebyincorporated by reference in its entirety.

Per FDA guidelines, a drug product (a “test composition”) isbioequivalent to a reference drug product (the “reference composition”)when the rate and extent of absorption of the drug substance (i.e., theactive ingredient) from the test composition do not show a significantdifference from the rate and extent of absorption of the drug substancewhen administered using the reference composition, under similarexperimental conditions. For many drug substances that are orallybioavailable, including nilotinib, the preferred method for assessingbioequivalence is by assessing the pharmacokinetic profile attained uponoral administration of the test and reference compositions.

The bioequivalence assessment frequently relies on pharmacokineticendpoints such as C_(max) and AUC that are reflective of rate and extentof absorption, respectively. Generally speaking, using pooled data froma suitable number of subjects, bioequivalence between the testcomposition and reference composition is established when the 90 percentconfidence interval (“CI”) for the ratio of population geometric meansbetween test composition and reference composition administrations,based on log-transformed data, is contained in the equivalence limits of80% to 125% for both AUC_(0-inf) (or AUC_(0-t) when appropriate) andC_(max). On the other hand, bioequivalence is not established if the 90percent CI for the ratio of population geometric means between testcomposition and reference composition administrations, based onlog-transformed data, is not contained in the equivalence limits of 80%to 125% for either AUC_(0-inf) (or AUC_(0-t) when appropriate) orC_(max).

As discussed above, a pharmacokinetic profile is assessed by monitoringthe subject's blood plasma over time for the presence of the activeingredient (or in some cases a suitable surrogate, such as a metabolite)after administration of the pharmaceutical composition of interest. Perthe FDA draft guidance for nilotinib hydrochloride monohydratecompositions, the plasma analyte of interest is nilotinib. Nilotinib isalso the relevant plasma analyte for the pharmaceutical compositions ofthe present disclosure.

Depending on the nature of the drug substance and the reference and testcompositions, the required showing may require single-dose ormultiple-dose studies. The most recent FDA guidance document (draftguidance, July 2014) on bioequivalence studies pertaining to nilotinibhydrochloride monohydrate oral capsules (200 mg) recommend a single-dosetwo-way crossover study under fasting conditions.

Per FDA guidelines, a test composition can only be bioequivalent whendosed at the same molar dose of the active ingredient as the referencecomposition. As discussed above, however, administration of an ASD orpharmaceutical composition of the present disclosure may result in apharmacokinetic profile that is comparable to the pharmacokineticprofile obtained by orally administering a conventionalimmediate-release nilotinib formulation, but administered at a fractionof the dosage. For such embodiments, a more appropriate comparison is toassess the relative bioavailability when the test composition is dosedat a fraction of the corresponding molar dose of the chosen referencecomposition. As used herein, the phrases “effectively bioequivalent” and“effective bioequivalence” are used to refer to the situation where atest composition and reference composition meet stated bioequivalencecriteria, but at different molar doses.

In one embodiment, the disclosure provides a pharmaceutical compositioncomprising 100 mg nilotinib in an oral dosage form; wherein, when theoral dosage form is administered to a healthy human subjects in a fastedstate, achieves an AUC_(0-inf) and C_(max) within the 80% to 125%bioequivalence criteria as compared to AUC_(0-inf) and C_(max) achievedupon administration of a reference composition, wherein the referencecomposition is a conventional immediate-release nilotinib compositioncomprising 200 mg nilotinib monohydrochloride monohydrate.

In another embodiment, the disclosure provides a pharmaceuticalcomposition comprising an amorphous solid dispersion including nilotiniband one or more polymers, wherein the composition is contained in anoral dosage form comprising 100 mg nilotinib; and wherein, when the oraldosage form is administered to a healthy human subjects in a fastedstate, achieves an AUC_(0-inf) and C_(max) within the 80% to 125%bioequivalence criteria as compared to AUC_(0-inf) and C_(max) achievedupon administration of a reference composition, wherein the referencecomposition is conventional immediate-release nilotinib compositioncomprising 200 mg nilotinib monohydrochloride monohydrate.

In another embodiment, the disclosure provides a pharmaceuticalcomposition comprising 100 mg nilotinib in an oral dosage form, whereinthe pharmaceutical composition is effectively bioequivalent underfasting conditions to a reference composition which is a conventionalimmediate-release nilotinib composition comprising 200 mg nilotinibmonohydrochloride monohydrate; where effective bioequivalence isestablished by: (a) a 90% confidence interval for AUC which is between80% and 125%; and (b) a 90% confidence interval for C_(max), which isbetween 80% and 125%.

In another aspect, the disclosure provides pharmaceutical compositionsthat meet one or more bioequivalence criteria when administered tohealthy human subjects in either a fasted or fed state, as compared to asuitable reference composition when administered to healthy humansubjects in a fasted state, but at a lower molar dose of the activeingredient as compared to the reference composition.

In any of the foregoing embodiments, the AUC can be AUC_(0-24 h),AUC_(0-last), or AUC_(0-inf), for example, as appropriate.

In some embodiments, the reference composition is a conventionalimmediate-release nilotinib composition comprising nilotinibmonohydrochloride monohydrate. In some embodiments, the referencecomposition comprises crystalline nilotinib monohydrochloridemonohydrate. In some embodiments, the reference composition is incapsule form. In some embodiments, the reference composition is TASIGNAIR Capsule.

Methods of Co-Administering with a Gastric Acid-Reducing Agent

Other embodiments of the present disclosure relate to the use of thenilotinib ASDs and the pharmaceutical compositions of the presentdisclosure with a gastric acid-reducing agent.

In one aspect, the present disclosure relates to a method of deliveringnilotinib concurrently with a gastric acid-reducing agent to a patientin need thereof, comprising co-administering to the patient (a) atherapeutically effective amount of a pharmaceutical composition of thepresent disclosure, and (b) a therapeutically effective amount of thegastric acid-reducing agent.

In another aspect, the present disclosure relates to a method oftreating a patient who has a proliferative disorder and is sufferingfrom condition caused by the overproduction of stomach acid orexacerbated by stomach acid, the method comprising co-administering tothe patient (a) a therapeutically effective amount of a pharmaceuticalcomposition of the present disclosure, and (b) a therapeuticallyeffective amount of a gastric acid-reducing agent.

In yet another aspect, the present disclosure relates to a method ofdelivering a therapeutically effective amount of nilotinib to a patientwithout regard to whether the patient is concurrently administered agastric acid-reducing agent, comprising administering a therapeuticallyeffective amount of a pharmaceutical composition of the presentdisclosure to the patient.

“Gastric acid-reducing agent” refers herein to any agent that acts tosignificantly reduce the amount of acid in a subject's stomach. Acidreduction can be due to suppression or blocking of acid secretion, or byneutralization of stomach acid. Examples of gastric acid-reducing agentsinclude, but are not limited to, proton pump inhibitors, histamine-2receptor antagonists (or H₂ antagonists), and antacids.

Proton pump inhibitors reduce stomach acid production by blocking thehydrogen/potassium adenosine triphosphatase enzyme (i.e., the gastricproton pump) of the parietal cells, which are the epithelial cells thatsecrete stomach acid. Examples of proton pump inhibitors include, butare not limited to, rabeprazole, esomeprazole, lansoprazole, omeprazole,pantoprazole, and dexlansoprazole.

H₂ antagonists block histamine from binding to the H₂ receptors ofparietal cells, thereby suppressing both the normal secretion andmeal-stimulated secretion of acid by parietal cells. Examples of H₂antagonists include, but are not limited to, famotidine, cimetidine,nizatidine, and ranitidine.

Antacids contain alkaline ions that chemically neutralize stomachgastric acid. Examples of antacids include, but are not limited to,aluminum hydroxide, magnesium hydroxide, sodium citrate, sodiumcarbonate, sodium bicarbonate, calcium carbonate, and magnesiumtrisilicate.

The gastric acid-reducing agent may be administered in accordance withthe dosing information that is known in the art for the agent, oraccording to a physician's instructions. A “therapeutically effectiveamount” of the gastric acid-reducing agent may be the amount set forthin the dosing information that is known in the art for the gastricacid-reducing agent, or according to a physician's instructions. A“standard dosage” is a dosage in accordance with a product's labeledinstructions. In particular, a standard dosage is appropriate forgastric acid-reducing agents that are available over-the-counter (i.e.,without a physician's prescription), such as most antacids, certain H₂antagonists, and certain proton pump inhibitors.

As used herein, a condition caused by the overproduction of stomach acidor exacerbated by stomach acid may be any condition that can be treatedby reducing the amount of acid or the acidity in the subject's stomach.Examples of such a condition include, but are not limited to, dyspepsia(i.e., indigestion), gastroesophageal reflux disease, duodenal orstomach ulcers, erosive esophagitis, stress gastritis, Barrett'sesophagus, and gastrinomas.

As used herein, “co-administration” (or “co-administered”) refers to theadministration of two or more therapeutic agents within a relevantperiod of time (such as one day, or 12 hours, or 8 hours, or 6 hours,for example), such that consideration must be given to whether theadministration of one of the therapeutic agents may affect theabsorption or efficacy of the other. Such administration may be for thetreatment of two or more conditions simultaneously, such as, by way ofexample only, a patient requiring treatment for a proliferative disorderas described herein with nilotinib as a therapeutic agent, while alsobeing treated for another condition, such as acid reflux or ulcers, witha second therapeutic agent such as a gastric acid-reducing agent (e.g.,a proton pump inhibitor). Since both therapeutic agents are dosed atleast once daily, the two therapeutic agents are “co-administered,” andconsideration must be given to whether the administration of one of thetherapeutic agents may affect the absorption or efficacy of the other.

In the context of the present disclosure, the phrase “can beco-administered” means that the two (or more) therapeutic agents ofinterest can be co-administered without a detrimental reduction in theexposure of nilotinib. “Without a detrimental reduction” indicates thatthe realized exposure would be comparable to the exposure realized whenthe gastric acid-reducing agent is not co-administered. Any differencein the realized exposure would be insubstantial and/or therapeuticallyinconsequential. In contrast, when a detrimental reduction in exposurewould be realized, then co-administration should be avoided. A“detrimental reduction” means a substantial and material reduction inthe realized exposure. By way of example, if the realized exposure wouldbe less than or equal to a level recognized as a sub-therapeuticexposure, then the co-administration would result in a detrimentalreduction in exposure.

As used herein, the phrase “gastric acid-insensitive composition”indicates a pharmaceutical composition of the present disclosure thatcan be administered without regard to the patient or subject's gastricpH. A gastric acid-insensitive composition provides a therapeuticallyrelevant exposure to the patient or subject across a range of gastric pHvalues. Accordingly, a gastric acid-insensitive composition can beadministered whether or not the patient or subject has ingested agastric acid-reducing agent, or whether or not the patient has acondition that causes elevated gastric pH (as further discussed below).

Embodiments of the disclosure relate to administering a gastricacid-reducing agent shortly before, concurrently with, or shortly afterthe nilotinib ASDs or pharmaceutical compositions of the disclosure. Theterm “shortly before” as used herein may mean that a gastricacid-reducing agent was administered to the subject 10 hours or less, or8 hours or less, or 6 hours or less, or 5 hours or less, or 4 hours orless, or 3 hours or less, or 2 hours or less, or 1 hour or less, or 45minutes or less, or 30 minutes or less, or 15 minutes or less, prior tothe administration of the pharmaceutical composition of the disclosure.The term “concurrently” or “concomitantly” as used herein may mean thata gastric acid-reducing agent was administered to the subject within 30minutes or less, or within 20 minutes or less, or within 15 minutes orless, or within 10 minutes or less, or within 5 minutes or less, orwithin 4 minutes or less, or within 3 minutes or less, or within 2minutes or less, or within 1 minute or less, or simultaneously, of theadministration of the pharmaceutical composition. The term “shortlyafter” as used herein means that a gastric acid-reducing agent wasadministered to the subject 6 hours or less, or 5 hours or less, or 4hours or less, or 3 hours or less, or 2 hours or less, or 1 hour orless, or 45 minutes or less, or 30 minutes or less, or 15 minutes orless, after the administration of the pharmaceutical composition.

In some embodiments, administration of an ASD or pharmaceuticalcomposition of the present disclosure to a subject who was concurrently,shortly before, or shortly after administered a gastric acid-reducingagent exhibits a pharmacokinetic profile of nilotinib that is similar tothe pharmacokinetic profile resulting from administration of the ASD orpharmaceutical composition to a subject who was not concurrently,shortly before, or shortly after administered a gastric acid-reducingagent. In certain embodiments, single administration of the ASD orpharmaceutical composition to a subject who was concurrently, shortlybefore, or shortly after administered a gastric acid-reducing agentresults in an AUC of nilotinib that is within 50%, or within 40%, orwithin 30%, of the AUC of nilotinib that results from administration ofthe ASD or pharmaceutical composition without being administered thegastric acid-reducing agent concurrently, shortly before, or shortlyafter. In certain embodiments, the AUC is AUC_(0-24 h). In otherembodiments, the AUC is AUC_(0-inf).

Aspects of the present disclosure further relate to treatment regimensinvolving the administration of pharmaceutical composition of thedisclosure, and a gastric acid-reducing agent. Such treatment regimensmay be for treating a proliferative disorder in a patient in needthereof, or for treating a proliferative disorder and a condition causedby the overproduction of stomach acid or exacerbated by stomach acid ina patient in need thereof.

In some embodiments, the treatment regimen may comprise (a)administering to the patient a first dose, the first dose comprising atherapeutically effective amount of a proton pump inhibitor; and (b)within 2 hours after the first dose, administering a second dose to thepatient, the second dose comprising a pharmaceutical composition of thepresent disclosure. In certain embodiments, the treatment regimen maycomprise (a) administering to the patient a first dose, the first dosecomprising a therapeutically effective amount of a proton pumpinhibitor; and (b) concurrently administering a second dose to thepatient, the second dose comprising a pharmaceutical composition of thepresent disclosure.

In some embodiments, the treatment regimen may comprise (a)administering to the patient a first dose, the first dose comprising atherapeutically effective amount of an H₂ antagonist; and (b) within 10hours after the first dose, administering a second dose to the patient,the second dose comprising a pharmaceutical composition of the presentdisclosure. In some embodiments, the treatment regimen may comprise (a)administering to the patient a first dose, the first dose comprising apharmaceutical composition of the present disclosure; and (b) within 2hours after the first dose, administering a second dose to the patient,the second dose comprising a therapeutically effective amount of an H₂antagonist.

In some embodiments, the treatment regimen may comprise (a)administering to the patient a first dose, the first dose comprising atherapeutically effective amount of an antacid; and (b) within 2 hoursafter the first dose, administering a second dose to the patient, thesecond dose comprising a pharmaceutical composition of the presentdisclosure. In some embodiments, the treatment regimen may comprise (a)administering to the patient a first dose, the first dose comprising apharmaceutical composition of the present disclosure; and (b) within 2hours after the first dose, administering a second dose to the patient,the second dose comprising a therapeutically effective amount of anantacid.

Methods of Treating a Patient Having Elevated Gastric pH

The pharmaceutical compositions of the present disclosure may besuitably administered to subjects or patients with an elevated gastricpH.

One aspect of the present disclosure relates to the use of the nilotinibASDs or pharmaceutical compositions of the present disclosure to delivernilotinib to a subject or patient with elevated gastric pH. Someembodiments relate to a method of delivering nilotinib to a subject withelevated gastric pH, the method comprising administering the ASD orpharmaceutical composition of the present disclosure to the subject orpatient. Some embodiments relate to a use of a nilotinib ASD orpharmaceutical composition of the present disclosure for deliveringnilotinib to a subject or patient with elevated gastric pH, the usecomprising administering the ASD or pharmaceutical composition to thesubject or patient. Some embodiments relate to a nilotinib ASD orpharmaceutical composition of the present disclosure for use indelivering nilotinib to a subject or patient with elevated gastric pH,the use comprising administering the ASD or pharmaceutical compositionto the subject or patient. Some embodiments relate to a use of anilotinib ASD or pharmaceutical composition of the present disclosure inthe manufacture of a medicament for delivering nilotinib to a subject orpatient with elevated gastric pH, the delivery comprising administeringthe ASD or pharmaceutical composition to the subject or patient.

As used herein, “gastric pH” refers to the pH inside a subject's orpatient's stomach. Gastric pH may be considered as “elevated” when it isgreater than 3.5, or greater than 4, or greater than 5, measured underfasting conditions. Gastric pH can be evaluated using standard methods,or an elevated gastric pH can be inferred from the known effects of, forexample, treatment with gastric acid-reducing agents or an identifiedcondition that regularly leads to a measurable elevated gastric pH.

In the practice of the present disclosure, subject or patient may havean elevated gastric pH due to different reasons, including, but notlimited to, the subject or patient was administered a gastricacid-reducing agent, or the subject or patient may have a condition thatleads to elevated gastric pH. Elevated gastric pH can result fromconditions such as hypochlorhydria or achlorhydria, or infection byHelicobacter pylori (H. pylori) bacteria, for example.

As used herein, the phrase “chronically elevated” in reference togastric pH means that the subject or patient experiences elevatedgastric pH on a persistent or recurring basis. Chronically elevatedgastric pH can result from, for example, conditions such ashypochlorhydria or achlorhydria, or infection by Helicobacter pyloribacteria.

In some embodiments, the methods of the disclosure may contain a step ofidentifying a condition by which the patient's gastric pH is elevated(including conditions by which it is chronically elevated). Such a stepmay comprise diagnosing the underlying cause of the elevated gastric pH.It is known in medical practice how to diagnose hypochlorhydria orachlorhydria in patient, or how to test for a Helicobacter pyloribacteria infection. Hypochlorhydria or achlorhydria can be diagnosed,for example, by measuring stomach acid levels under differentconditions. Helicobacter pylori bacterial infection can be diagnosed byan appropriate blood test, stool test, breath test, or scope test, forexample.

In some embodiments, the nilotinib ASD or pharmaceutical composition maybe administered to a subject or patient without regard to gastric pH.Thus, the subject or patient may be administered the nilotinib ASD orpharmaceutical composition no matter whether the subject or patient hasnormal gastric pH (i.e., gastric pH below 3.5, generally in the range1.5 to 3) or has elevated gastric pH as described herein. This isbeneficial when, for example, the subject or patient has gastric pH thatfluctuates due to irregular or episodic use of gastric acid-reducingagents, or if the subject or patient has hypochlorhydria (resulting in agastric pH that may fluctuate depending on factors such as whether thesubject or patient has recently eaten).

In some embodiments, administration of an ASD or pharmaceuticalcomposition of the present disclosure to a subject or patient who haselevated gastric pH exhibits a pharmacokinetic profile for nilotinibthat is similar to the pharmacokinetic profile resulting fromadministration of the ASD or pharmaceutical composition to a subject orpatient who has normal gastric pH. In certain embodiments, singleadministration of the ASD or pharmaceutical composition to a subject orpatient with elevated gastric pH results in AUC_(0-t) (such asAUC_(0-24 h), AUC_(0-last) or AUC_(0-inf)) and/or C_(max) of nilotinibthat is within 50%, or within 40%, or within 30%, of the AUC_(0-t)and/or C_(max) of nilotinib that results from single administration ofthe ASD or pharmaceutical composition to a subject or patient withnormal gastric pH. In certain embodiments, the AUC_(0-t) isAUC_(0-24 h). In other embodiments, the AUC_(0-t) is AUC_(0-inf).

In certain embodiments, administration of the ASD or pharmaceuticalcomposition of the present disclosure in a subject or patient withelevated gastric pH may provide AUC_(0-t) (such as AUC_(0-24 h),AUC_(0-last) or AUC_(0-inf)) and C_(max) in the subject's or patient'splasma that are within the 80% to 125% bioequivalence criteria comparedto administration of a conventional immediate-release nilotinibcomposition dosed to subjects or patients with normal gastric pH. Incertain embodiments, the AUC_(0-t) is AUC_(0-24 h). In otherembodiments, the AUC_(0-t) is AUC_(0-inf).

In the practice of the present disclosure, administration of an ASD or apharmaceutical composition can provide enhanced exposure as compared tostandard immediate-release compositions. In some embodiments, singleadministration of an ASD or pharmaceutical composition of the presentdisclosure to a subject or patient who has elevated gastric pH exhibitsgreater AUC and/or C_(max) as compared to single administration of aconventional immediate-release composition of nilotinib (e.g., TASIGNA)to a subject or patient who has elevated gastric pH. (It should beunderstood that the same molar quantity or “label claim” of nilotinib isadministered in each case.) In certain embodiments, the AUC isAUC_(0-24 h). In other embodiments, the AUC is AUC_(0-inf). In certainembodiments, single administration of the ASD or pharmaceuticalcomposition to a subject or patient with elevated gastric pH results inAUC_(0-t) and/or C_(max) of nilotinib that is at least 80% greater, orat least 100% greater, or at least 150% greater, or at least 200%greater, than the AUC_(0-t) and/or C_(max) of nilotinib that resultsfrom administration of a conventional immediate-release composition ofnilotinib to the subject or patient with elevated gastric pH. In certainembodiments, the AUC_(0-t) is AUC_(0-24 h). In other embodiments, theAUC_(0-t) is AUC_(0-inf).

Further, one aspect of the present disclosure relates to the use of thenilotinib ASDs or pharmaceutical compositions of the present disclosureto deliver nilotinib to a subject without regard to the subject'sgastric pH. Some embodiments relate to a method of delivering nilotinibto a subject without regard to the subject's gastric pH, the methodcomprising administering the ASD or pharmaceutical composition of thepresent disclosure to the subject. Some embodiments relate to a use of anilotinib ASD or pharmaceutical composition of the present disclosurefor delivering nilotinib to a subject without regard to the subject'sgastric pH, the use comprising administering the ASD or pharmaceuticalcomposition to the subject. Some embodiments relate to a nilotinib ASDor pharmaceutical composition of the present disclosure for use indelivering nilotinib to a subject without regard to the subject'sgastric pH, the use comprising administering the ASD or pharmaceuticalcomposition to the subject. Some embodiments relate to a use of anilotinib ASD or pharmaceutical composition of the present disclosure inthe manufacture of a medicament for delivering nilotinib to a subjectwithout regard to the subject's gastric pH, the delivery comprisingadministering the ASD or pharmaceutical composition to the subject.According to these embodiments, the subject may be administered thenilotinib ASD or pharmaceutical composition no matter whether thesubject has normal gastric pH or has elevated gastric pH as describedherein.

Pharmaceutical Composition Having Improved Variability

The pharmaceutical compositions of the present disclosure may, in someembodiments, provide a less variable in vivo pharmacokineticperformance.

As used herein, the phrase “improved variability composition” refers toa composition of the present disclosure that exhibits a lowercoefficient of variation with respect to one or more pharmacokineticparameters when administered to an appropriate set of healthy humansubjects, as compared to the coefficient of variation observed for aconventional immediate-release formulation of nilotinib (e.g., TASIGNA)when administered under similar conditions. For this assessment, the setof healthy human subjects should include a suitable number of subjectssuch that the study would be sufficiently powered to demonstratebioequivalence, according to standard practices and relevant FDAguidelines.

In some embodiments, the improved variability composition provides acoefficient of variation with respect to at least one pharmacokineticparameter that is 30% lower, 25% lower, 20% lower, 15% lower, 10% lower,or 5% lower than the coefficient of variation observed for the standardcommercial, immediate-release composition of nilotinib (e.g., TASIGNA)when administered under similar conditions. The pharmacokineticparameter can be any of C_(max), AUC_(last) and AUC_(0-inf). In someembodiments, the improved variability composition provides animprovement with respect to C_(max) and at least one of AUC_(last) andAUC_(0-inf). In other embodiments, the improved variability compositionprovides an improvement with respect to all of C_(max), AUC_(last) andAUC_(0-inf).

In particular, it has been observed that compositions according to thepresent disclosure can provide a lower coefficient of variation forpharmacokinetic parameters when administered to healthy human subjectsin a fasted state. As shown in Example 5 (Table 24), test compositionsexhibited a lower coefficient of variation with respect to C_(max),AUC_(last) and AUC_(0-inf) under these conditions. The observed CV forthe test compositions was at least 30% lower with respect to C_(max), ascompared to the reference composition.

Kits Comprising a Pharmaceutical Composition and a Package Insert

In some embodiments, the disclosure provides a kit containing apharmaceutical composition according to any of the above-describedaspects of the disclosure, as well as a package insert. As used herein,a “kit” is a commercial unit of sale, which may comprise a fixed numberof doses of the pharmaceutical composition. By way of example only, akit may provide a 30-day supply of dosage units of one or more fixedstrengths, the kit comprising 30 dosage units, 60 dosage units, 90dosage units, 120 dosage units, or other appropriate number according toa physician's instruction. As another example, a kit may provide a90-day supply of dosage units.

As used herein, “package insert” means a document which providesinformation on the use of the pharmaceutical composition, safetyinformation, and other information required by a regulatory agency. Apackage insert can be a physical printed document in some embodiments.Alternatively, a package insert can be made available electronically tothe user, such as via the Daily Med service of the National Library ofMedicines of the National Institute of Health, which provides up-to-dateprescribing information (seehttps://dailymed.nlm.nih.gov/dailymed/index.cfm).

In some embodiments, the package insert informs a user of the kit thatthe pharmaceutical composition can be administered with food. In someembodiments, the package insert informs a user of the kit that thepharmaceutical composition can be administered with or without food. Insome embodiments, the package insert does not include a warning that thepharmaceutical composition should not be administered with food.

In some embodiments, the package insert informs a user of the kit thatthe pharmaceutical composition can be co-administered with a gastricacid-reducing agent. In some embodiments, the package insert does notcomprise a warning that the pharmaceutical composition should not beco-administered with H₂ antagonists or proton pump inhibitors.

In some embodiments, the package insert informs a user of the kit that aproton pump inhibitor can be co-administered with the pharmaceuticalcomposition. In some embodiments, the package insert does not include awarning that concomitant use of a proton pump inhibitor with thepharmaceutical composition should be avoided.

In some embodiments, the package insert informs a user of the kit thatan H₂ antagonist can be co-administered with the pharmaceuticalcomposition. In some embodiments, the package insert does not inform theuser to use an H₂ antagonist approximately 10 hours before orapproximately 2 hours after administration of the pharmaceuticalcomposition. In some embodiments, the package insert informs the userthat an H₂ antagonist can be used within approximately 10 hours beforeor within approximately 2 hours after administration of thepharmaceutical composition.

In some embodiments, the package insert informs a user of the kit thatan antacid can be co-administered with the pharmaceutical composition.In some embodiments, the package insert does not inform the user to usean antacid approximately 2 hours before or approximately 2 hours afteradministration of the pharmaceutical composition. In some embodiments,the package insert informs the user that an antacid can be used withinapproximately 2 hours before or within approximately 2 hours afteradministration of the pharmaceutical composition.

In some embodiments, the package insert informs a user of the kit thatthe pharmaceutical composition can be suitably administered to a userhaving chronically elevated gastric pH. In some embodiments, the packageinsert informs a user of the kit that the pharmaceutical composition canbe suitably administered to a patient diagnosed with or afflicted byachlorhydria or hypochlorhydria. In some embodiments, the package insertinforms a user of the kit that the pharmaceutical composition can besuitably administered to a patient diagnosed with or afflicted byHelicobacter pylori infection.

The present disclosure will be further illustrated and/or demonstratedin the following Examples, which are given forillustration/demonstration purposes only and are not intended to limitthe disclosure in any way.

Embodiments of the Disclosure Include:

Embodiment ASD1 is an amorphous solid dispersion comprising nilotiniband one or more polymers.

Embodiment ASD2 is an amorphous solid dispersion comprising nilotiniband one or more polymers; wherein the nilotinib and the one or morepolymers are present in the amorphous solid dispersion in a w/w ratio of20:80 to 95:5 (nilotinib:polymer). Embodiment ASD3 is an amorphous soliddispersion comprising nilotinib and one or more polymers, wherein thenilotinib and the one or more polymers are present in the amorphoussolid dispersion in a w/w ratio of 40:60 to 70:30 (nilotinib:polymer).Embodiment ASD4 is an amorphous solid dispersion comprising nilotiniband one or more polymers, wherein the nilotinib and the one or morepolymers are present in the amorphous solid dispersion in a w/w ratio of50:50 (nilotinib:polymer).

Embodiment ASD5 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD4, wherein the one or more polymers exhibitspH-dependent solubility.

Embodiment ASD6 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD5, wherein the one or more polymers comprises ahydroxypropyl methylcellulose acetate succinate. Embodiment ASD7 is theamorphous solid dispersion according to Embodiment ASD6, wherein the oneor more polymers consists essentially of a hydroxypropyl methylcelluloseacetate succinate. Embodiment ASD8 is the amorphous solid dispersionaccording to any of Embodiments ASD6 to ASD7, wherein the one or morepolymers comprise a hydroxypropyl methylcellulose acetate succinatecharacterized by an acetyl substitution of 7 to 11% and a succinylsubstitution of 10 to 14%.

Embodiment ASD9 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD5, wherein the one or more polymers comprises amethacrylic acid and ethyl acrylate copolymer. Embodiment ASD10 is theamorphous solid dispersion according to Embodiment ASD9, wherein the oneor more polymers consists essentially of a methacrylic acid and ethylacrylate copolymer. Embodiment ASD11 is the amorphous solid dispersionaccording to any of Embodiments ASD9 to ASD10, wherein the one or morepolymers comprise a methacrylic acid and ethyl acrylate copolymer thatis insoluble in an aqueous medium at pH of 5 or lower, and soluble in anaqueous medium at pH 5.5 or greater.

Embodiment ASD12 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD11 wherein the amorphous solid dispersionconsists essentially of nilotinib and the one or more polymers.

Embodiment ASD13 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD12, wherein the amorphous solid dispersioncomprises one or more antioxidants. Embodiment ASD14 is the amorphoussolid dispersion according to any of Embodiments ASD1 to ASD13, whereinthe amorphous solid dispersion comprises one or more antioxidants thatare present in an amount of 0.001% to 2% by weight of the amorphoussolid dispersion. Embodiment ASD15 is the amorphous solid dispersionaccording to any of Embodiments ASD1 to ASD14, wherein the amorphoussolid dispersion comprises one or more antioxidants that are present inan amount of 0.05% to 0.5% by weight of the amorphous solid dispersion.Embodiment ASD16 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD15, wherein the amorphous solid dispersioncomprises one or more antioxidants selected from butylatedhydroxytoluene.

Embodiment ASD17 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD16, wherein the amorphous solid dispersion isprepared by a process comprising electrospraying. Embodiment ASD18 isthe amorphous solid dispersion according to any of Embodiments ASD1 toASD16, wherein the amorphous solid dispersion is an electrosprayedamorphous solid dispersion.

Embodiment ASD19 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD16, wherein the amorphous solid dispersion isprepared by a process comprising spray drying. Embodiment ASD20 is theamorphous solid dispersion according to any of Embodiments ASD1 toASD16, wherein the amorphous solid dispersion is a spray-dried amorphoussolid dispersion.

Embodiment ASD21 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD20, wherein the amorphous solid dispersionremains amorphous or essentially amorphous as determined by powder X-raydiffraction after storage at 40° C./75% relative humidity for 6 months.Embodiment ASD22 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD20, wherein the amorphous solid dispersionremains amorphous or essentially amorphous as determined by powder X-raydiffraction after storage at 25° C./60% relative humidity for 6 months.

Embodiment ASD23 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD20, wherein the amorphous solid dispersioncomprises a water content as measured by coulometric Karl Fischertitration of not more than 4% after storage at 25° C./60% RH for 12months. Embodiment ASD24 is the amorphous solid dispersion according toany of Embodiments ASD1 to ASD20, wherein the amorphous solid dispersioncomprises a water content as measured by coulometric Karl Fischertitration of not more than 4% after storage at 40° C./75% RH for 6months.

Embodiment ASD25 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD20, wherein the amorphous solid dispersion ischaracterized by an assay level of at least 90% as measured by highperformance liquid chromatography (HPLC) after storage at 25° C./60%relative humidity for 12 months. Embodiment ASD26 is the amorphous soliddispersion according to any of Embodiments ASD1 to ASD20, wherein theassay level of the amorphous solid dispersion is at least 90% afterstorage at 40° C./75% relative humidity for 6 months.

Embodiment ASD27 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD20, wherein the amorphous solid dispersioncomprises a total related substances as measured by HPLC of not morethan 1% after storage at 25° C./60% RH for 12 months. Embodiment ASD28is the amorphous solid dispersion according to any of Embodiments ASD1to ASD20, wherein the amorphous solid dispersion comprises a totalrelated substances as measured by HPLC of not more than 1% after storageat 40° C./75% RH for 6 months.

Embodiment ASD29 is the amorphous solid dispersion according to any ofEmbodiments ASD1 to ASD20, wherein the amorphous solid dispersioncomprises a glass transition temperature as measured by modulateddifferential scanning calorimetry that does not change by more than 5°C. after storage at 25° C./60% RH for 12 months. Embodiment ASD30 is theamorphous solid dispersion according to any of Embodiments ASD1 toASD20, wherein the amorphous solid dispersion comprises a glasstransition temperature as measured by modulated differential scanningcalorimetry that does not change by more than 5° C. after storage at 40°C./75% RH for 6 months.

Embodiment PC1 is a pharmaceutical composition comprising the amorphoussolid dispersion according to any of Embodiments ASD1 to ASD30.

Embodiment PC2 is a pharmaceutical composition comprising the amorphoussolid dispersion according to any of Embodiments ASD1 to ASD30, and oneor more pharmaceutically acceptable additives. Embodiment PC3 is thepharmaceutical composition of Embodiment PC2, wherein the one or morepharmaceutically acceptable additives comprises one or moresolubilizers, one or more buffering agent, one or more pH-adjustingagents, one or more surfactants, one or more antioxidants, one or morecarriers, or a combination thereof. Embodiment PC4 is the pharmaceuticalcomposition of Embodiment PC2, wherein the one or more pharmaceuticallyacceptable additives comprises one or more filling agents, one or morebinding agents, one or more lubricants, one or more disintegrants, oneor more glidants, or a combination thereof. Embodiment PC5 is thepharmaceutical composition of Embodiment PC4, wherein the pharmaceuticalcomposition is a solid dosage form suitable for oral administration.Embodiment PC6 is the pharmaceutical composition of Embodiment PC4,wherein the pharmaceutical composition is presented as a solid dosageform suitable for oral administration, and comprising 25 to 100 mgnilotinib.

Embodiment PC7 is the pharmaceutical composition of Embodiment PC6,wherein, when the oral dosage form is administered to a healthy humansubjects in a fasted state, achieves an AUC_(0-inf) and C_(max) withinthe 80% to 125% bioequivalence criteria as compared to AUC_(0-inf) andC_(max) achieved upon administration of a reference composition, whereinthe reference composition is a conventional immediate-release nilotinibcomposition comprising 200 mg nilotinib monohydrochloride monohydrate.

Embodiment PC8 is the pharmaceutical composition of Embodiment PC6,wherein the pharmaceutical composition is effectively bioequivalentunder fasting conditions to a reference composition which is aconventional immediate-release nilotinib composition comprising 200 mgnilotinib monohydrochloride monohydrate; where effective bioequivalenceis established by: (a) a 90% confidence interval for AUC which isbetween 80% and 125%; and (b) a 90% confidence interval for C_(max),which is between 80% and 125%.

Embodiment PC9 is the pharmaceutical composition of Embodiment PC1 toPC8, wherein the pharmaceutical composition is a food-insensitivecomposition.

Embodiment PC10 is the pharmaceutical composition of Embodiment PC1 toPC9, wherein the pharmaceutical composition is a gastricacid-insensitive composition.

Embodiment PC11 is the pharmaceutical composition of Embodiment PC1 toPC10, wherein the pharmaceutical composition is an improved variabilitycomposition.

Embodiment MT1 is a method of treating a proliferative disorder in apatient in need thereof, the method comprising administering to thepatient a pharmaceutical composition according to any of Embodiments PC1to PC11.

Embodiment MT2 is a method of treating a proliferative disorder in apatient in need thereof, the method comprising administering to thepatient a pharmaceutical composition according to any of Embodiments PC1to PC11, wherein the pharmaceutical composition is administered withoutregard to consumption of food. Embodiment MT3 is a method of treating aproliferative disorder in a patient in need thereof, the methodcomprising administering to the patient a pharmaceutical compositionaccording to any of Embodiments PC1 to PC11, wherein the pharmaceuticalcomposition is administered without regard to whether the patient is ina fasted state or a fed state. Embodiment MT4 is a method of treating aproliferative disorder in a patient in need thereof, the methodcomprising administering to the patient a pharmaceutical compositionaccording to any of Embodiments PC1 to PC11, without a food effect.

Embodiment MT5 is a method of safely delivering nilotinib to a patientin need thereof, the method comprising: (a) administering to the patienta therapeutically effective amount of a pharmaceutical compositionaccording to any of Embodiments PC1 to PC11, and (b) administering ameal to the patient; wherein steps (a) and (b) occur within less thantwo hours of each other.

Embodiment MT6 is a method of delivering a therapeutically effectiveamount of nilotinib to a patient without regard to consumption of food,comprising administering to the patient a pharmaceutical compositionaccording to any of Embodiments PC1 to PC11. Embodiment MT7 is a methodof delivering a therapeutically effective amount of nilotinib to apatient without regard to whether the patient is in a fasted state or afed state, comprising administering to the patient a pharmaceuticalcomposition according to any of Embodiments PC1 to PC11.

Embodiment MT8 is the method according to any of Embodiments MT1 to MT7,wherein administration of the pharmaceutical composition to the patientin a fed state results in plasma C_(max) of nilotinib that is less thanthe plasma C_(max) of nilotinib resulting from administration of thepharmaceutical composition to the patient in a fasted state. EmbodimentMT9 is the method according to any of Embodiments MT1 to MT7, whereinadministration of the pharmaceutical composition to the patient in a fedstate results in plasma C_(max) of nilotinib that is within 30% of theplasma C_(max) of nilotinib resulting from administration of thepharmaceutical composition to the patient in a fasted state.

Embodiment MT10 is the method according to any of Embodiments MT1 toMT9, wherein administration of the pharmaceutical composition to thepatient in a fed state results in plasma AUC of nilotinib that is lessthan the plasma AUC of nilotinib resulting from administration of thepharmaceutical composition to the patient in a fasted state. EmbodimentMT11 is the method according to any of Embodiments MT1 to MT9, whereinadministration of the pharmaceutical composition to the patient in a fedstate results in plasma AUC of nilotinib that is within 30% of theplasma AUC of nilotinib resulting from administration of thepharmaceutical composition to the patient in a fasted state. EmbodimentMT12 is the method according to any of Embodiments MT1 to MT9, whereinadministration of the pharmaceutical composition to the patient in a fedstate results in plasma AUC of nilotinib that is within 15% of theplasma AUC of nilotinib resulting from administration of thepharmaceutical composition to the patient in a fasted state. EmbodimentMT13 is the method according to any of Embodiments MT10 to MT12, whereinAUC is AUC_(0-12 h). Embodiment MT14 is the method according to any ofEmbodiments MT10 to MT12, wherein AUC is AUC_(0-24 h). Embodiment MT15is the method according to any of Embodiments MT10 to MT12, wherein AUCis AUC_(0-last). Embodiment MT16 is the method according to any ofEmbodiments MT10 to MT12, wherein AUC is AUC_(0-inf).

Embodiment MT17 is the method according to any of Embodiments MT1 toMT7, wherein administration of the pharmaceutical composition to thepatient in a fasted state results in plasma C_(max) of nilotinib that isgreater than the plasma C_(max) of nilotinib resulting fromadministration of an immediate-release crystalline nilotinib formulationthat has two times to four times the amount of nilotinib as thepharmaceutical composition. Embodiment MT18 is the method according toany of Embodiments MT1 to MT7, wherein administration of thepharmaceutical composition to the patient in a fed state results inplasma C_(max) of nilotinib that is within 25% of the plasma C_(max) ofnilotinib resulting from administration of an immediate-releasecrystalline nilotinib formulation that has two times to four times theamount of nilotinib as the pharmaceutical composition.

Embodiment MT19 is the method according to any of Embodiments MT1 toMT7, wherein administration of the pharmaceutical composition to thepatient in a fasted state results in plasma AUC of nilotinib that isgreater than the plasma AUC of nilotinib resulting from administrationof an immediate-release crystalline nilotinib formulation that has twotimes to four times the amount of nilotinib as the pharmaceuticalcomposition. Embodiment MT20 is the method according to any ofEmbodiments MT1 to MT7, wherein administration of the pharmaceuticalcomposition to the patient in a fed state results in plasma AUC ofnilotinib that is within 25% of the plasma AUC of nilotinib resultingfrom administration of an immediate-release crystalline nilotinibformulation that has two times to four times the amount of nilotinib asthe pharmaceutical composition. Embodiment MT21 is the method accordingto any of Embodiments MT1 to MT7, wherein administration of thepharmaceutical composition to the patient in a fed state results inplasma AUC of nilotinib that is within 20% of the plasma AUC ofnilotinib resulting from administration of an immediate-releasecrystalline nilotinib formulation that has two times to four times theamount of nilotinib as the pharmaceutical composition. Embodiment MT22is the method according to any of Embodiments MT19 to MT21, wherein AUCis AUC_(0-12 h). Embodiment MT23 is the method according to any ofEmbodiments MT19 to MT21, wherein AUC is AUC_(0-24 h). Embodiment MT24is the method according to any of Embodiments MT19 to MT21, wherein AUCis AUC_(0-last). Embodiment MT25 is the method according to any ofEmbodiments MT19 to MT21, wherein AUC is AUC_(0-inf).

Embodiment MT26 is a method of treating a proliferative disorder in apatient in need thereof, the method comprising administering to thepatient a pharmaceutical composition according to any of Embodiments PC1to PC11, without regard to whether the patient is co-administered aproton pump inhibitor. Embodiment MT27 is a method of delivering atherapeutically effective amount of nilotinib to a patient who isco-administered a proton pump inhibitor, comprising administering to thepatient (a) a pharmaceutical composition according to any of EmbodimentsPC1 to PC11, and (b) a proton pump inhibitor.

Embodiment MT28 is the method according to any of Embodiments MT1 toMT27, wherein the proliferative disorder is cancer. Embodiment MT29 isthe method according to any of Embodiments MT1 to MT27, wherein theproliferative disorder is Philadelphia chromosome positive chronicmyeloid leukemia. Embodiment MT30 is the method according to any ofEmbodiments MT1 to MT27, wherein the proliferative disorder is chronicphase Philadelphia chromosome positive chronic myeloid leukemiaresistant or intolerant to prior tyrosine kinase inhibitor therapy.

Embodiment MS1 is a method of delivering a therapeutically relevantexposure of nilotinib to a subject without regard to whether the subjectis in a fasted state or a fed state, the method comprising administeringto the subject a pharmaceutical composition according to any ofEmbodiments PC1 to PC11.

Embodiment MS2 is the method according to Embodiment MS1, whereinadministration of the pharmaceutical composition to the subject in a fedstate results in plasma C_(max) of nilotinib that is less than theplasma C_(max) of nilotinib resulting from administration of thepharmaceutical composition to the subject in a fasted state. EmbodimentMS3 is the method according to Embodiment MS1, wherein administration ofthe pharmaceutical composition to the subject in a fed state results inplasma C_(max) of nilotinib that is within 30% of the plasma C_(max) ofnilotinib resulting from administration of the pharmaceuticalcomposition to the subject in a fasted state.

Embodiment MS4 is the method according to Embodiment MS1, whereinadministration of the pharmaceutical composition to the subject in a fedstate results in plasma AUC of nilotinib that is less than the plasmaAUC of nilotinib resulting from administration of the pharmaceuticalcomposition to the subject in a fasted state. Embodiment MS5 is themethod according to Embodiment MS1, wherein administration of thepharmaceutical composition to the subject in a fed state results inplasma AUC of nilotinib that is within 30% of the plasma AUC ofnilotinib resulting from administration of the pharmaceuticalcomposition to the subject in a fasted state. Embodiment MS6 is themethod according to Embodiment MS1, wherein administration of thepharmaceutical composition to the subject in a fed state results inplasma AUC of nilotinib that is within 15% of the plasma AUC ofnilotinib resulting from administration of the pharmaceuticalcomposition to the subject in a fasted state. Embodiment MS7 is themethod according to any of Embodiments MS4 to MS6, wherein AUC isAUC_(0-12 h). Embodiment MS8 is the method according to any ofEmbodiments MS4 to MS6, wherein AUC is AUC_(0-24 h). Embodiment MS9 isthe method according to any of Embodiments MS4 to MS6, wherein AUC isAUC_(0-last). Embodiment MS10 is the method according to any ofEmbodiments MS4 to MS6, wherein AUC is AUC_(0-inf).

Embodiment MS11 is the method according to Embodiment MS1, whereinadministration of the pharmaceutical composition to the subject in afasted state results in plasma C_(max) of nilotinib that is greater thanthe plasma C_(max) of nilotinib resulting from administration of animmediate-release crystalline nilotinib formulation that has two timesto four times the amount of nilotinib as the pharmaceutical composition.Embodiment MS12 is the method according to Embodiment MS1, whereinadministration of the pharmaceutical composition to the subject in a fedstate results in plasma C_(max) of nilotinib that is within 25% of theplasma C_(max) of nilotinib resulting from administration in a fastedstate of an immediate-release crystalline nilotinib formulation that hastwo times to four times the amount of nilotinib as the pharmaceuticalcomposition.

Embodiment MS13 is the method according to Embodiment MS1, whereinadministration of the pharmaceutical composition to the subject in afasted state results in plasma AUC of nilotinib that is greater than theplasma AUC of nilotinib resulting from administration of animmediate-release crystalline nilotinib formulation that has two timesto four times the amount of nilotinib as the pharmaceutical composition.Embodiment MS14 is the method according to Embodiment MS1, whereinadministration of the pharmaceutical composition to the subject in a fedstate results in plasma AUC of nilotinib that is within 25% of theplasma AUC of nilotinib resulting from administration in a fasted stateof an immediate-release crystalline nilotinib formulation that has twotimes to four times the amount of nilotinib as the pharmaceuticalcomposition. Embodiment MS15 is the method according to Embodiment MS1,wherein administration of the pharmaceutical composition to the subjectin a fed state results in plasma AUC of nilotinib that is within 20% ofthe plasma AUC of nilotinib resulting from administration in a fastedstate of an immediate-release crystalline nilotinib formulation that hastwo times to four times the amount of nilotinib as the pharmaceuticalcomposition. Embodiment MS16 is the method according to any ofEmbodiments MS13 to MS15, wherein AUC is AUC_(0-12 h). Embodiment MS17is the method according to any of Embodiments MS13 to MS15, wherein AUCis AUC_(0-24 h). Embodiment MS18 is the method according to any ofEmbodiments MS13 to MS15, wherein AUC is AUC_(0-last). Embodiment MS19is the method according to any of Embodiments MS13 to MS15, wherein AUCis AUC_(0-inf).

Embodiment TR1 is a treatment regimen for treating a proliferativedisorder in a patient in need thereof, the regimen comprising: (a)administering to the patient a first dose, the first dose comprising aproton pump inhibitor; and (b) within 12 hours of the first dose,administering a second dose to the patient, the second dose comprising apharmaceutical composition according to any of Embodiments PC1 to PC11.

Embodiment TR2 is a treatment regimen for treating a proliferativedisorder and a condition caused by the overproduction of stomach acid orexacerbated by stomach acid in a patient in need thereof, the regimencomprising: (a) administering to the patient a first dose, the firstdose comprising therapeutically effective amount of a proton pumpinhibitor; and (b) within 12 hours of the first dose, administering asecond dose to the patient, the second dose comprising a pharmaceuticalcomposition according to any of Embodiments PC1 to PC11.

Embodiment TR3 is the treatment regimen according to any of EmbodimentsTR1 to TR2, wherein the first dose comprises a standard dosage of aproton pump inhibitor selected from rabeprazole, esomeprazole,lansoprazole, omeprazole, pantoprazole, dexlansoprazole, or acombination thereof. Embodiment TR4 is the treatment regimen accordingto any of Embodiments TR1 to TR2, wherein the first dose comprises astandard dosage of omeprazole.

Embodiment TR5 is the treatment regimen according to any of EmbodimentsTR1 to TR4, wherein step (a) occurs before step (b). Embodiment TR6 isthe treatment regimen according to any of Embodiments TR1 to TR4,wherein step (b) occurs before step (a). Embodiment TR7 is the treatmentregimen according to any of Embodiments TR1 to TR6, wherein the seconddose is administered within 8 hours of the first dose. Embodiment TR8 isthe treatment regimen according to any of Embodiments TR1 to TR6,wherein the second dose is administered within 6 hours of the firstdose. Embodiment TR9 is the treatment regimen according to any ofEmbodiments TR1 to TR6, wherein the second dose is administered within 4hours of the first dose. Embodiment TR10 is the treatment regimenaccording to any of Embodiments TR1 to TR6, wherein the second dose isadministered within 2 hours of the first dose. Embodiment TR11 is thetreatment regimen according to any of Embodiments TR1 to TR6, whereinthe first dose and the second dose are administered concurrently.

Embodiment TR12 is a treatment regimen for treating a proliferativedisorder in a patient in need thereof, the regimen comprising: (a)administering to the patient a first dose, the first dose comprising anH₂ antagonist; and (b) within 10 hours after the first dose,administering a second dose to the patient, the second dose comprising apharmaceutical composition according to any of Embodiments PC1 to PC11.Embodiment TR13 is a treatment regimen for treating a proliferativedisorder and a condition caused by the overproduction of stomach acid orexacerbated by stomach acid in a patient in need thereof, the regimencomprising: (a) administering to the patient a first dose, the firstdose comprising a therapeutically effective amount of an H₂ antagonist;and (b) within 10 hours after the first dose, administering a seconddose to the patient, the second dose comprising a pharmaceuticalcomposition according to any of Embodiments PC1 to PC11. Embodiment TR14is the treatment regimen according to any of Embodiments TR12 to TR13,wherein the second dose is administered within 8 hours of the firstdose. Embodiment TR15 is the treatment regimen according to any ofEmbodiments TR12 to TR13, wherein the second dose is administered within6 hours of the first dose. Embodiment TR16 is the treatment regimenaccording to any of Embodiments TR12 to TR13, wherein the second dose isadministered within 4 hours of the first dose. Embodiment TR17 is thetreatment regimen according to any of Embodiments TR12 to TR13, whereinthe second dose is administered within 2 hours of the first dose.Embodiment TR18 is the treatment regimen according to any of EmbodimentsTR12 to TR13, wherein the first dose and the second dose areadministered concurrently.

Embodiment TR19 is a treatment regimen for treating a proliferativedisorder in a patient in need thereof, the regimen comprising: (a)administering to the patient a first dose, the first dose comprising apharmaceutical composition according to any of Embodiments PC1 to PC11;and (b) within 2 hours after the first dose, administering a second doseto the patient, the second dose comprising an H₂ antagonist. EmbodimentTR20 is a treatment regimen for treating a proliferative disorder and acondition caused by the overproduction of stomach acid or exacerbated bystomach acid in a patient in need thereof, the regimen comprising: (a)administering to the patient a first dose, the first dose comprising apharmaceutical composition according to any of Embodiments PC1 to PC11;and (b) within 2 hours after the first dose, administering a second doseto the patient, the second dose comprising a therapeutically effectiveamount of an H₂ antagonist. Embodiment TR21 is the treatment regimenaccording to any of Embodiments TR19 to TR20, wherein the first dose andthe second dose are administered concurrently. Embodiment TR22 is thetreatment regimen according to any of Embodiments TR12 to TR21, whereinthe H₂ antagonist is selected from famotidine, cimetidine, nizatidine,ranitidine, or a combination thereof. Embodiment TR23 is the treatmentregimen according to any of Embodiments TR12 to TR21, wherein the H₂antagonist is famotidine.

Embodiment TR24 is a treatment regimen for treating a proliferativedisorder in a patient in need thereof, the regimen comprising: (a)administering to the patient a first dose, the first dose comprising anantacid; and (b) within 2 hours of the first dose, administering asecond dose to the patient, the second dose comprising a pharmaceuticalcomposition according to any of Embodiments PC1 to PC11. Embodiment TR25is a treatment regimen for treating a proliferative disorder and acondition caused by the overproduction of stomach acid or exacerbated bystomach acid in a patient in need thereof, the regimen comprising: (a)administering to the patient a first dose, the first dose comprising apharmaceutical composition according to any of Embodiments PC1 to PC11;and (b) within 2 hours of the first dose, administering a second dose tothe patient, the second dose comprising a therapeutically effectiveamount of an antacid. Embodiment TR26 is the treatment regimen accordingto any of Embodiments TR24 to TR25, wherein the first dose and thesecond dose are administered concurrently. Embodiment TR27 is thetreatment regimen according to any of Embodiments TR24 to TR26, whereinthe antacid is selected from aluminum hydroxide, magnesium hydroxide,and combinations thereof.

Embodiment TR28 is the treatment regimen according to any of EmbodimentsTR1 to TR27, wherein the proliferative disorder is cancer. EmbodimentTR29 is the treatment regimen according to any of Embodiments TR1 toTR27, wherein the proliferative disorder is Philadelphia chromosomepositive chronic myeloid leukemia. Embodiment TR30 is the treatmentregimen according to any of Embodiments TR1 to TR27, wherein theproliferative disorder is chronic phase Philadelphia chromosome positivechronic myeloid leukemia resistant or intolerant to prior tyrosinekinase inhibitor therapy.

Embodiment TR31 is the treatment regimen according to any of EmbodimentsTR1 to TR30, wherein administration of the pharmaceutical compositionprovides a therapeutically relevant exposure of nilotinib to thepatient.

Embodiment KT1 is a kit for sale to a user, the kit comprising apharmaceutical composition according to any of Embodiments PC1 to PC11and a package insert, wherein the package insert informs the user thatthe pharmaceutical composition can be administered with food. EmbodimentKT2 is a kit for sale to a user, the kit comprising a pharmaceuticalcomposition according to any of Embodiments PC1 to PC11 and a packageinsert, wherein the package insert informs the user that thepharmaceutical composition can be administered with or without food.Embodiment KT3 is a kit for sale to a user, the kit comprising apharmaceutical composition according to any of Embodiments PC1 to PC11and a package insert, wherein the package insert does not include awarning that the pharmaceutical composition should not be administeredwith food.

Embodiment KT4 is a kit for sale to a user, the kit comprising apharmaceutical composition according to any of Embodiments PC1 to PC11and a package insert, wherein the package insert that informs the userthat a proton pump inhibitor can be co-administered with thepharmaceutical composition. Embodiment KT5 is a kit for sale to a user,the kit comprising a pharmaceutical composition according to any ofEmbodiments PC1 to PC11 and a package insert, wherein the package insertdoes not include a warning that concomitant use of a proton pumpinhibitor with the pharmaceutical composition should be avoided.

Embodiment KT6 is a kit for sale to a user, the kit comprising apharmaceutical composition according to any of Embodiments PC1 to PC11and a package insert, wherein the package insert informs the user thatan H₂ antagonist can be co-administered with the pharmaceuticalcomposition. Embodiment KT7 is a kit for sale to a user, the kitcomprising a pharmaceutical composition according to any of EmbodimentsPC1 to PC11 and a package insert, wherein the package insert does notinform a user of the kit to use an H₂ antagonist approximately 10 hoursbefore or approximately 2 hours after administration of thepharmaceutical composition. Embodiment KT8 is a kit for sale to a user,the kit comprising a pharmaceutical composition according to any ofEmbodiments PC1 to PC11 and a package insert, wherein the package insertinforms a user of the kit that an H₂ antagonist can be used withinapproximately 10 hours before or within approximately 2 hours afteradministration of the pharmaceutical composition.

Embodiment KT9 is a kit for sale to a user, the kit comprising apharmaceutical composition according to any of Embodiments PC1 to PC11and a package insert, wherein the package insert informs the user thatan antacid can be co-administered with the pharmaceutical composition.Embodiment KT10 is a kit for sale to a user, the kit comprising apharmaceutical composition according to any of Embodiments PC1 to PC11and a package insert, wherein the package insert does not inform a userof the kit to use an antacid approximately 2 hours before orapproximately 2 hours after administration of the pharmaceuticalcomposition. Embodiment KT11 is a kit for sale to a user, the kitcomprising a pharmaceutical composition according to any of EmbodimentsPC1 to PC11 and a package insert, wherein the package insert informs auser of the kit that an antacid can be used within approximately 2 hoursbefore or within approximately 2 hours after administration of thepharmaceutical composition.

Embodiment KT12 is a kit for sale to a user, the kit comprising apharmaceutical composition according to any of Embodiments PC1 to PC11and a package insert, wherein the package insert informs the user thatthe pharmaceutical composition can be suitably administered if the userhas chronically elevated gastric pH. Embodiment KT13 is a kit for saleto a user, the kit comprising a pharmaceutical composition according toany of Embodiments PC1 to PC11 and a package insert, wherein packageinsert informs the user that the pharmaceutical composition can besuitably administered if the user has been diagnosed with or isafflicted by achlorhydria or hypochlorhydria. Embodiment KT14 is a kitfor sale to a user, the kit comprising a pharmaceutical compositionaccording to any of Embodiments PC1 to PC11 and a package insert,wherein the package insert informs the user that the pharmaceuticalcomposition can be suitably administered if the user has been diagnosedwith or is afflicted by Helicobacter pylori infection.

EXAMPLES Example 1. Preparation of Nilotinib ASDs and Stability StudyUnder Harsh Conditions

Nilotinib ASDs were prepared according to embodiments of the presentdisclosure. A study was then performed to assess the chemical andphysical stability of the nilotinib ASDs under harsh acceleratedconditions.

Nilotinib ASDs were prepared with either EUDRAGIT L100-55 or HPMC-AS asthe polymer, in the ratios shown in Table 2. To prepare eachcomposition, appropriate quantities of the polymer and nilotinib weredissolved in a 50:50 (v/v) solvent mixture of tetrahydrofuran andmethanol to provide a liquid feedstock. (The tetrahydrofuran wasstabilized with a small quantity of BHT as an antioxidant; therefore,the ASDs prepared in this example will contain a small, unquantifiedamount of BHT along with nilotinib and polymer.)

TABLE 2 Composition of the nilotinib ASDs for Example 1. ComponentsNilotinib:Polymer Ratio (w/w) Nilotinib:EUDRAGIT L100-55 50:50 60:4070:30 80:20 Nilotinib:HPMC-AS 50:50 60:40 70:30 80:20

The resulting feedstocks were sprayed at a total solid concentration of20 mg/ml using the Nanocopoeia ES machine ENS-P. For each spray run, thespray process parameters, such as extractor voltage and flow rate, wereadjusted to achieve an acceptable spray plume.

Following the electrospray processing, each ASD (now in the form of apowder) was subjected to a secondary drying procedure to reduce thelevels of residual solvents and moisture. For secondary drying, the ASDpowders were placed in an appropriate container and placed into an oven(Lindberg Blue M, Model V01218A) which was heated to 80° C. The powderswere dried under vacuum (negative 20″ to 28″ Hg) for six hours.

For compositions that required multiple spray sub-batches in order toprovide enough ASD material to support the stability study, materialobtained from sub-batches was combined into a single blend using aResodyn LabRam II acoustic mixer. Sub-batches were placed into a singlecontainer and blended for 2 minutes at a force setting of 40 G.

The resulting ASDs were placed on stability in an open dish underaggressive conditions at 50° C./80% RH. The ASD powders were assessed att=0, 1 week, 2 weeks, and 4 weeks for amorphicity (XRD), water content(Karl Fisher), glass transition temperature (DSC), and assay/relatedsubstances (HPLC).

Amorphicity

Amorphicity (i.e., the lack of crystallinity) for the ASDs was assessedby XRD. Diffraction patterns were obtained by x-ray diffraction using aRigaku MiniFlex 600. The X-ray source was a long anode Cu Kα. Sampleswere prepared by placing a small amount of ASD powder on a Rigakuzero-background sample holder with a 0.1 mm indent. A glass slide wasthen used to firmly pack the powder and ensure the surface of the samplewas level with the edge of the sample holder. Instrument details andmeasurement conditions are specified in Table 3.

TABLE 3 Rigaku MiniFlex instrument and measurement conditions. ParameterCondition Spin On Slit condition Variable and fixed slit system OpticalSoller (inc.): 5.0° IHS: 10.0 mm DS: 1.250° SS: 8.0 mm device Soller(rec.): 5.0° IHS: 13.0 mm Monochromatization: Kb filter (X2, 0.03 mm)Detector D/tex Measurement Scan axis: Mode: Start: 5.0° Stop: 40°condition theta/2-theta continuous Step: 0.02° Speed: 5.0°/ Voltage:Current: min 40 kV 15 mA

The ASDs were evaluated for amorphicity post-spray (t=0) and afterstability. Each XRD scan was assessed for the presence of crystallinepeaks, with the results listed in Table 4.

TABLE 4 Summary of ASD amorphicity data for ASDs of Example 1. TimeNilotinib:EUDRAGIT L100-55 Nilotinib:HPMC-AS Point 50:50 60:40 70:3080:20 50:50 60:40 70:30 80:20 0 Amorphous Amorphous Amorphous AmorphousAmorphous Amorphous Amorphous Amorphous 1 week  Amorphous AmorphousCrystalline Crystalline Amorphous Amorphous Amorphous Crystalline 2weeks Amorphous Amorphous Crystalline Crystalline Amorphous CrystallineCrystalline Crystalline 4 weeks Amorphous Amorphous CrystallineCrystalline Amorphous Crystalline Crystalline Crystalline

As shown in Table 4, each ASD was amorphous post-electrosprayprocessing. After one week on stability at 50° C./80% RH, the ASDs witha lower drug load (Nilotinib:EUDRAGIT L100-55 at 50:50 and 60:40;Nilotinib:HPMC-AS at 50:50, 60:40 and 70:30) remained amorphous;however, the ASDs with a higher drug load had begun to show signs ofcrystallization in the XRD scans. Only the ASD formulations with thelowest drug loads (Nilotinib:EUDRAGIT L100-55 at 50:50 and 60:40;Nilotinib:HPMC-AS at 50:50) were amorphous at week 2, and remainedamorphous throughout the entire four-week study; all other ASDs showedthe presence of crystalline peaks by week 2. Despite the fact thatcrystallinity was observed after some time for many of these ASDs, thisresult was considered promising because of the harsh accelerated storageconditions (which are not reflective of real-world storage conditions).

Water Content

Water content was determined by Karl Fischer coulometric titrationmethod, using a Mettler Toledo C30S Karl Fischer with Stromboli OvenSampler. Approximately 40-50 mg of ASD powder was weighed into a glassStromboli sample vial and vial was immediately sealed. The vial was thenplaced onto instrument and analysis was conducted using nitrogen carriergas. Instrument details and measurement conditions are specified inTable 5.

TABLE 5 Karl Fisher instrument and measurement conditions. ParameterCondition Drift duration 3 min Drift wait time 60 sec Maximum driftallowance 25 μg/min Oven temperature 110° C. Mix time 60 sec Stir speed50%

The initial moisture levels were very consistent for all eight ASDs, asshown in Table 6. Likewise, all ASDs demonstrated a rapid increase inwater content after exposure for one week to high humidity, whichleveled off and remained fairly constant (3.5%-5%) for the remainder ofthe study. Despite some variability in the data, the ASDs comprisingeither EUDRAGIT L100-55 or HPMC-AS exhibited some hygroscopic character.

TABLE 6 Summary of ASD water content (KF) data for ASDs of Example 1.Time Nilotmib:EUDRAGIT L100-55 Nilotinib:HPMC-AS Point 50:50 60:40 70:3080:20 50:50 60:40 70:30 80:20 0 0.7% 1.3% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%1 week  4.4% 4.1% 4.1% 4.5% 4.7% 5.1% 4.8% 3.5% 2 weeks 4.6% 3.9% 4.0%4.1% 5.4% 4.9% 4.9% 3.7% 4 weeks 4.1% 4.1% 4.3% 4.5% 4.6% 4.1% 4.1% 4.1%

Glass Transition Temperature

Modulated differential scanning calorimetry (mDSC) analysis was run on aTA Instruments Model Q200, equipped with a RCS90 refrigerated coolingsystem, to assess glass transition temperatures. In general, about 5-10mg of ASD powder was loaded in a TA T_(zero) low-mass aluminum pan andsealed with a T_(zero) lid. Instrument details and measurementconditions are specified in Table 7. Results are provided in Table 8.

TABLE 7 TA Q200 DSC instrument and measurement conditions. ParameterCondition DSC Model Modulated Test MDSC heat only Method Modulate ±0.48° C. every 60 sec Temperature ramp 3° C./min from 0° C. to 200° C.Data sampling interval 0.20 sec

TABLE 8 Summary of observed glass transition temperature (DSC) data(T_(g)) for ASDs of Example 1. Time Nilotinib:EUDRAGIT L100-55Nilotinib:HPMC-AS Point 50:50 60:40 70:30 80:20 50:50 60:40 70:30 80:200 131.3° C. 130.1° C. 124.5° C. 103.2° C. 101.2° C. 100.6° C. 99.1° C.98.1° C. 1 week  133.5° C. 132.7° C. 126.5° C. 115.7° C. 101.0° C.100.5° C. 98.8° C. ¹ ND 2 weeks 134.9° C. 131.6° C. 124.3° C. 116.7° C.101.5° C. 100.2° C. 98.6° C. ¹ ND 4 weeks 135.4° C. 134.8° C. 126.2° C.117.0° C. 100.2° C. ND ND ND ¹ possible second T_(g) observed near 60°C. ND = none detected

As can be seen from the results in Table 8, the ASDs comprising EUDRAGITL100-55 exhibited decreasing T_(g) value with increasing drug load. Forall four drug load levels, there was essentially no change in T_(g) onstability.

In the case of the ASDs comprising HPMC-AS, T_(g) values were similaracross the four drug-load levels. The 60:40 ASD had stable T_(g) for thefirst two weeks; however, no T_(g) was detected at four weeks. The 70:30ASD also had a stable T_(g) for the first two weeks; however, a weakthermal event that may indicate a second T_(g) near 60° C. was observed,suggesting that the sample may have been undergoing a phase separationwhile on stability. No T_(g) could be detected for the 80:20 ASD sampleon stability. The lack of a measurable T_(g) for these samples suggestedthat some type of physical change may have occurred with the HPMC-ASASDs held under accelerated conditions during stability testing.

Assay/Related Substances

Assay and related substances (e.g., impurities) were determined using anAgilent 1200 HPLC utilizing an Agilent Poroshell C18 3.0 mm×150 mm×2.7μm column. Sample solutions of each ASD were prepared by accuratelyweighing approximately 50 mg of ASD powder into a 50 ml volumetricflask. The ASD powder was initially dissolved in a flask inapproximately 40 ml of methanol, and then the flask was vortexed andsonicated until the ASD powder was completely dissolved. The sampleflasks were then brought to volume with methanol and mixed well. Thissample solution was then diluted 10× in diluent (50:50 acetonitrile(ACN):0.1% phosphoric acid in water). The final concentration of theanalyte (nilotinib) in the sample was approximately 0.05 mg/ml. Theinstrument and measurement conditions are specified in Table 9, whilethe gradient profile is listed in Table 10.

TABLE 9 HPLC instrument and measurement conditions. Parameter ConditionMobile Phase A 0.29% TEA and 0.1% AA in water Mobile Phase B 0.29% TEAand 0.1% AA in acetonitrile Flow 0.5 ml/min, gradient Injection volume16.0 μL Column temperature 45° Wavelength 260 nm Run-time 40 min TEA =triethylamine AA = acetic acid

TABLE 10 HPLC instrument gradient profile. Time (mm) % Mobile Phase A %Mobile Phase B 0 80.0 20.0 5 80.0 20.0 30 20.0 80.0 35 20.0 80.0 36 80.020.0 40 80.0 20.0

Assay results are provided in Table 11. Assay values for the ASDscomprising EUDRAGIT L100-55 (96.2%-98.4%) and the ASDs comprisingHPMC-AS (96.5%-97.9%) were as expected given the relatively high totalrelated substances levels observed for the as-supplied drug substance(˜2%) and the measured initial water content of the ASD samples (˜1%).In general, all ASDs demonstrated a decrease in assay over time onstability. This decrease was more pronounced for the ASDs comprisingHPMC-AS as compared to the ASDs comprising EUDRAGIT L100-55. Withreference to Table 6, increased moisture content was likely responsiblefor some of the measured potency loss, as ASDs on stability were foundto contain between 4%-5% water after one week, and assay measurementswere not corrected for water content. Nilotinib peaks were abundantenough to enable determination of percent impurities for each sample.

TABLE 11 Summary of assay (HPLC) data for ASDs of Example 1. TimeNilotinib:EUDRAGIT L100-55 Nilotinib:HPMC-AS Point 50:50 60:40 70:3080:20 50:50 60:40 70:30 80:20 0 98.0% 96.3% 96.2% 98.4% 100.8% 97.9%97.2% 96.5% 1 week  96.0% 93.9% 94.8% 92.7%  96.7% 92.9% 93.7% 94.4% 2weeks 91.4% 95.7% 95.5% 94.0% n/a 91.9% 95.0% 94.3% 4 weeks 87.1% 91.1%91.2% 93.3%  91.8% 87.2% 91.3% 85.7% n/a - data not available

Related substances results are provided in Table 12. Levels of relatedsubstances were similar for all eight ASDs at all time points. Based onthis data, the electrospray process did not appear to increase the levelof related substances, and all ASDs appeared chemically stable underaccelerated conditions on stability despite exposure to high levels ofheat and humidity.

TABLE 12 Summary of total related substances (HPLC) data for ASDs ofExample 1. Time Nilotinib:EUDRAGIT L100-55 Nilotinib:HPMC-AS Point 50:5060:40 70:30 80:20 50:50 60:40 70:30 80:20 0 1.9% 2.2% 2.0% 1.9% 1.9%2.1% 2.1% 1.9% 1 week  1.8% 2.4% 2.1% 2.1% 1.6% 2.3% 2.3% 2.0% 2 weeks1.8% 2.3% 2.1% 2.0% 1.9% 2.2% 2.3% 2.0% 4 weeks 1.8% 2.4% 1.9% 1.9% 1.7%2.2% 2.3% 2.0%

Example 2. Stability of Nilotinib ASD Under Accelerated StorageConditions

A study was performed to evaluate the stability of a nilotinib ASDaccording to embodiments of the present disclosure under differentaccelerated storage conditions.

The ASD was prepared similarly to the ASDs described in Example 1,except the solvent mixture was tetrahydrofuran and methanol in a 60:40(v/v) ratio. (The tetrahydrofuran was stabilized with a small quantityof BHT as an antioxidant; therefore, the ASDs prepared in this examplewill contain a small, unquantified amount of BHT along with nilotiniband polymer.) Equal quantities of nilotinib and HPMC-AS were dissolvedin the solvent mixture to prepare a liquid feedstock, which waselectrosprayed to provide the ASD powder.

The resulting ASD powder contained nilotinib and HPMC-AS in a ratio of50:50 (w/w), and was stored under accelerated conditions at 25° C./60%RH for 24 months, and at 40° C./75% RH for six months. The ASD powderwas assessed for each storage condition at t=0 and at 1 month, 2 months,3 months, and 6 months for amorphicity (XRD), water content (KarlFisher), glass transition temperature (DSC), and assay/relatedsubstances (HPLC). For the samples stored at 25° C./60% RH, additionalassessments were done at later time points up to 24 months.

Amorphicity

Amorphicity was assessed as in Example 1, above. The ASD remainedamorphous throughout the entire stability study for both sets of storageconditions.

Water Content

Water content was measured by coulometric Karl Fischer titration, as inExample 1, except that sample size was approximately 50-100 mg of ASDpowder.

As indicated in Table 13, water content remained substantiallyconsistent across stability timepoints, and no adverse hygroscopicity isobserved for the ASDs.

TABLE 13 Summary of water content (KF) data for ASD of Example 2. TimePoint Storage Condition (months) 25° C./60% RH 40° C./75% RH 0 1.52%1.52% 1 3.25% 3.71% 2 3.41% 3.63% 3 3.37% 3.51% 6 3.15% 3.70% 9 0.88% 122.82%

Glass Transition Temperature

Glass transition temperature (T_(g)) of the ASD stored under acceleratedconditions was assessed as in Example 1. Results are provided in Table14.

TABLE 14 Summary of glass transition (mDSC) data (T_(g)) for ASD ofExample 2. Time Point Storage Condition (months) 25° C./60% RH 40°C./75% RH 0 98.8° C.  98.8° C. 1 101.7° C. 101.2° C. 2 101.4° C. 101.4°C. 3 100.1° C. 102.8° C. 6 100.2° C. 102.3° C. 9 100.6° C. 12  99.7° C.18 100.5° C. 24 100.6° C.

The results show that, for each storage condition, the glass transitiontemperature of the ASD was generally unchanged over time, whichindicates that the ASD was physically stable.

Assay/Related Substances

Assay and related substances (e.g., impurities) of the ASD were assessedthrough HPLC, utilizing an Agilent Poroshell HPH-C18 3.0 mm×150 mm×2.7μm column. Sample solutions were prepared by accurately weighingapproximately the equivalent of 10 mg of the ASD powder into a 100 mlvolumetric flask. The ASD powder was dissolved in approximately 90 ml ofmethanol (MeOH):water (80:20). The sample flasks were then brought tovolume with 80:20 MeOH:water and mixed well until the ASD powder wasfully dissolved. The final concentration of the analyte (nilotinib) inthe sample was approximately 0.1 mg/ml. The instrument and measurementconditions are specified in Table 15, while the gradient profile islisted in Table 16.

!TABLE 15 HPLC instrument and measurement conditions. ParameterCondition Column Agilent Poroshell HPH-C18, 3.0 mm × 150 mm × 2.7 μmFlow rate 0.5 ml/min Mobile Phase A 20 mM ammonium bicarbonate, pH 9.0Mobile Phase B ACN:MeOH (80:20) Mobile Phase C ACN:MeOH (90:10) Elutionprogram Gradient Injection Volume 5 μL (assay); 10 μL (relatedsubstances) Column Temperature 45° C. Detector Wavelength 260 nm

TABLE 16 HPLC instrument gradient program. Analysis Time (mm) % MobilePhase A % Mobile Phase B Assay Method 0 55 45 7 30 70 8 0 100 9 0 1009.1 55 45 12 55 45 Related 0 90 10 Substances 2 90 10 Method 5 65 35 3552 48 40 0 100 41 0 100 41.1 90 10 44 90 10

Assay values were determined for the ASD post-spray (t=0) and atdesignated stability timepoints under each storage condition. Measuredassay values of the ASD for each storage condition are listed in Table17. The reported assay values are not corrected for water content.

TABLE 17 Summary of assay (HPLC) data for ASD of Example 2. Time PointStorage Condition (months) 25° C./60% RH 40° C./75% RH 0 95.8% 95.8% 193.5% 93.7% 2 95.0% 94.7% 3 95.5% 95.3% 6 95.6% 96.4% 9 97.7% 12 95.0%18 93.3% 24 94.4%

Total related substances measured values for the ASD under each storagecondition are listed in Table 18.

TABLE 18 Summary of total related substances (HPLC) data for ASD ofExample 2. Time Point Storage Condition (months) 25° C./60% RH 40°C./75% RH 0 0.60% 0.60% 1 0.56% 0.63% 2 0.72% 0.81% 3 0.80% 0.78% 60.52% 0.57% 9 0.68% 12 0.71% 18 0.62% 24 0.71%

As demonstrated in Tables 17 and 18, the ASD exhibited suitably highassay values and suitably low related substances values that did notappreciably change over time, indicating that the ASD was chemicallystable.

Example 3. Stability of Nilotinib ASD Suspension Formulations

A study was performed to evaluate the stability of two pharmaceuticalcompositions according to embodiments of the disclosure, in the form ofsuspensions. The components of the two pharmaceutical compositions,labeled as “Composition 1” and “Composition 2”, are shown in Table 19.

TABLE 19 Components of the pharmaceutical compositions for Example 3.Components Composition 1 Composition 2 Nilotinib ASD 11.340 g 11.340 g(Nilotinib:HPMC-AS 50:50 w/w) SOLUPLUS (solubilizer) - 0 - 5.5625 g 0.5%methylcellulose in 0.5 mM 435 ml 435 ml citric acid buffer (pH 4)(carrier)

The ASD powder contained nilotinib free base (49.78% by weight of theASD), HPMC-AS (49.78%), and BHT (0.44%). (The BHT amount was quantitatedby analysis of the as-prepared ASD.) Composition 1 was prepared bymixing the ASD powder into 0.5% methylcellulose in 0.5 mM citric acidbuffer to form a suspension. Composition 2 was prepared by mixing theASD and the SOLUPLUS (commercially available from BASF North America)until blended, and then mixing into the 0.5% methylcellulose in 0.5 mMcitric acid buffer to form a suspension. For both compositions, thenominal concentration of nilotinib was 12.5 mg/ml.

Each composition was stored in a closed container on a bench at standardroom temperature and humidity throughout this study. The assay of eachpharmaceutical composition was assessed over a 4-hour period by HPLC asdescribed above for Example 2. The measured assay values for eachpharmaceutical composition are provided in Table 20.

TABLE 20 Summary of suspension assay data over a 24-hour period forcompositions of Example 3. Time Point (hours) Composition 1 Composition2 0 101.7% 99.0% 2 102.7% 99.0% 4  99.9% 98.1%

Amorphicity of each pharmaceutical composition was assessed by XRD asdescribed above for Example 1 at T=0, 2, and 4. Both pharmaceuticalcompositions remained amorphous throughout the entire stability study,regardless of the presence or absence of SOLUPLUS.

Example 4. Canine In Vivo Studies

Studies were performed in beagle dogs to investigate the impact ofstomach pH and food on the in vivo exposure obtained usingpharmaceutical compositions of the disclosure (formulated as asuspension, capsule, and tablet) compared to exposures obtained bydosing a conventional immediate-release formulation of nilotinib, suchas TASIGNA IR Capsule.

For selected conditions, the studies incorporated pretreatments toadjust the stomach pH of the dogs prior to dosing. Based on publishedprotocols, pretreatment of the canines with pentagastrin would controlthe pH to a range between 1 and 2, while pretreatment with a phosphatebuffer would achieve a pH between 2 and 3.

The study design is provided in Table 21. For Legs A1 and A3, asuspension (“TASIGNA Suspension”) was prepared at a nilotinibconcentration of 10 mg/mL using the decanted contents of TASIGNA IRCapsules, in a vehicle comprising 0.5% methylcellulose in 0.5 mM citricacid buffer (pH 4). For Leg B1, a quantity of decanted contents inpowder form from TASIGNA IR Capsules was weighed to accurately provide adose of 5 mg/kg, and the weighed powder was then filled into aconventional gelatin capsule for dosing (“TASIGNA Capsule”).

Legs B2, B3, B4, C2, and C3 employed an ASD comprising nilotinib andHPMC-AS in a nilotinib:HPMC-AS ratio of 50:50 (w/w) (prepared as inExample 2 above), in a suitable pharmaceutical composition, prepared asfollows. For Leg B2, the ASD was mixed with suitable excipients andformulated into granules (nilotinib drug load of 15%) by slugging; asuitable quantity of granules was then filled into a conventionalgelatin capsule for dosing (“ASD Capsule”). For Legs B3 and C3, an ASDsuspension was prepared according to Composition 1 of Example 3 (Table19). For Leg B4, granules (as for Leg B2) were combined withconventional excipients and manually pressed into a slug tablet(nilotinib drug load of 7.7%) using a tablet press (“ASD Tablet”). ForLeg C2, an ASD suspension comprising SOLUPLUS was prepared according toComposition 2 of Example 3 (Table 19).

For Leg C1, an ASD suspension was prepared according to Composition 2 ofExample 3 (Table 19), except the nilotinib ASD comprised nilotinib andEUDRAGIT L100-55 in a nilotinib:EUDRAGIT L100-55 ratio of 50:50 (w/w).This suspension had been prepared by electrospraying from a methanol:THFsolvent mixture (1:1 v/v).

TABLE 21 Canine in vivo study design for Example 4. Study Fed/ Leg StudyProduct Fasted Pretreatment A1 TASIGNA Suspension Fasted Pentagastrin A3TASIGNA Suspension Fed None B1 TASIGNA Capsule Fasted Phosphate BufferB2 ASD Capsule Fasted Phosphate Buffer B3 ASD suspension (HPMC-AS)Fasted Phosphate Buffer (Composition 1) B4 ASD Tablet Fasted PhosphateBuffer C1 ASD suspension (EUDRAGIT Fasted Phosphate Buffer L100-55) withSOLUPLUS C2 ASD suspension (HPMC-AS) with SOLUPLUS Fasted PhosphateBuffer (Composition 2) C3 ASD suspension (HPMC-AS) Fasted PhosphateBuffer (Composition 1)

All dogs were fasted for a minimum of ten hours prior to doseadministration. The animals were supplied with water ad libitum. Eachstudy leg had ten dogs. The study employed a cross-over study design,with the same dogs receiving each dose following a one-week washoutperiod between each leg of the study.

For the fasted legs, food was withheld from the animals for a minimum oftwelve hours prior to dosing. In addition, water was removed two hoursprior to dosing.

For the fed study Leg A3, animals were acclimated to a high fat meal forfive days prior to dosing. Animals were fasted for a minimum of tenhours overnight and then fed a pre-weighed portion (˜50 grams) of apuree consisting of McDonald's Bacon and Egg McMuffin. Animals wereallowed 30 minutes to consume the food, after which time any remainingfood was removed and the test articles administered.

Normal dog chow was provided to the animals four hours post-dose. Waterwas provided immediately following dosing for all study legs.

In study Leg A1, each dog received an intramuscular injection ofpentagastrin (6 μg/kg) approximately 30 minutes prior to dosing toensure the gastric pH of the fasted animals would be acidic (pH 1-2).

For study legs incorporating a phosphate buffer pretreatment, each dogreceived 25 mL of 100 mM phosphate buffer (pH 2.5) via gavage tube priorto dosing. After dosing, each dog received an additional 10 mL of thebuffer as a flush.

For each study leg, all dogs received the appropriate oral dose of theappropriate study product to deliver 5 mg/kg nilotinib, at t=0.Following dosing, blood samples were collected at 30 minutes, 1, 1.5, 2,3, 4, 6, 8, 12, 18, and 24 hours.

Pharmacokinetic parameters were calculated from the time course of theplasma concentrations. Pharmacokinetic analysis was conducted byAbsorption Systems by a non-compartmental model using Phoenix WinNonlin(v7.0) software. C_(max) and the time to reach maximum plasma drugconcentration (T_(max)) after dosing were observed from the data. AUCwas calculated using the linear trapezoidal rule with calculation to thelast quantifiable data point, and with extrapolation to infinity. Plasmahalf-life (t_(1/2)) was calculated from 0.693/slope of the terminalelimination phase. Mean residence time (MRT) was calculated by dividingthe area under the moment curve (AUMC) by the AUC. Any samples below thelimit of quantitation (0.5 ng/mL) were treated as zero forpharmacokinetic data analysis.

Table 22 provides the key pharmacokinetic parameters calculated frompooled data, and comparisons between select legs of the study are shownin FIGS. 1-4.

TABLE 22 Key pharmacokinetic parameters from canine in vivo studies ofExample 4. C_(max)* T_(max) t_(1/2) MRT_((0-last)) AUC_((0-last))AUC_((0-inf)) Regimen (ng/ml) (hr) (h) (hr) (ng · h/ml) (ng · h/ml) LegA1: 1215 1.8 4.13 4.09 5054 5129 TASIGNA Suspension-fasted (403) (0.6)(1.17) (1.19) (2432) (2514) (pretreat: pentagastrin) Leg A3: 1203 2.34.36 5.08 6784 6978 TASIGNA Suspension-fed (471) (0.8) (1.34) (1.16)(4156) (4448) (pretreat: none) Leg B1: 265 2.5 3.27 5.35 1331 1243TASIGNA Capsule-fasted (240) (1.1) (0.804) (1.61) (1334) (1518)(pretreat: phosphate buffer, pH 2.5) Leg B2: 372 2.1 3.69 4.62 1586 1619ASD Capsule-fasted (201) (0.55) (1.27) (0.772) (997) (1053) (pretreat:phosphate buffer, pH 2.5) Leg B3: 661 1.5 3.68 4.53 3116 3208 ASDsuspension (HPMC-AS)-fasted (277) (0.33) (1.11) (1.12) (2170) (2361)(pretreat: phosphate buffer, pH 2.5) Leg B4: 427 1.8 4.05 4.60 1897 1937ASD TABLEt-fasted (180) (0.89) (0.998) (0.849) (1316) (1385) (pretreat:phosphate buffer, pH 2.5) Leg C1: 948 1.8 3.80 4.35 4497 4655 ASDsuspension (EUDRAGIT (482) (0.9) (0.916) (0.958) (3478) (4306) L100-55)with SOLUPLUS-fasted (pretreat: phosphate buffer, pH 2.5) Leg C2: 9531.4 3.56 4.34 4876 5334 ASD suspension (HPMC-AS) with (293) (0.4) (1.15)(1.18) (2880) (3181) SOLUPLUS-fasted (pretreat: phosphate buffer, pH2.5) Leg C3: 473 1.4 5.11 5.08 2337 1617 ASD suspension (HPMC-AS)-fasted(251) (0.7) (4.85) (2.35) (1992) (801) (pretreat: phosphate buffer, pH2.5) *mean (SD)

As shown in FIG. 1, the TASIGNA Capsule-fasted exposure (Leg B1) wasdramatically reduced as compared to the TASIGNA IR Suspension-fastedexposure following pretreatment with pentagastrin (Leg A1). Theseresults demonstrate that the pentagastrin pretreatment increasednilotinib solubility in the dog stomach by reducing the gastric pH,resulting in higher exposure in the fasted state. These results alsoindicate that the 100 mM phosphate buffer (pH 2.5) pretreatment waseffective at creating gastric conditions in the dog that were morediscriminating for the TASIGNA Capsule under fasting conditions.

FIG. 2 compares TASIGNA Capsule-fasted exposure (Leg B1) and TASIGNA IRSuspension-fed exposure (Leg A3). These results show that the protocolin this study using phosphate buffer pretreatment was successful atcreating conditions that enabled the dog model to successfullydemonstrate the known large, positive food effect observed in human forconventional immediate-release nilotinib. A statistical analysis ofthese results shows that C_(max) (p-value: <0.0001) and AUC (p-value:<0.0019) was significantly greater following fed dosing versusfasted-dosing.

FIG. 3 shows the pharmacokinetic profiles for three nilotinib ASDcompositions (ASD Capsule—Leg B2; ASD suspension (HPMC-AS)—Leg B3; ASDTablet—Leg B4), along with the TASIGNA Capsule (Leg B1), under fastingconditions at pH˜2.5. All three ASD compositions demonstrated increasedexposure compared to the TASIGNA Capsule under fasting conditions. TheASD Tablet and ASD Capsule showed increases in C_(max) and AUC comparedto the TASIGNA Capsule, while the ASD suspension (HPMC-AS) showedsignificant increases in both C_(max) and AUC.

FIG. 4 shows the pharmacokinetic profiles for three nilotinib ASDsuspension compositions (ASD suspension of nilotinib and EUDRAGITL100-55 with SOLUPLUS—Leg C1; ASD suspension of nilotinib and HPMC-ASwith SOLUPLUS—Leg C2; ASD suspension of nilotinib and HPMC-AS—Leg C3),along with the TASIGNA Capsule (Leg B1), administered under fastingconditions at pH˜2.5. All three ASD suspension compositions demonstratedincreased exposure compared to the TASIGNA Capsule under fastingconditions. The ASD suspension without SOLUPLUS showed increases inC_(max) and AUC compared to the TASIGNA Capsule, while the twosuspension formulations with SOLUPLUS showed significant increases inboth C_(max) and AUC.

These results showed that nilotinib ASD according to the disclosure canbe used to increase nilotinib exposure in the fasted state, potentiallyfacilitating a lower delivered dose and improved food effect profilecompared to the TASIGNA Capsule.

Example 5. Human In Vivo Studies

A study was performed in human subjects to assess the pharmacokineticsobserved upon administration of Compositions 1 and 2 of Example 3, ascompared to pharmacokinetics observed upon administration ofconventional commercially available 200 mg TASIGNA IR Capsule; and toassess the effect of food on the pharmacokinetics observed uponadministration of the pharmaceutical compositions.

Healthy subjects (n=26) were orally administered either TASIGNA IRCapsule (200 mg) or an appropriate quantity of Composition 1 orComposition 2 (Example 3) in accordance with the regimens described inTable 23. The study employed a cross-over study design, in which eachsubject participated in each regimen for each period of the study. (Notethat TASIGNA IR Capsule could not be dosed under fed conditions inaccordance with the product's labeling).

TABLE 23 Human in vivo dosing regimens for Example 5. AdministrationRegimen Study Product Dose Condition A TASIGNA IR Capsule 200 mg fastedB Composition 1  50 mg fasted C Composition 2  50 mg fasted DComposition 1  50 mg fed E Composition 2  65 mg fasted F Composition 2 65 mg fed

Subjects were screened for inclusion in the study up to 28 days beforedosing. Each study period followed the same design. Subjects wereadmitted to the clinical unit on the morning of the day prior toadministration of the study product (Day −1) where eligibility wasreviewed and confirmed. After an overnight fast of a minimum of 10hours, subjects were dosed on the morning of Day 1 of each period, andsubjects continued to fast for approximately 4 hours post-dose. For fedregimens, subjects were dosed 30 minutes after the start of a high-fatbreakfast. Following oral administration, plasma samples were taken atthe following time points to assess the plasma concentration ofnilotinib: 0 (prior to administration), 0.5, 1, 2, 3, 4, 5, 6, 8, 10,12, 18, 24, 36, 48, and 72 hours. Subjects remained on site for thefirst 48 hours post-dose and returned to the clinical unit for apharmacokinetic blood sample and safety assessments at 72 hourspost-dose. There was a minimum washout of 7 days between each studyperiod.

A subject was considered evaluable for the pharmacokinetic assessment ifthe subject received the TASIGNA IR Capsule and at least one of testCompositions 1 and 2 in the fasted state, and if pharmacokinetic andsafety data up to 72 hours post-dose were obtained. A subject wasconsidered evaluable for the food effect assessment if the subjectreceived at least one of test Compositions 1 and 2 in both the fed andfasted state (i.e., the same composition in both states) at the samedose level, and if pharmacokinetic and safety data up to 72 hourspost-dose were obtained.

Key pharmacokinetic parameters were calculated using pooled data forevaluable subjects (n=24 to 26). Table 24 provides the geometric mean ofkey pharmacokinetic parameters and Table 25 shows geometric mean ofnon-dose adjusted relative bioavailabilities (Frei) in subjectsfollowing administrations of each regimen. A comparison of Regimens A-C(see FIG. 5) shows that Compositions 1 (Regimen B) and 2 (Regimen C)exhibited AUC and C_(max) values that are comparable or higher than theAUC and C_(max) of the 200 mg TASIGNA IR Capsule (Regimen A), despitethat the TASIGNA IR Capsule contained 200 mg of nilotinib andCompositions 1 and 2 contained only 50 mg of nilotinib. In addition,Composition 1 (Regimen B), which did not contain SOLUPLUS, exhibitedhigher AUC and C_(max) values than Composition 2 (Regimen C).

A comparison among Regimens B and D (see FIG. 6) shows thatadministration of the nilotinib pharmaceutical compositions under fedconditions did not result in appreciably elevated nilotinib plasmaconcentration levels relative to administration under fastingconditions, as the concentration levels and key pharmacokineticparameters resulting from Regimen D (50 mg of Composition 1 administeredunder fed conditions) were not significantly greater than thoseresulting from Regimen B (50 mg of Composition 1 administered underfasting conditions) (see FIG. 6, Tables 24 and 25).

A similar result is evident in the comparison of Regimens E and F (seeFIG. 7), as the nilotinib plasma concentration levels and keypharmacokinetic parameters resulting from Regimen F (65 mg ofComposition 1 administered under fed conditions) are similar or lowerthan the nilotinib plasma concentration levels and key pharmacokineticparameters resulting from Regimen E (65 mg of Composition 2 administeredunder fed conditions) (see Tables 24 and 25). These results aresurprising in light of the food effect associated with conventionalcommercially available immediate-release compositions of nilotinib (suchas TASIGNA IR Capsule) that is known in the art.

TABLE 24 Geometric mean (coefficient of variation, or CV %) keypharmacokinetic parameters of nilotinib in healthy volunteers followingoral administration of TASIGNA IR Capsule and select nilotinib ASDcompositions according to embodiments of the disclosure. T_(max)*C_(max) AUC₍₀₋₁₂₎ AUC₍₀₋₂₄₎ AUC_((0-last)) AUC_((0-inf)) t_(1/2) Regimen(h) (ng/ml) (ng · h/ml) (ng · h/ml) (ng · h/ml) (ng · h/ml) (h) A: 200mg TASIGNA 4.00 537 4170 6620 11100 12600 19.8 IR Capsule-fasted(2.00-6.00) (39.5) (35.4) (38.4) (45.3) (53.6) (62.3) B: 50 mg NilotinibASD 2.00 621 4670 7050 10200 10500 12.4 Composition 1-fasted (1.00-5.00)(27.4) (22.2) (25.2) (38.3) (42.3) (42.3) C: 50 mg Nilotinib ASD 2.00501 3790 5590 7610 7760 11.3 Composition 2-fasted (1.00-5.00) (25.9)(23.0) (28.5) (40.1) (42.1) (30.8) D: 50 mg Nilotinib ASD 4.00 456 37706310 9490 9840 12.9 Composition 1-fed (3.00-12.00) (19.9) (18.6) (23.3)(38.6) (41.3) (33.5) E: 65 mg Nilotinib ASD 2.00 616 4820 7340 1060011000 13.2 Composition 2-fasted (1.00-4.00) (25.5) (24.0) (29.5) (44.4)(48.9) (42.1) F: 65 mg Nilotinib ASD 4.50 525 4320 7130 11000 11300 12.4Composition 2-fed (3.00-6.00) (23.0) (22.2) (25.7) (39.6) (42.4) (33.9)*median (range)

TABLE 25 Geometric mean (CV%) non-dose adjusted relativebioavailabilities (F_(rel)) of nilotinib in healthy volunteers followingoral administration of nilotinib ASD compositions according to thedisclosure. F_(rel) F_(rel) F_(rel) C_(max) AUC_((0-last)) AUC_((0-inf))Regimen Comparator (%) (%) (%) B: 50 mg Nilotinib A: 200 mg 116 91.983.4 ASD Composition TASIGNA IR (28.1) (26.0) (28.6) 1 - fastedCapsule - fasted C: 50 mg Nilotinib A: 200 mg 93.3 68.7 61.6 ASDComposition TASIGNA IR (31.8) (26.5) (24.7) 2 - fasted Capsule - fastedD: 50 mg Nilotinib B: 50 mg Nilotinib 74.3 92.5 92.5 ASD Composition ASDComposition (22.2) (17.9) (18.7) 1 - fed 1 - fasted E: 65 mg NilotinibA: 200 mg 111 93.4 86.9 ASD Composition TASIGNA IR (30.1) (29.1) (31.9)2 - fasted Capsule - fasted B: 50 mg Nilotinib 99.6 103 104 ASDComposition (17.8) (18.9) (20.3) 1 - fasted F: 65 mg Nilotinib A: 200 mg94.8 96.6 89.3 ASD Composition TASIGNA IR (38.0) (28.8) (30.3) 2 - fedCapsule - fasted E: 65 mg Nilotinib 85.2 103 103 ASD Composition (16.6)(15.4) (16.7) 2 - fasted

The foregoing description is given for clearness of understanding only,and no unnecessary limitations should be understood therefrom. Variousmodifications and alterations to this disclosure will become apparent tothose skilled in the art without departing from the scope and spirit ofthis disclosure. It should be understood that this disclosure is notintended to be unduly limited by the illustrative embodiments andexamples set forth herein, and such examples and embodiments arepresented by way of example only.

Reference throughout this specification to “one embodiment,” “anembodiment,” “certain embodiments,” or “some embodiments,” etc., meansthat a particular feature, configuration, composition, or characteristicdescribed in connection with the embodiment is included in at least oneembodiment of the disclosure. Thus, the appearances of such phrases invarious places throughout this specification are not necessarilyreferring to the same embodiment of the disclosure. Furthermore, theparticular features, configurations, compositions, or characteristicsmay be combined in any suitable manner in one or more embodiments.

Throughout the specification, where compositions are described asincluding components or materials, it is contemplated that thecompositions can also consist essentially of, or consist of, anycombination of the recited components or materials, unless describedotherwise. Likewise, where methods are described as including particularsteps, it is contemplated that the methods can also consist essentiallyof, or consist of, any combination of the recited steps, unlessdescribed otherwise.

The practice of a method disclosed herein, and individual steps thereof,can be performed manually and/or with the aid of or automation providedby electronic equipment. Although processes have been described withreference to particular embodiments, a person of ordinary skill in theart will readily appreciate that other ways of performing the actsassociated with the methods may be used. For example, the order ofvarious steps may be changed without departing from the scope or spiritof the method, unless described otherwise. In addition, some of theindividual steps can be combined, omitted, or further subdivided intoadditional steps.

The term “comprises” and variations such as “comprises” and “comprising”do not have a limiting meaning where these terms appear in thedescription and claims. Such terms will be understood to imply theinclusion of a stated step or element or group of steps or elements butnot the exclusion of any other step or element or group of steps orelements.

By “consists of” (or similarly “consisting of”) is meant including, andlimited to, whatever follows the phrase “consists of.” Thus, the phrase“consists of” in dictates that the listed elements are required ormandatory, and that no other elements may be present. By “consistsessentially of” (or similarly “consisting essentially of”) is meantincluding any elements listed after the phrase, and limited to otherelements that do not interfere with or contribute to the activity oraction specified in the disclosure for the listed elements. Thus, thephrase “consists essentially of” indicates that the listed elements arerequired or mandatory, but that other elements are optional and may ormay not be present depending upon whether or not they materially affectthe activity or action of the listed elements.

The words “preferred” and “preferably” refer to embodiments of thedisclosure that may afford certain benefits, under certaincircumstances. However, other embodiments may also be preferred, underthe same or other circumstances. Furthermore, the recitation of one ormore preferred embodiments does not imply that other embodiments are notuseful, and is not intended to exclude other embodiments from the scopeof the disclosure.

In this application, terms such as “a,” “an,” and “the” are not intendedto refer to only a singular entity, but include the general class ofwhich a specific example may be used for illustration. The terms “a,”“an,” and “the” are used interchangeably with the term “at least one.”The phrases “at least one of” and “comprises at least one of” followedby a list refer to any one of the items in the list and any combinationof two or more items in the list.

As used herein, the term “or” is generally employed in its usual senseincluding “and/or” unless the content clearly dictates otherwise. Theterm “and/or” means one or all of the listed elements or a combinationof any two or more of the listed elements (e.g., preventing and/ortreating an affliction means preventing, treating, or both treating andpreventing further afflictions).

Also herein, all numbers are assumed to be modified by the term “about”and preferably by the term “exactly.” As used herein in connection witha measured quantity, the term “about” refers to that variation in themeasured quantity as would be expected by the skilled artisan making themeasurement and exercising a level of care commensurate with theobjective of the measurement and the precision of the measuringequipment used. Herein, “up to” a number (e.g., up to 50) includes thenumber (e.g., 50). Also herein, the recitations of numerical ranges byendpoints include all numbers subsumed within that range as well as theendpoints (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.)and any sub-ranges (e.g., 1 to 5 includes 1 to 4, 1 to 3, 2 to 4, etc.).

The complete disclosures of the patents, patent documents, andpublications cited herein are incorporated by reference in theirentirety as if each were individually incorporated. To the extent thatthere is any conflict or discrepancy between the present disclosure andthe disclosure in any document that is incorporated by reference, thisdisclosure as written will control.

1-30. (canceled)
 31. A pharmaceutical composition comprising anamorphous solid dispersion, the amorphous solid dispersion comprisingnilotinib and one or more polymers; wherein the one or more polymerscomprises a hydroxypropyl methylcellulose acetate succinate thatexhibits pH-dependent solubility; and wherein the nilotinib and the oneor more polymers are present in the amorphous solid dispersion in a w/wratio of 25:75 to 90:10 (nilotinib:polymer).
 32. The pharmaceuticalcomposition of claim 31, wherein the one or more polymers comprise ahydroxypropyl methylcellulose acetate succinate characterized by anacetyl substitution of 7 to 11% and a succinyl substitution of 10 to14%.
 33. The pharmaceutical composition of claim 31, wherein the one ormore polymers consists essentially of a hydroxypropyl methylcelluloseacetate succinate.
 34. The pharmaceutical composition of claim 31,wherein the amorphous solid dispersion comprises one or moreantioxidants that are present in an amount of 0.001% to 2% by weight ofthe amorphous solid dispersion.
 35. The pharmaceutical composition ofclaim 34, wherein the one or more antioxidants comprises butylatedhydroxytoluene.
 36. The pharmaceutical composition of claim 31, whereinthe amorphous solid dispersion consists essentially of nilotinib and theone or more polymers.
 37. The pharmaceutical composition of claim 31,wherein the nilotinib and the one or more polymers are present in theamorphous solid dispersion in a w/w ratio of 40:60 to 70:30(nilotinib:polymer).
 38. The pharmaceutical composition of claim 31,wherein the nilotinib and the one or more polymers are present in theamorphous solid dispersion in a w/w ratio of 50:50 (nilotinib:polymer).39. The pharmaceutical composition of claim 31, comprising the amorphoussolid dispersion and one or more pharmaceutically acceptable additives.40. The pharmaceutical composition of claim 31, wherein thepharmaceutical composition is a solid dosage form suitable for oraladministration.
 41. The pharmaceutical composition of claim 31, whereinthe pharmaceutical composition is presented as a solid dosage formsuitable for oral administration, and comprising 25 to 100 mg nilotinib.42. A method of safely delivering nilotinib to a patient in need of suchtherapy, the method comprising: (a) administering to the patient atherapeutically effective amount of a pharmaceutical compositioncomprising nilotinib and one or more polymers; and (b) administering ameal to the patient; wherein steps (a) and (b) occur within less thantwo hours of each other; wherein the one or more polymers comprises ahydroxypropyl methylcellulose acetate succinate that exhibitspH-dependent solubility; and wherein the nilotinib and the one or morepolymers are present in the amorphous solid dispersion in a w/w ratio of25:75 to 90:10 (nilotinib:polymer).
 43. The method of claim 42, whereinthe patient suffers from a proliferative disorder.
 44. The method ofclaim 43, wherein the proliferative disorder is Philadelphia chromosomepositive chronic myeloid leukemia.
 45. The method of claim 43, whereinthe proliferative disorder is chronic phase Philadelphia chromosomepositive chronic myeloid leukemia resistant or intolerant to priortyrosine kinase inhibitor therapy.
 46. The method of claim 42, whereinthe one or more polymers comprise a hydroxypropyl methylcelluloseacetate succinate characterized by an acetyl substitution of 7 to 11%and a succinyl substitution of 10 to 14%.
 47. The method of claim 42,wherein the one or more polymers consists essentially of a hydroxypropylmethylcellulose acetate succinate.
 48. The method of claim 42, whereinthe amorphous solid dispersion comprises one or more antioxidants thatare present in an amount of 0.001% to 2% by weight of the amorphoussolid dispersion.
 49. The method of claim 48, wherein the one or moreantioxidants comprises butylated hydroxytoluene.
 50. The method of claim42, wherein the amorphous solid dispersion consists essentially ofnilotinib and the one or more polymers.
 51. The method of claim 42,wherein the nilotinib and the one or more polymers are present in theamorphous solid dispersion in a w/w ratio of 40:60 to 70:30(nilotinib:polymer).
 52. The method of claim 42, wherein the nilotiniband the one or more polymers are present in the amorphous soliddispersion in a w/w ratio of 50:50 (nilotinib:polymer).
 53. The methodof claim 42, comprising the amorphous solid dispersion and one or morepharmaceutically acceptable additives.
 54. The method of claim 42,wherein the pharmaceutical composition is a solid dosage form suitablefor oral administration.
 55. The method of claim 42, wherein thepharmaceutical composition is presented as a solid dosage form suitablefor oral administration, and comprising 25 to 100 mg nilotinib.
 56. Amethod of delivering a therapeutically relevant exposure of nilotinib toa subject without regard to whether the subject is in a fasted state ora fed state, comprising administering to the subject a pharmaceuticalcomprising an amorphous solid dispersion, the amorphous solid dispersioncomprising nilotinib and one or more polymers; wherein the one or morepolymers comprises a hydroxypropyl methylcellulose acetate succinatethat exhibits pH-dependent solubility; and wherein the nilotinib and theone or more polymers are present in the amorphous solid dispersion in aw/w ratio of 25:75 to 90:10 (nilotinib:polymer).
 57. The method of claim56, wherein administration of the pharmaceutical composition to thesubject in a fed state results in plasma C_(max) of nilotinib that iswithin 30% of the plasma C_(max) of nilotinib resulting fromadministration of the pharmaceutical composition to the subject in afasted state.
 58. The method of claim 56, wherein administration of thepharmaceutical composition to the subject in a fed state results inplasma AUC of nilotinib that is within 30% of the plasma AUC ofnilotinib resulting from administration of the pharmaceuticalcomposition to the subject in a fasted state.
 59. The method of claim56, wherein administration of the pharmaceutical composition to thesubject in a fed state results in plasma C_(max) of nilotinib that iswithin 25% of the plasma C_(max) of nilotinib resulting fromadministration in a fasted state of an immediate-release crystallinenilotinib formulation that has two times to four times the amount ofnilotinib as the pharmaceutical composition.
 60. The method of claim 56,wherein administration of the pharmaceutical composition to the subjectin a fed state results in plasma AUC of nilotinib that is within 25% ofthe plasma AUC of nilotinib resulting from administration in a fastedstate of an immediate-release crystalline nilotinib formulation that hastwo times to four times the amount of nilotinib as the pharmaceuticalcomposition.